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Background: Thyroid dysfunction is a common health issue in women, with a higher 
prevalence found in postpartum women. Postnatal depression (PND) is a maternal 
health issue which can exacerbate negative health effects on their newborns. Iodine, 
selenium, and iron are three essential nutrients for the synthesis of thyroid hormones. 
Historically, dietary insufficiency of iodine and selenium exist in New Zealand. To 
improve iodine status, the New Zealand government introduced mandatory 
fortification of bread with iodised salt (2009), and recommended iodine 
supplementation (150 µg/day) for all pregnant and breastfeeding women (2010). 
Mostly, the iron status of postpartum women in New Zealand is rarely medically 
examined, unless high levels of blood loss during childbirth are recorded. 
Objectives: The overall aim of this PhD thesis was to investigate maternal thyroid 
function, postnatal depression, and the intake and status of iodine, selenium and iron 
in mothers and infants during their first postpartum year. 
Method: This observational longitudinal cohort study was conducted in Palmerston 
North, New Zealand, from June 2016 to December 2017. Mother-infant pairs attended 
study visits at three, six and twelve months postpartum (3MPP, 6MPP, and 12MPP). 
Online questionnaires investigated maternal iodine knowledge, supplement use, 
mode of infant feeding, and sociodemographic characteristics. Weighed four-day 
dietary diary, with urine/blood/breastmilk samples, were taken to measure maternal 
iodine, selenium, and iron intake/status. Infant iodine and selenium concentrations 
were determined in spot urine samples. The Edinburgh Postnatal Depression Scale 
was used to screen for PND. At 6MPP, serum thyroid hormones [free triiodothyronine, 
free thyroxine, thyroid stimulating hormone (TSH), thyroglobulin (Tg) and anti-Tg 
and thyroid peroxidase antibodies] and thyroid volume were measured. 
Results: At 3MPP, 87 breastfeeding mother-infant pairs were recruited, followed up 
at 6MPP (n = 78) and 12MPP (n = 71). At 6MPP, 18% of women had thyroid dysfunction. 
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Median total thyroid volume was 6.1 mL. Median (p25, p75) Tg was 11.4 (8.6, 18.6) µg/L, 
above 10 µg/L. Median maternal plasma selenium was 105.8 (95.6, 115.3) µg/L; 23% 
(17/74) being below 95 µg/L; with 4% of women experiencing iron deficiency without 
anaemia. Women with marginally lower plasma selenium were 1.14% times more likely 
to have abnormal TSH concentrations. 
Over the first postpartum year, maternal median urinary iodine concentration 
(MUIC) was 82 (46, 157) µg/L, 85 (43, 134) µg/L, and 95 (51, 169) µg/L, all below 100 
µg/L; median BMIC was 69 (52, 119) µg/L, 59 (39, 108) µg/L, and 35 (26, 54) µg/L, all 
below the recommended 75 µg/L. Median maternal iodine intake was 151 (99, 285) 
µg/day, with 58% below the Estimated Average Requirement (EAR). At 3MPP, 46% of 
women took iodine-containing supplements, this reduced to 11% at 6MPP, and 6% at 
12MPP. Women who used iodine-containing supplements had significantly higher 
MUIC (111 vs 68 µg/L) and BMIC (84 vs 62 µg/L) than non-users (P < 0.001). Infants 
fed by women using iodine-containing supplements had a higher MUIC (150 vs 86 
µg/L, P = 0.036) than those of non-users. Infant MUIC at 3MPP [115 (69, 182) µg/L] and 
6MPP [120 (60, 196) µg/L] were below 125 µg/L (suggested cut-point for iodine 
adequacy in infants). Median maternal selenium intake was 62 (51, 85) µg/day and 
56% had intakes below the EAR. Median infant selenium intakes at 3MPP and 6MPP 
were 9 and 8 µg/day. Median maternal urinary selenium concentrations were 22, 22, 
and 26 µg/L across three time points, respectively. The highest prevalence of minor 
depression was observed in women with mean plasma selenium at 106 µg/L. 
Conclusions: A high prevalence of thyroid dysfunction was observed in a cohort of 
postpartum women who were iodine deficient, with suboptimal selenium intake, but 
having mostly adequate iron status. Women with low plasma selenium were likely to 
experience thyroid dysfunction. Iodine deficiency of lactating women remains, 
particularly for those who did not use iodine-containing supplements. The low use of 
iodine-containing supplements is concerning during later breastfeeding. Maternal 
selenium intake/status was suboptimal. Relation between selenium status and risk of 
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Chapter 1 Introduction 
 
This Chapter introduces the background of the thesis and provides justification for the 
research work undertaken. It also presents the study aims, objectives and hypotheses of 
the thesis. The thesis structure is outlined, then concluded by a table describing each 




Women’s health during the first year after childbirth is important for their newborn 
infants’ growth and development, as well as for their own long-term health. Maternal 
endocrine hormones adjust to support foetal development during the pregnancy 
period, and continuous readjustment is needed to maintain homeostasis after 
parturition. Thyroid hormones play an essential role in metabolic function within the 
human body, and are responsible for adequate myelination, neuron maturation, and 
central nervous system development in a human developing brain (1). These 
hormones are tightly controlled by the hypothalamic-pituitary axis with a negative 
feedback system. Women with limited thyroidal reserves or iodine deficiency may 
develop thyroid dysfunction during the postpartum period (postpartum thyroiditis) 
(2); this remains one of the most common endocrine disorders that postpartum 
women experience (3). In 2017, the American Thyroid Association reported from 
different studies the prevalence of postpartum thyroiditis ranged from 1.1% to 16.7% 
(4). Maternal thyroid dysfunction has been linked to the development of postnatal 
depression (3, 5), is weakly associated with reduced breastmilk production and milk-
ejection reflex (“let-down”) (4), and potentially affects the infant’s neurodevelopment 
due to thyroid dependent processes, such as neural proliferation and 
differentiation(6). 
Optimal thyroid function relies on adequate biosynthesis of thyroid hormones, which 
depends on three trace elements: iodine, selenium, and iron (7, 8). Mostly, pregnant 
women made dietary changes to support foetal health, such as increase dietary intakes 
of iron and calcium, either through carefully selected food choices for food cravings 
and safety, or dietary supplements encouraged by health care providers (9). However, 
after childbirth, the centre of attention shifts considerably to nurture the newborn 
infants, rather than remaining with the new mothers themselves. There is some 
published research investigated breastfeeding women and their infants’ iodine and 
selenium status. There are only a few studies which  has examined women’s iron status 
postnatally. Maintaining optimal maternal nutrition during the post-partum period is 
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important to enable women to meet both the demands of their breastfed infant and 
their own needs. More importantly, having adequate iodine, selenium and iron 
intakes ensures optimal thyroid function. 
In New Zealand, both iodine and selenium are insufficiently contained within local 
food supplies. Iodine deficiency was a concern in New Zealand in the early 20th 
century, but its prevalence was mostly reduced through the introduction of iodised 
salt from the 1930s (10). However, mild iodine deficiency re-emerged in the 1990s (9, 
11, 12, 13, 14). This has resulted in mandatory addition of iodised salt in commercially 
made New Zealand bread and bread products, introduced in September 2009 (15); and 
in 2010, a New Zealand government subsidised iodine only supplement (150 µg/day) 
was recommended to all pregnant and breastfeeding women (16). Subsequent studies 
have demonstrated that most school children (17, 18) and adults (19, 20) in New 
Zealand have achieved adequate iodine intake and status, but the status of pregnant 
and breastfeeding women is unclear. 
Low selenium status in New Zealand has been partially reversed by increased 
consumption of imported flour from Australia (which generally has higher selenium 
concentrations than flour produced in New Zealand) (21, 22). Previous local research, 
which investigated selenium status in postpartum women and their infants in 2001 
(23), found these women were at that time at risk of selenium deficiency (after the 
importation of flour from Australia). With continuous dietary practice changes in the 
recent decade (including consuming plant-based diets) (24), limited research has 
since investigated selenium intake and the status of postpartum women and their 
newborn infants in New Zealand. 
Health professionals closely monitor the iron status of women during pregnancy (25). 
However, after childbirth, management of iron status can be inconsistent (25). The 
general belief is that lactational amenorrhea lowers the risk of iron deficiency without 
anaemia (ID) or iron deficiency anaemia (IDA) for breastfeeding women, and their 
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iron status recovers (26). Consequently, the iron status of postpartum women remains 
largely unreported, due mainly to infrequent research studies. 
Most previous research in women of childbearing age (27) and postmenopausal 
women (28) have investigated iodine, selenium, and iron intake/status separately, or 
a combination of any two of them. However, there is little up to date data on 
investigating the status of iodine, selenium, and iron together, as all three nutrients 
are important for the synthesis of thyroid hormones. 
1.2 Thyroid function and its relation to iodine, selenium, and iron  
Studies have shown mild-to-moderate iodine deficiency could impact on thyroid 
hormone synthesis (29). Both insufficient and excess iodine intake may be associated 
with a development of goitre (enlarged thyroid gland) and thyroid autoimmune 
disease (30). Both deficient and excessive selenium intake have been linked to 
increased risk of thyroid disorders in epidemiological studies (31). Lower serum 
selenium was reported to increase risk for goitre, or possible development of multiple 
thyroid nodules, in women, rather than men (32, 33). However, the effects of selenium 
supplementation on thyroid status are not yet conclusive after several selenium 
supplementation studies on elderly populations (34, 35, 36), and pregnant women (37, 
38). The degree of effect from selenium supplementation would depend on selenium 
status at the baseline, and the dose and duration of selenium supplementation 
implemented. 
Both animal and human studies have suggested ID or IDA may impair thyroid 
metabolism (39, 40, 41). A series of intervention study investigated the thyroid 
responses of goitrous-children to one oral dose of iodised oil containing 200 mg 
iodine, where, after 30 weeks, prevalence of goitre reduced dramatically within non-
anaemic children (12%) when compared to children with IDA (64%) (42); a following-
up trial provided oral iron supplementation (60 mg, 4 times/week for 12 weeks) to 
children with IDA and observed a  further reduction  in goitre prevalence to 20%. It 
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suggested that goitrous children with IDA may benefit from concurrent 
supplementation of iodine and iron (42). 
Most women return to normal thyroid function at three months postpartum after 
prenatal increase of thyroid hormone production (4). However, globally, postpartum 
women experience abnormalities in thyroid function at twice the prevalence of the 
general population (43). Pregnant women with positive antithyroid peroxidase 
antibodies (TPOAb) are at increased risk of experiencing postpartum thyroiditis 
(PPT). Although other micronutrients, such as zinc, copper, vitamins A and D, may 
also support thyroid hormone synthesis, only iodine, selenium and iron are 
preeminently essential, and therefore, all three were selected for this study among 
postpartum women in New Zealand. 
1.3 Iodine intake and status in New Zealand 
Iodine is the key component of thyroid hormones which play an essential role in brain 
development (44). Animal studies suggest that normal brain development requires 
optimal thyroid hormones and adequate supply of iodine (39). The World Health 
Organization (WHO) has estimated that iodine deficiency is the most preventable 
cause of compromised neurodevelopment which affects around two billion people 
spread over 130 countries. Most research has been focused on children’s development 
(45, 46) rather than younger infants (aged less than two years old). Alongside the 
recognised importance of prenatal development, achieving adequate iodine status is 
crucial for postnatal development (47). 
Due to the persistent inadequacy of iodine intake, a government subsidised iodine 
only supplement (150 µg/day) has been recommended for all breastfeeding women in 
New Zealand since the year 2010. The effectiveness of such prophylaxis was 
investigated in 2011, and a pilot study indicated a low awareness of the government 
subsidised iodine supplements for breastfeeding women, with only a 35% reported 
usage of any iodine-containing supplements (48). Investigation of the current use of 
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iodine-containing supplements by breastfeeding women, and their impact on the 
iodine status of women and their infants is warranted as the most recent data was 
collected in 2011 and was only a small sample. 
1.4 Selenium and postnatal depression 
A meta-analysis of 59 studies from across the globe has reported that 13% of women 
are affected by postnatal depression (49). A 1999 postal survey of New Zealand women 
at four months postpartum (n = 224) found a higher prevalence of PND (16%) than 
the global average (50). The same study reported that approximately one quarter of 
affected women were still depressed when their infant reached their first birthday. 
Mothers were often reluctant to seek available help (50), which echoes a recent report 
from the 2015 New Zealand new mothers’ mental health cross-sectional survey (n = 
805) (51). This survey indicated a prevalence of PND was 14% and those women were 
less likely to seek help (51). Such under-diagnosed and, at times, untreated mental 
health conditions (50, 51) affect both the mother and their children’s ongoing 
cognitive, emotional and behavioural development (52). 
In addition to socioeconomic status (53), dietary patterns (54), and thyroid hormones, 
micronutrient deficiencies have been suggested to adversely affect mental health (7, 
55, 56). Results from a longitudinal prospective Canadian study (Alberta Pregnancy 
Outcomes and Nutrition, n = 475) found that women who used selenium 
supplementation during their pregnancy experienced a lower risk of having future 
postpartum depressive symptoms (57), but details on the dose, frequency and 
duration of selenium supplements were unreported, and neither was selenium status 
assessed. A few studies have examined women’s selenium status in relation to the risk 
of PND, particularly during the first postpartum year.  
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1.5 Study aims and hypotheses 
The overall aim of this PhD thesis is to investigate maternal thyroid function, 
postnatal depression, and the intake/status of iodine, selenium and iron among 
mothers and infants during their first postpartum year. 
Study 1 – Secondary analysis on the Mother and Baby Study 
Study 1 was a secondary analysis of existing data collected from the 2009/2011 Mother 
and Baby Study. The study aim was to investigate selenium intakes of pregnant, 
lactating women, and their breastfed infants, in Palmerston North, in the North Island 
of New Zealand. 
Study 2 - Mother and Infant Nutrition Investigation (MINI) 
Study 2 was a longitudinal observational study following a cohort of mother-infant 
pairs at three, six and twelve months postpartum. The study’s aims included an 
investigation of thyroid function, and its relation to the intake and status of iodine, 
selenium, and iron of postpartum women, conjointly with the risk of developing 
postnatal depression. 
The objectives of Study 2 were to: 
• investigate the role of iodine, selenium, and iron status in maternal thyroid 
function; 
• compare breastfeeding women’s iodine intake and status in iodine-containing 
supplement users and non-users; 
• examine iodine and selenium intake and status of mothers and their infants 
at three, six and twelve months postpartum; 
• determine maternal selenium status in relation to the risk of postnatal 
depression during the first postpartum year; 
• explore maternal iron status at six months postpartum. 
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Hypothesis 1: Suboptimal iodine, selenium or iron status will impede maternal 
thyroid function at six months postpartum. 
Hypothesis 2: Breastfeeding women who used iodine-containing supplements will 
achieve better iodine status for themselves and their infants. 
Hypothesis 3: Postpartum women and their infants will remain iodine deficient, 
despite two New Zealand government initiatives to improve iodine status. 
Hypothesis 4: Suboptimal selenium intake and status exist among New Zealand 
postpartum women. 
Hypothesis 5:  Selenium intakes of breastfed infants aged three and six months are 
suboptimal. 
Hypothesis 6: Low plasma selenium will increase the risk of postnatal depression at 
three, six and twelve months postpartum. 
Hypothesis 7: High prevalence of iron deficiency and iron deficiency anaemia exist 
in women at six months postpartum. 
1.6 Structure of thesis 
The thesis is presented in nine chapters. Six of those chapters are either published or 
forthcoming articles, with two submitted for publication to peer review journals which 
are currently under review. All six articles are written in the style of the journals they 
have been submitted to, however, referencing and text formatting have been modified 
to match the flow of the thesis. 
This thesis begins with an introduction (Chapter One). Chapter Two provides a review 
of literature on the prevalence of thyroid dysfunction in postpartum women, and the 
central roles of iodine, selenium, and iron in thyroid function. It reviews the intake 
and status of the three nutrients in published studies both in New Zealand and 
globally, and summarises literature focused on biological factors associated with an 
increased risk of postnatal depression. Perceived research gaps are highlighted. This 
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is followed by Chapter Three which was published in the journal Nutrients, and 
presents the results from an analysis of the data collected in the 2009/2011 Mother and 
Baby study (Study 1), which explored selenium intake in iodine-deficient pregnant and 
breastfeeding women in Palmerston North, in the North Island of New Zealand. 
Chapter Four presents the MINI (Study 2) research method which has been published 
in the JMIR (Journal of Medical Internet Research) Research Protocols, detailing 
the study cohort recruitment and data collection procedure, together with methods 
used in this longitudinal follow-up cohort study investigation. 
Results from the MINI study (Study 2) are presented in Chapters Five (Hypotheses 1 
and 7), Six (Hypothesis 2), Seven (Hypothesis 3), and Eight (Hypotheses 4, 5 and 6). 
The findings of thyroid function, including thyroid hormone concentrations and 
thyroid volumes of postpartum women, together with their interactions with iodine, 
selenium, and iron status, are discussed in Chapter Five. Chapter Six focuses on iodine 
intake and the status of breastfeeding women who used iodine-containing 
supplements, making comparisons to those who were non-users; in addition, current 
iodine knowledge and practice are discussed. This chapter has been published in the 
Biological Trace Element Research. Chapter Seven examines iodine status of 
postpartum women and their infants at three, six and twelve months postpartum. 
Further, it explores iodine partitioning in urine and breastmilk among exclusively 
breastfeeding women at three months after parturition. Chapter Eight which has been 
published in the Journal of Trace Elements in Medicine and Biology, investigates 
maternal and infant selenium intake and status during the first postpartum year and 
the relationship with postnatal depression and anxiety. 
The final discussion in Chapter Nine presents a summary of the main findings, 
strengths, and limitations from two studies, and considerations of the significant 
contribution and relevance to the subject field. Final concluding points are 
summarised, together with relevant implications for public health practice and the 
identification of future research priorities. 
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Chapter 2 Review of the Literature 
 
Chapter 2 begins by outlining the framework of the literature review. It provides a 
detailed synthesis of important early and current published literature on the prevalence 
of thyroid dysfunction in postpartum women, the physiology of thyroid hormone 
regulation and synthesis, and the central roles of iodine, selenium, and iron in thyroid 
function. 
This is followed by a review of each of the three individual micronutrients and their 
pivotal importance to health; it contains details relating to the intake and status of 
iodine, selenium and iron in published studies, both in New Zealand and globally, with 
specific reference to postpartum women and their newborn infants. The prevalence of 
postnatal depression worldwide, including New Zealand, is presented, and literature 
centred on inadequate thyroid hormones, selenium, and iron in relation to the risk of 
postnatal depression is reviewed. 
Lastly, this review summarises notable research gaps across a wide research area. These 
feed into the research hypotheses and overall design of the Mother and Infant Nutrition 
Investigation (MINI). The research objectives of the MINI study aim to direct attention 




Thyroid dysfunction is a common health issue among women (1), with a higher 
prevalence found in postpartum women (2, 3).  Most of what is understood regarding 
the role of thyroid hormones, their regulation, synthesis, and release in the body, 
comes from experiments with animals, which will be described first in detail. Current 
knowledge of the prevalence of thyroid dysfunction in postpartum women will be 
reviewed. A wealth of research has emerged investigating the central roles of 
micronutrients in optimal thyroid function. Specific literature in this section will give 
insight into the contributions made by iodine, selenium, and iron in maintaining 
adequate thyroid function. 
Literature relating to iodine, selenium and iron intake and status will then follow, each 
in turn, within the global context. For each nutrient examined in the MINI study, 
literature involving postpartum women and their infants will be carefully reviewed. 
Literature discussing the impact of iodine deficiency on brain development also will 
be included. 
One important step in investigating nutrient intake and status is the selection and 
justification of choosing assessment methods. This literature review includes dietary 
assessment and measurement of nutrient intake methods related to iodine, selenium, 
and iron. The advantages and limitations of a range of biological assessment methods 
of iodine, selenium and iron status will be discussed to clarify the choice of methods 
used in the MINI study. 
It is well established that local food supplies in New Zealand contain low iodine and 
selenium, leading to low dietary intake (4). An abundance of literature has scrutinised 
knowledge gained in the study of iodine and selenium intake and status within New 
Zealand. This review will cover available major research work completed to date and 
emerging studies currently examining the effectiveness of two government iodine 
initiatives in New Zealand populations. These initiatives include mandatory 
fortification of all bread (except organic and unleavened) with iodised salt (2009) (5); 
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and the provision of subsidised 150 µg daily iodine supplement for all pregnant and 
breastfeeding women (2010) (6). 
Finally, the literature review examines previous research regarding the prevalence of 
postnatal depression and the role played by micronutrients. The suspected role of 
thyroid function in affecting the risk of postnatal depression will also be discussed. 
2.2 Thyroid function 
Optimal thyroid function relies on the biosynthesis of adequate thyroid hormones, 
which are essential in maintaining the human body’s metabolism, temperature 
(thermoregulation), and psychological mood (7). In a developing brain, thyroid 
hormones are responsible for adequate myelination, neuron cells maturation, and the 
central nervous system development (8). Three dietary minerals: iodine, selenium and 
iron play a pivotal role in the synthesis of thyroid hormones (9, 10). As one of the main 
research objectives, this thesis examines iodine, selenium, and iron status in relation 
to thyroid function. 
2.2.1 Thyroid dysfunction in postpartum women 
Thyroid function can be altered which results in hypothyroidism (underactive 
thyroid) or hyperthyroidism (overactive thyroid). A 2014 meta-analysis of 17 studies 
from European countries reported a higher prevalence of thyroid dysfunction in 
women than men, including both overt (6% vs 1%) and subclinical (8% vs 5%) 
categories (1). Globally, new mothers are more likely to experience thyroid 
dysfunction (7-23%), when compared to a prevalence of 3-4% in the general 
population (2, 3). Maternal hypothyroidism and hyperthyroidism have been suggested 
to negatively impact on breastmilk production and milk ejection reflex (“let-down”) 
(11). Although evidence was weak, the American Thyroid Association continues to 
recommend thyroid function testing for those who experience poor lactation without 
obvious identifiable reasons (11). 
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Postpartum thyroiditis (PPT) refers to thyroid dysfunction occurring in the first year 
after parturition, including transient (temporary) hyperthyroidism, hypothyroidism, 
or both, excluding Graves’ disease (11). The prevalence of PPT, ranging from 1.1% to 
16.7%, has been reported by the American Thyroid Association in 2017 (11). Increased 
risk of PPT has been observed for those with other autoimmune conditions, such as 
diabetes mellitus type 1 (12). Women with positive thyroid peroxidase antibodies 
(TPOAb) in early pregnancy may have an 50% increased risk in developing PPT (13). 
It was postulated that the presence of thyroid antibodies such as TPOAb may link to 
an increased risk of developing PPT due to the activation of the complement system 
(14). Antenatal screening of TPOAb and/or antithyroglobulin antibody (TgAb) status 
have been suggested to be part of a cost-effective strategy in identifying risks for PPT 
(15). Measuring TgAb may be more sensitive in detecting thyroid autoimmune 
abnormalities although further evaluation on the usefulness in predicting PPT is 
required (16). 
An 80-90% of women with PPT experience a transitional period of hypothyroidism 
and have normal thyroid hormones concentrations by the end of their first 
postpartum year (11). However, women with PPT might develop permanent 
hypothyroidism or experience PPT again in each subsequent pregnancy (16, 17). A 
large prospective study screened 4384 women at six and twelve months postpartum 
from an area of mild iodine deficiency in Southern Italy and reported the incidence of 
PPT was 3.9% (169/4384), and, of these, 54% (92/169) of women continued to be 
affected by hypothyroidism at the end of their first postpartum year (18). Combined 
data from 54 Welsh women who participated in three studies between 1983 and 1995 
showed those women who recovered from the initial PPT had a 70% (9/13 examined) 
risk of experiencing a recurrence in a subsequent pregnancy (14). After examining a 
cohort of Iranian women with subclinical (abnormal TSH concentrations but fT4 
within the normal reference range) and overt (abnormal TSH and fT4 concentrations) 
PPT, undergoing T4 therapy, Azizi found that slightly more women with subclinical 
PPT developed permanent thyroid dysfunction than those with overt PPT, although 
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it was non-significant (19). However, Azizi suggested that identifying both subclinical 
and overt cases of PPT early allows timely interventions. To the best of our knowledge, 
there are no current data available regarding the prevalence of postpartum thyroid 
dysfunction in New Zealand. 
2.2.2 Thyroid hormone regulation and biosynthesis 
The thyroid gland is a butterfly-shaped endocrine organ and consists of left and right 
lobes joined by the isthmus, which is located anterior to the trachea. This gland is 
responsible for synthesising and secreting thyroid hormones, including 
triiodothyronine (T3) and thyroxine (T4). Since the receptors for both T3 and T4 are 
abundant on most human body cells, thyroid hormones can stimulate protein 
synthesis, and promote the usage of lipids and glucose for adenosine triphosphate 
(ATP) production, thus effectively accelerating the human body’s metabolism (20). To 
maintain the body’s metabolic homeostasis, thyroid hormone synthesis and secretion 
are tightly regulated by the Hypothalamic-Pituitary-Axis. For example, low levels of 
thyroid hormones in the blood stimulate the hypothalamus to release a thyroidtropin-
releasing hormone (TRH) which promotes the secretion of thyroid stimulating 
hormones (TSH) from the pituitary gland. An increased level of TSH stimulates the 
thyroid gland to secrete thyroid hormones controlled by a tightly regulated negative 
feedback mechanism; any increase of thyroid hormones detected in the blood will 
inhibit the secretion of both TRH and TSH (Figure 2.1). Therefore, the levels of thyroid 




Figure 2.1 Illustration of the regulation of thyroid hormone secretion 
Thyroid hormone synthesis involves a series of reactions which require several 
essential micronutrients, notably, iodine, selenium, and iron [Figure 2.2 (20)]. 
Initially, iodine absorbed from the diet is converted to iodide circulating in blood 
plasma. Iodide is actively transported into thyroid cells via a sodium-potassium 
ATPase pump. Upon entering the thyroid cells, iodide is oxidised into iodine by the 
reduction of hydrogen peroxide (H2O2). At this moment, iodine combines with 
tyrosine residues of thyroglobulin, a large glycoprotein, to produce precursors of 
thyroid hormones. If one iodine atom binds to a thyroglobulin, it produces 
monoiodotyrosine (Thg-MIT). If two iodine atoms bind, diiodotyrosine (Thg-DIT) is 
produced. The process of forming Thg-MIT and Thg-DIT is catalyzed by the thyroid 
peroxidase (TPO) which requires iron for its activity (21). Excess H2O2generated from 
thyroid hormone synthesis is neutralised by the actions of selenium-containing 
enzymes, such as glutathione peroxidase (GPx). Following this, Thg-MIT and Thg-DIT 
are then transported into a thyroid colloid where Thg-DIT condenses with another 
Thg-DIT molecule to form Thg-thyroxine (Thg-T4), or alternatively condenses with a 
Thg-MIT molecule to form Thg-triiodothyronine (Thg-T3). 
Lastly, newly formed Thg-T4 and Thg-T3 are released to thyroid cells via exocytosis, 
and their amino acid components are removed before T3 and T4 are released into 
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blood circulation. The concentration of T4 in blood plasma is 40 times higher than 
that of T3, but T3 is the more metabolically active form of thyroid hormone. Most T3 
and T4 are bound with transport proteins in blood; a very small portion circulates as 
free forms, which can actively bind with target cell receptors. At the target tissue, T4 
is deiodinated into T3, with the removed iodine from T4 returned to blood for later 
use (20). To enable the conversion from T4 to T3, a selenium dependent iodothyronine 
5’-deiodinase is required (20). 
 
Figure 2.2 Thyroid hormone synthesis pathways [Gropper, Smith, Groff, 2005 (20)]  
 
2.2.3 Contribution of iodine, selenium and iron to optimal thyroid function 
2.2.3.1 Iodine in thyroid function 
Thyroid function can be impaired by deficient iodine intakes. A thyroid gland from a 
healthy adult resident in an iodine sufficient area can trap 60 µg of iodine per day to 
provide adequate thyroid hormone synthesis (22). At a low threshold of approximately 
50 µg iodine intake per day, the thyroid gland also maintains adequate synthesis of 
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thyroid hormones (22). When iodine deficient, TSH secretion from the pituitary gland 
is raised, which increases the available sodium-iodide symporters on thyroid cells to 
allow a maximum iodine update. Consequently, renal clearance of iodine is reduced 
(23). However, when iodine deficiency is severe, the depleted iodine stores 
continuously stimulate the thyroid gland for hormone synthesis. This process may 
result in hypothyroidism and, at extreme levels, the development of a goitre (enlarged 
thyroid gland) via hyperplasia.  
Thyroid function can be impaired by excessive iodine intakes. Generally, excessive 
iodine intake can be tolerant by euthyroid adults (up to 2g/day without any clinical 
signs) (24). The acute Wolff-Chaikoff effect (down regulation of NIS then decreasing 
organic binding of iodine to synthesise thyroid hormones) is described as a protective 
mechanism to prevent large quantities of iodine uptake. Most people escape from this 
effect without long-term adverse consequences, and their thyroid hormone 
productions resume (25). However, people with autoimmune thyroiditis, or history of 
PPT, continue to experience the Wolff-Chaikoff effect which results in 
hypothyroidism (24, 25). A five-year epidemiological survey investigated the 
incidences of thyroid diseases presenting in three communities in China (n= 3761) 
(24). Based on the median urinary iodine concentrations (MUIC), iodine status of 
three Chinese communities was classified as mildly iodine deficient (88 µg/L), more 
than adequate iodine (214 µg/L) and severe iodine excess (634 µg/L). This Chinese 
study found no significant differences in the cumulative incidence of hyperthyroidism 
(1.4%, 0.9%, and 0.8%, respectively, P > 0.05) related to their iodine status, indicating 
that high iodine intakes may not increase the risk of hyperthyroidism (26). However, 
excessive intakes were more likely to result in hypothyroidism as the incidence of 
subclinical hypothyroidism significantly increased from 0.2%, to 2.6% and 2.9% (P < 
0.001) (27).  
To correct iodine deficiency, mandatory legislation of the provision of iodised salt 
programs were reported in 108 countries prior to May 2018 (28). Increasing iodine 
intake from fortification in a mild-to-moderate iodine deficient population may 
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temporally increase the incidence of overt-hyperthyroidism [the Jod-Basedow effect 
(28)]. Possible explanations include the existence of autonomous thyroid nodules in 
the elderly population and the presence of autoimmune disease in young adults (23, 
29). This phenomenon was demonstrated in Danish adults with mild-to-moderate 
iodine deficiency (MUIC ranged 45 -61 µg/L) by an increased incidence of 
hyperthyroidism from 102.8 (baseline in 1997-1998) to 140.7 cases per 100, 000 people 
annually soon after the introduction of iodised salt (2001-2002) (30). Further, a 20% 
increase in the incidence of overt-hypothyroidism was reported in a seven-year follow-
up study in Denmark (the period of mandatory iodine fortification) within a mildly 
iodine deficient female population aged 20-59 years (Overall population MUIC 86 
µg/L in Aalborg and 99 µg/L in Copenhagen) (31). It has been suggested to gradually 
introduce iodised salt fortification to an optimal level in a population of existing mild 
and moderate iodine deficiency (23). Even a small change of iodine intake may result 
in increasing or decreasing prevalence or incidence of thyroid dysfunction. This 
suggests the importance of continuously monitoring thyroid function after the 
establishment of an iodine fortification programme. 
Iodine supplementation has been implemented to reduce iodine deficiency for 
pregnant and lactating women, as they are at greater risk of iodine deficiency due to 
increased requirement. A few interventional studies have evaluated its effects on the 
prevalence of PPT; however, the results are inconsistent. Swedish postpartum women 
in a 1990 interventional study were allocated into two treatment groups: 0.1 mg of 
levothyroxine daily for 38 weeks (n = 18), or a 150 µg/day iodine supplement for 40 
weeks (n = 20), and a separate control group (n = 20) (32). Women in the iodine 
supplementation group developed more severe episodes of PPT when compared to 
the control, suggesting the extra iodine aggravated thyroid dysfunction, however the 
iodine status of these women was not examined at baseline. To further examine the 
effect of iodine supplementation, a randomised placebo-controlled trial was 
conducted in Denmark, a moderately iodine-deficient area (33). Euthyroid pregnant 
women (n = 72) were assigned into three groups: a 150 µg/day iodine supplementation 
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during both pregnancy and postpartum, or only during pregnancy, or given a placebo 
(supplement without iodine). No significant differences in PPT prevalence, severity, 
or duration among three groups was reported. Danish authors suggested both 
prenatal and postpartum iodine supplementation of 150 µg/day were safe (33).  
Findings may differ if these women at the beginning of the study were iodine deficient, 
a sudden increase of iodine may trigger the Wolff-Chaikoff effect which results in 
hypothyroidism (24, 25). 
Enlarged thyroid and changes in thyroid hormone levels are related to iodine status. 
The prevalence of 5% or more goitres in school children may indicate a public health 
issue of iodine deficiency within a population, based on the WHO guideline updated 
in 2014 (34). A recent population study in Denmark [the Danish investigation on 
iodine intake and thyroid disease (The DanThyr)] found that the prevalence of goitre 
(thyroid volume more than 18 mL examined by ultrasound) was as high as 33% within 
women aged 60-65 years old who had mild-to-moderate iodine deficiency (29). Iodine 
fortification has greatly reduced the rates of thyroid enlargement in the Danish adults 
who live in areas of moderate iodine deficiency pre-fortification, when compared to 
those residing in the mild iodine deficiency areas (35). Similar effects were reported 
from a study in an Italian village fifteen years after the implementation of a voluntary 
iodised salt programme, with a lower goitre rate observed at 10% post-fortification 
compared with 34% within the same cohort pre-fortification (36). Thyroid hormone 
levels (serum T3 and T4) can remain within normal ranges despite of presenting mild-
to-moderate iodine deficiency in a population (37); however, with the presence of 
moderate-to-severe iodine deficiency, TSH concentrations may be elevated, but 
would appear to be lower within a population demonstrating mild iodine deficiency 
(38). Furthermore, serum T4 decreases while T3 may be normal or slightly increased, 
because T3 is more likely to be secreted than T4 during iodine deficiency. 
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2.2.3.2 Selenium in thyroid function 
The thyroid gland is one of the endocrine tissues containing the highest level of 
selenium per mass unit (39), and a hierarchical system exists in the thyroid to 
maintain its selenium content, even in conditions of limited supply (40). The 
functional role of selenium rests with its integral part of specific enzymes - 
iodothyronine 5’-deiodinases (a family of selenocysteine-containing proteins). These 
enzymes then convert the inactive form of thyroid hormone (T4) into active 
triiodothyronine (T3), which is then subsequently released into blood circulation (20). 
Of the three types of deiodinase (type I, II and III), type I is the most sensitive to 
selenium deficiency (41). Selenium as a component of the glutathione peroxidase 
(GPx) protects the thyroid from oxidative damage (41). 
Experimental studies in rats have been undertaken to determine the role of selenium 
deficiency interacting in iodine metabolism, which continues to affect thyroid 
function. An animal study from Dumont’s group suggested selenium and iodine status 
both contribute in thyroid hormone synthesis but fail to model co-deficiency in 
thyroid degeneration (42). Their data reported selenium deficient rats had decreased 
thyroid GPx activity, but a protective effect from selenium deficiency was observed on 
the thyroid gland (reduced thyroid weight and increased serum T3 and T4) in the 
animal model (42). Further histological analysis on the thyroid tissue of rats having 
iodine and selenium co-deficiency, evidenced an increased thyroid fibrosis and 
proliferation of thyroidal epithelial cells. This phenomenon suggested the existence of 
a possible connection between selenium deficiency and myxedematous cretinism (a 
type of cretinism characterised by mental retardation and hypothyroidism) (43). 
Previously, human evidence was reported of the coexistence of selenium deficiency 
and iodine deficiency in Zaire, Central Africa in the 1980s (44, 45, 46). In an area of 
high endemic goitre and cretinism, lower serum selenium and plasma GPx were 
recorded, compared to those residing in non-endemic areas. This presented evidence 
that selenium deficiency may modulate negative effects from any iodine deficiency. 
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Combined iodine and selenium deficiency may be an etiologic factor in the 
pathogenesis of endemic myxedematous cretinism, which remains highly prevalent in 
Central Africa (46, 47). During iodine deficiency, the production of hydrogen peroxide 
is increased due to the stimulation from TSH on the thyroid during hormone 
synthesis. Deficiency of selenium results in a negative impact of the GPx defense 
mechanism (protecting the thyroid gland from excessive hydrogen peroxide 
production). Concurrent selenium deficiency reduces the negative effect of low active 
thyroid hormone from iodine deficiency affecting the brain, the proposed diagram 
(Figure 2.3) suggests a mechanism for the development of myxedematous cretinism 
in combined selenium and iodine deficiency (41). 
 
Figure 2.3 A mechanism for the development of myxoedematous cretinism [Arthur, 
Beckett, Mitchell, 1999 (41)] 
Both cross-sectional and interventional studies have investigated the relationship 
between selenium status and thyroid function in adult, elderly, and pregnant 
populations. Within mild iodine deficiency areas, lower serum selenium was reported 
to increase the risk of enlarged thyroid glands or possible development of multiple 
thyroid nodules in women, rather than in men (48, 49). A small sample placebo-
controlled Italian trial of elderly persons aged over 85 years (n = 36) found a marked 
decrease in serum total T4 (67 vs 62 nmol/L), but not in free T4 (9.4 to 9.3 pmol/L) 
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after supplementation of 100 µg selenium (sodium selenite) daily for three months, 
giving the baseline mean serum selenium as 66 µg/L, raised to 106 µg/L after 
supplementation (50). However, a randomised double-blinded placebo-controlled 
trial of selenium supplementation in UK elderly participants (n = 501) reported no 
significantly measurable beneficial effect on the conversion from T4 to T3, despite 
consumption of 100, 200 or 300 µg daily for six months (51). This observation could be 
explained by selenium status at baseline (mean plasma selenium of 91 µg/L) being less 
likely to impact on the activity of the iodothyronine deiodinases. Pregnant women 
with positive TPOAb are more likely to develop PPT, selenium supplementation may 
reduce such incidence by decreasing inflammation activity (52). A randomised 
placebo-controlled Italian study reported women in their first trimester with positive 
TPOAb had a lower incidence of PPTs (28.6%), compared to 48.6% in the non-
supplementation group, after supplementing with selenium as selenomethionine at 
200 µg/day during both pregnancy and their postpartum period; however, the result 
still warrants further examination concerning the aspect of reverse-effects after 
stopping supplementation (52). Of interest, study subjects were advised to use iodised 
salt, but iodine status was not measured and remained unconfirmed, as deficiency of 
both iodine and selenium may impair thyroid function.  
Low levels of selenium are found in New Zealand soils, leading to low levels in the 
food supply (53).  The effects of selenium on thyroid status have been examined in 
New Zealand following instances of inadequate selenium status reported by 
Robinson’s trace element research group from Dunedin (53, 54). Based on the data 
from five different local studies of adults aged 18-68 living in the South Island, New 
Zealand, between 1993 and 2001 (55), it was suggested that selenium levels were 
borderline in maintaining optimal function of selenoproteins, as they exerted only a 
minor effect on serum T4 levels and T3:T4 ratios after supplementation. To explore 
further the effect of iodine and selenium supplementation on thyroid function, a 
randomised placebo-controlled trial was conducted in a group of moderately iodine 
deficient (MUIC as 48 µg/L) volunteers aged 60-80 years (n = 102) (56). The 
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participants were given a treatment of selenium solely (100 µg L-selenomethionine); 
or of 80 µg iodine solely; or with a combination of both iodine and selenium 
supplements; or a placebo for three months. No additional beneficial effect from 
either selenium supplementation in improving the thyroid hormone status was 
observed, apart from an increase in plasma selenium and whole blood GPx activity 
(56). The mean plasma selenium at baseline was 95 µg/L, so the deiodinases activities 
were likely maintained with less effect on thyroid function (56). Any effect of selenium 
supplementation on thyroid status among the elderly is yet to prove conclusive. 
Further studies are required to identify and understand as to what extent current 
selenium status might interact with mild iodine deficiency in relation to thyroid 
function.  
2.2.3.3 Iron in thyroid function 
Iron is another essential trace element believed to play an important role in thyroid 
hormone metabolism. Animal studies of iron deficient anaemic rats by Beard, Tobin 
and Green (1989) suggested an impaired response in thyroid hormone regulation, 
where, for example, rats failed to respond appropriately to TRH stimulation, resulting 
in decreased plasma levels of T3 and T4 (57). In addition, decreased activity of hepatic 
iodothyronine 5’-deiodinase was observed in severely affected iron deficient anaemic 
rats (57), which may result in a decreased production of T3. Furthermore, a randomly 
controlled trial provided strong evidence that the activity of TPO (a haem-iron 
dependent enzyme which enables the addition of iodine to tyrosine residue for thyroid 
hormone synthesis) reduced markedly within food-induced iron deficient anaemic 
male rats when compared to the controls in situ. The study used pair-fed controls to 
distinguish lower effects of serum thyroid hormones from reduced food intake due to 
iron deficiency anaemia (IDA) (58). 
Human studies have also suggested that iron deficiency without anaemia (ID) or IDA 
may impair thyroid metabolism. For example, lower T3, T4 and increased TSH were 
observed in subjects with moderate-to-severe IDA (haemoglobin < 75 g/l) (59) and 
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mild IDA (75 g/l < haemoglobin < 110 g/l) (60). Observational studies from Ethiopia 
and Philippines found no differences in goitre rate assessed by palpation of an 
enlarged thyroid gland (one of the measures for iodine deficiency) between anaemic 
and non-anaemic children (61, 62), pregnant and lactating women (62). However, 
anaemic status in these two studies were not classified as IDA which may due to 
deficiencies in folate, zinc, or vitamin B 12. Research has investigated the interaction 
between iron deficiency and goitre rate. An Iranian school children study reported a 
higher goitre rate (3.8 times, measured by palpation) in children with low serum 
ferritin (< 12 µg/dL), when compared to those with normal serum ferritin (63). 
One interventional study in the Ivory Coast investigated the thyroid responses of 
goitrous-children with IDA to iodine supplementation. Firstly, goitrous-children aged 
6-12 years were supplemented with one dose of 200 mg oral iodine; after 30 weeks, 
children without anaemia gained a higher percentage of thyroid volume reduction 
(45%) compared to children with IDA (22%), and the prevalence of goitre was 12% 
compared to 64% in children with IDA (64). This result indicated IDA may reduce the 
effectiveness of iodine prophylaxis. From the beginning of 30 weeks, children with 
IDA were provided with 60 mg oral iron supplementation (4 times/week for 12 weeks), 
and, at 65 weeks, thyroid volume reduction was observed to be 38%; the overall 
prevalence of goitre was reduced to 20% when compared to non-anaemic children 
(12%) (65). However, the diets of the children were not controlled, although the 
nutritional status (height, weight, and growth) was measured during the trial; there 
was no control group arranged for anaemic children without iron treatment. By the 
end of the trial, the group of goitrous children with IDA remained at a higher goitre 
rate, and the research results suggest that goitrous children with IDA may benefit 
from concurrent supplementation of both iodine and iron. 
A subsequent nine month randomised double-blind control trial by the Zimmermann 
group provided dual-fortified salt (DFS) containing 25 µg iodine and 1mg iron per 
gram of salt to iodised salt given to 6-15 years-old goitrous Moroccan children who 
had a high prevalence of IDA at 25-35% (such fortification achieving 150-250µg/day 
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iodine or 7-12 mg/day iron) (66). The study found a higher reduction of thyroid 
volume (38%) at 40 weeks among children receiving DFS, when compared to the 
iodised salt-only group (18%) (66). This dual fortification trial confirmed that 
concurrent supplementation with iron and iodine may achieve a reduction of both 
goitrous and iron deficiency in such vulnerable groups of children. A recent study of 
reproductive aged women with IDA in Turkey (a country with mild iodine deficiency) 
subsequent to a six-month oral iron supplementation (100 mg elemental iron per 
capsule, twice a day) reported a decreased mean thyroid volume at 13 mL, when 
compared to the baseline of 17 mL (67). However, selenium status remained untested 
during the clinic trials on school children and women detailed above. 
Although other micronutrients such as zinc, copper, vitamin A and vitamin D may 
also support thyroid hormone synthesis. In New Zealand, traditionally, iodine and 
selenium intakes are inadequate, and iron deficiency and iron deficiency anaemia are 
present in women at reproductive ages. Therefore, these three nutrients were selected 
for investigation among postpartum women in this MINI study. 
2.3 Iodine 
Iodine plays a role in adequate thyroid hormone synthesis enabling optimal thyroid 
function in the body. Iodine deficiency can result in a broad spectrum of disorders – 
Iodine Deficiency Disorders (IDD), including hypothyroidism, hyperthyroidism, 
goitre, physical development retardation, and cretinism) (68, 69). IDD are prevalent 
in many countries of the world and is mostly associated with inadequate dietary iodine 
intake, which affects all ages and stages of human life. 
2.3.1 Iodine and health 
Knowledge of the impact of iodine deficiency on brain development has expanded 
over the last 30 years (70). Animal studies have confirmed that normal brain 
development requires optimal thyroid hormones which rely on an adequate supply of 
iodine (70). In humans, iodine is essential for growth and development during the 
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prenatal period and the first two to three years postnatally. Iodine deficiency has 
resulted in 11.2 million individuals in the world experiencing cretinism (a condition of 
impaired growth, defects of hearing and speech, and brain damage) and a further 43 
million people with different levels of mental impairment in the 1990s (71). The latest 
evaluation of global iodine nutrition (2020) from 194 WHO members reported that 28 
countries remained iodine deficient (72). Where there is severe iodine deficiency 
occurring in utero, children and adolescents may develop neurological cretinism 
(severe mental retardation with euthyroid) rather than hypothyroid cretinism 
(dwarfism, myxedema and skeletal retardation with severe hypothyroidism) (22); even 
mild iodine deficiency in uterus can have long-term negative effects on brain 
development, such as poor academic performance in school children (73, 74). 
Meta-analysis enquiries from 18 observational and experimental studies (published 
between 1969 and 1990) reported populations aged from infancy to adulthood who 
were living in iodine deficient areas have been reported to have a mean of 13.5 
intelligence quotient (IQ) points lower than those present in non-iodine deficient 
groups, based on the assumption that the scores in both groups exhibited normal 
distributions (75). Authors of this meta-analysis questioned whether the score for the 
iodine-deficient group was able to be normally distributed and called for further 
studies. Another meta-analysis based on 37 studies of Chinese children aged under 16 
years, reported a reduction of 12.5 IQ points among children being exposed to severe 
iodine deficiency, when compared to children living in iodine sufficient areas (76). 
Results from the Chinese meta-analysis also showed an increment of the IQ points (12 
Raven points or 17.25 Binet IQ points) of children born 3.5 years after the introduction 
of an iodine supplementation programme (75). 
A number of human cohort studies have reported that mild or moderate iodine 
deficiency during pregnancy has resulted in impaired/delayed neurodevelopment in 
utero and the consequences were detected at infancy (77) and also at ages of eight to 
nine years (73, 74). A 2018 population-based prospective cohort study of 851 
Norwegian mother-infants measured maternal urinary iodine concentrations (UIC) 
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and infant neurodevelopment at 6, 12 and 18 months (assessed by Bayley Scales of 
Infant and Toddler Development, Bayley-III) (77). The authors found evidence of poor 
communication skills by infants aged 18 months who were born to mothers with mild 
iodine deficiency. Studies from two other large cohorts – the Avon Longitudinal Study 
of Parents and Children (ALSPAC) in the United Kingdom (UK) (73) and the 
Gestational Iodine Cohort Australia (74) investigated maternal UIC during early 
gestation in relation to children’s later educational outcomes. In the first study, 
children’s long-term neurodevelopment was assessed by verbal IQ at eight years of 
age, reading accuracy, and comprehension assessed at nine years of age (UK); and, in 
the second study, school-based Australian academic performance was assessed based 
on the Australian numeracy and literacy curriculum, only literacy measures were 
associated with maternal UIC. In both studies, many adjustments were made 
including maternal and paternal education and occupation, home and family 
situations, life events as well as maternal age, gestational age, and birth weight, 
however, maternal IQ was not adjusted for evaluating neurodevelopment of their 
children.  In contrast, another Australian study in Adelaide, after adjusting for 
maternal IQ, failed to find any association between maternal UIC and children’s 
neurodevelopment outcomes (Bayley-III) at the age of 18 months (78). This Adelaide 
study also found children born to women with both high (≥ 391 µg/day) and low (< 
220 µg/day) iodine intake in pregnancy (assessed by a validated iodine food frequency 
questionnaire) showed poor neurodevelopment outcomes (cognitive, language and 
motor scores) (78). A large Norwegian study (MoBa)  found that inadequate maternal 
iodine intake during early gestation (assessed from a food frequency questionnaire) 
was associated with delayed children’s language skills at the age of three years (79) 
and poor school performance at the age of eight years based on maternal self-
reporting scores (78). These epidemiological studies discussed are well-designed and 
have shown clear association between mild iodine deficiency in utero and impaired 
neurodevelopment remained after adjusting a comprehensive range of confounders. 
However, assessing neurodevelopment is challenging as different tools (both objective 
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and subjective) are used.  Iodine is required for the neurodevelopment during 
gestation, it is inconclusive how much iodine is sufficient or excessive in terms of 
optimal neurodevelopment.  
Most research studies have focused on school children’s development rather than 
investigating younger infants (those less than two years old). The World Health 
Organization estimates that iodine deficiency is the most preventable cause of brain 
damage which affects around two billion people living in over 130 countries (70). The 
most recent up-to-date meta-analysis combined data from population-based birth 
cohorts - Generation R (Netherlands), INMA (Spain), and ALSPAC (United Kingdom) 
between 1990 to 2008, using iodine-to-creatinine ratio (µg/g) as an indicator of 
maternal iodine status during the first trimester. Findings suggest that infants born to 
women with a low urinary iodine creatinine ratio until 14 weeks gestation, were more 
likely to have a low verbal IQ score (80). The researchers indicated achieving optimal 
iodine status during the early gestational period remains critical in 
neurodevelopment. However, the first 1000 days of life is designated a “window of 
opportunity” for optimal growth and development (81). Therefore, preconception 
period and the first two years after birth are also crucial in support optimal 
neurodevelopment by achieving adequate iodine supply, which may require further 
research investigation. 
2.3.2 Iodine intake and status 
An individual’s iodine intake depends on the type and amount of iodine-containing 
food and/or water regularly consumed. The personal choice of consuming iodised salt 
can vary considerably from day to day, excluding those living in countries where 
iodisation of salt is mandatory. Food sources and water may vary in their iodine 
content due to natural reasons, such as region of origin, seasonal variation, and 
fortified food versus unmodified (82). Regular consumption of iodine-containing 
supplements may contribute to daily iodine intake. 
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2.3.2.1 Food sources 
Iodine content in food can vary between countries and differ when sourced from 
different regions of the same country. In general, fish, seafood, and plant material 
from the sea (high concentration of iodide in sea water, 50 µg/Liter) usually contain 
higher levels of iodine in comparison to other food sources, such as poultry and meat. 
Milk and dairy products are the major contributors to iodine intake due to their 
moderate concentration of iodine and frequent daily consumption in many 
Westernised populations. The iodine contribution from plant and animal foods 
depends on iodine taken up from local soil, water used for irrigation, fertilisers and 
livestock feed. However, soils in New Zealand typically provides low levels of available 
iodine, which results in low iodine concentrations in locally grown foods (83). 
In New Zealand, important dietary sources are fish and shellfish containing varied 
iodine concentrations ranging from 24 to 130 µg/100 g (84). The next highest iodine 
concentration occurs in eggs, due to most poultry feeds being supplemented by trace 
minerals including different farming types (battery, free-range, barn laid) (85). From 
the 1960s, iodophors were used to sanitise milking machines and related equipment 
in the local dairy industry; as a result, milk and other dairy products made a significant 
contribution to the iodine intake within a typical New Zealand diet. Concern over 
contamination led to reduced use of iodophors from the early 1970s (86), for example, 
the iodine concentration in trim milk decreased from 0.44 mg/kg in 1978 to 0.10 mg/kg 
in 2009 (84). The reduced iodine content in milk has contributed to the more recent 
inadequate iodine intake re-emerging within New Zealand in the 1990s (83, 85). 
Table 2.1 illustrates the changes of iodine concentration in food from the 1920s 
through to the 2000s, reported from an ongoing series of the New Zealand Total Diet 
Survey (84, 87, 88, 89). The changes observed over the time (between 1920s and later 
times) may be that recent methods are more sensitive in detecting iodine, or changes 
in iodine concentrations in the samples of individual food items assessed, for example, 
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lamb-mutton composite sample examined in 2016, or mandatory fortification of 
iodised salt in bread.  
Iodised table salt was introduced from the 1930s in New Zealand, which had reduced 
the goitre rates by the 1950s (85). However, public health messages have led to reduced 
salt consumption to prevent high blood pressure and reduce the risks of other chronic 
medical conditions. Another possible contributor is the recent shifting from 
traditional home cooking with iodised salt to commercially prepared food containing 
non-iodised salt (90). Modern dietary choices have expanded to include other 
conventional salts containing minimum levels of iodine, for example, pink salt, rock 
salt, and herbal salt, reducing the iodised salt intake even further. A proportionate to 
population sized survey of New Zealand school children from Dunedin and 
Wellington found half of the children did not use iodised salt at the table, and this 
was coupled with a low use of iodised salt in cooking within the household (85). 
Although iodised salt is not considered to be a major contributor to iodine intake, for 
those who regularly consume iodised salt, its contribution cannot be ignored.  
More recently, to combat iodine deficiency, mandatory fortification of bread with 
iodised salt (25-65 mg iodine/kg salt) was introduced in New Zealand in September 
2009, applying to all commercial bread other than organic and unleavened. A post-
fortification study from the Ministry for Primary Industries measured iodine 
concentrations in all bread in 2012 (91). The median iodine concentration of bread 
requiring fortification ranged between 30.1 and 45.9 µg/100 g; this was in contrast to 
1.6 µg/100 g within bread without fortification (91). Comparison of fortified bread with 
pre-fortification values based on the Concise New Zealand Food Composition Tables 
8th edition (2009) (92) (Table 2.2) shows a dramatic increase of iodine concentration 




Table 2.1 Iodine content (µg/kg) of New Zealand foods 
Food 1920s 2003-2004 2009 2016 
Animal food   
Fish, canned 360 130 180.1 182 
Fish, fresh 50-96 216 237 211 
Oysters 880 970 1298 1171 
Meat, bacon 15 11 16 35 
Beef 13 7-10 9-16 5-11 
Mutton/Lamb 10 32 10.6 294-297a 
Eggs 94 519 465 544 
Dairy, milk 20 86-96 94-103 78 
Cheese 31 63 61.4 44 
Cereal foods   
Bread, white 2 3.2 2 388b 
Bread, brown 12 4.8 13 414b 
Rice, white < 8 3.1 1.2 2-11 
Fruits and vegetables   
Apple 6 2 14 3 
Orange 2 2.1 2.3 1 
Tomato 8 1.1 1.0 0-2 
Carrot 8 4.4 17 7 
Kumara 3 2.9 2.3 3-4 
Lettuce 17 10.9 2.2 1-2 
Potato with skin 22 6.8 6.1 4-5 
Silver beet 27 27 16 9 
a
 This result was from a single lamb-mutton composite sample, and sheep may receive iodine supplementation, but meat from this area 
is rarely for human consumption. 
b 




Table 2.2 Iodine content (µg/100 g) of New Zealand foods (pre- and post-fortification). 
Bread and bread product category Median Iodine (µg/100 g) 
Pre-fortification  
Median Iodine (µg/100 g)  
Post-fortification 
Bread rolls, white 0.3 53.5 
Bread rolls, mixed grain 1.2 41.1 
English style muffin n/a 43.9 
Fibre white n/a 49.3 
Hamburger buns n/a 51.1 
Organic and unleavened n/a 1.6 
Pita bread 0.5 27.7 
Pizza bases 0.3 0.5 
White 0.3 41.3 
Whole meal 0.5 38.8 
 
After the government iodine fortification initiative, studies of school children in New 
Zealand found that bread contributed 28% of iodine intake immediately after 
fortification (93), it increased to 51% six years later (94). These studies concluded that 
mandatory fortification successfully improved iodine intake assisting New Zealand 
school children to reach adequate levels. The data from New Zealand Ministry for 
Primary Industries in 2016 have suggested that iodine intake for women of 
childbearing age also achieved adequacy (95). Consequently, bread has been 
estimated currently to be the primary dietary source of iodine now contributing to 
most adult diets, as evidenced in the 2016 New Zealand Total Diet Survey (89). 
However, such fortification may not always provide sufficient iodine for pregnant and 
breastfeeding women due to their increased requirements. To assist, in 2010, the use 
of government subsidised iodine-only supplements (150 µg/day) was recommended 
to all pregnant and breastfeeding women in New Zealand (96). A 2011 study in 
Palmerston North, New Zealand, indicated that there was a low awareness of this 
supplementation initiative for breastfeeding women, with only 35% of the women 
reporting use of any iodine-containing supplements (97). Low use of iodine-
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containing supplements among both pregnant and lactating women was similarly 
reported in the United States (98). Recently, a cross-sectional study of over 110 
pregnant Australians reported that only 58% consumed iodine-containing 
supplements  (150, 200, 250 or 300 µg/day) (99), which was similar to 66% reported 
by a Western Australian study of 425 pregnant participants in 2012/2013 (ranging from 
38-500 µg per day) (100). In New Zealand, government subsidised iodine-only 
supplements can be purchased on prescription and a range of dietary supplements 
containing iodine are available over the counter. Consumers, however, easily may 
become confused as to which may be the most appropriate product for their own 
personal circumstances. Women on a tight budget may not be able to afford the cost 
of government subsidised iodine-only supplements outside the free antenatal care 
period of six weeks after birth as offered by their registered General Practitioners 
(GPs). A New Zealand supplementation study reported that 13% of women who were 
prescribed with government subsidised iodine-only supplements did not fill their 
individual prescription (need to be paid) (101). Further investigation is warranted to 
determine current use and barriers to use iodine-containing supplements and their 
effect on iodine intake. 
2.3.2.2 Dietary inhibitors of iodine metabolism - goitrogens 
Goitrogenic compounds can block iodine uptake by the thyroid gland, thus interfering 
with thyroid hormone synthesis, release and utilisation. These compounds are found 
in several natural food items. High consumption of cruciferous vegetables such as 
cabbage, kale, broccoli, cauliflower, turnip, brussels sprouts, cassava, lima beans, 
linseed, sorghum, and sweet potato are associated with a higher consumption of 
goitrogens. Diets rich in these foods may contribute to an increased risk of goitre and 
other IDD among people who reside permanently in iodine-deficient areas (22, 102). 
Isoflavones are other substances which may impair TPO activity and thus inhibit 
thyroid hormone formation (103). The main dietary sources of isoflavones include soy-
based food, peas, and millet. In animal models, it has been shown that soy’s anti-
thyroid effects are more marked when iodine deficiency exists (104). In humans, 
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infants fed with soy-formula without added iodine have been shown to develop goitre 
or hypothyroidism which can be alleviated and corrected by iodine supplementation 
(104). However, isoflavones are believed to have negligible effects on the thyroid 
function of healthy adults (22, 103), but their impact on other groups, such as people 
who have mild iodine deficiency, or those who have an extremely high level of 
consumption of soy products, remains unclear (105). 
In addition, another goitrogenic exposure is tobacco smoke. It is believed that 
thiocyanate content in tobacco smoke decreases breastmilk iodine concentrations in 
women who smoke during their pregnancy (106), or during lactation (107). This 
phenomenon was explained by smokers accumulating thiocyanate in their blood and 
tissues, which inhibit the sodium-iodide symporters (NIS) in the mammary gland and 
result in blocking iodine from being secreted into breastmilk. Overall, it is important 
to assess goitrogenic food consumption/tobacco smoke exposure when evaluating 
iodine intake, since the negative effects from goitrogenic factors may depend on the 
quantities of consumption/exposure and their background iodine intake. 
2.3.2.3 Requirement of iodine intake 
The Estimated Average Requirement (EAR) of iodine for adult men and non-pregnant 
non-lactating women are 100 µg/day to adequately maintain iodine in blood plasma 
and sufficient storage in the thyroid gland (86). The Nutrient Reference Values (NRVs) 
for Australia and New Zealand recommends the EAR and Recommended Dietary 
Intake (RDI) are 160 µg/day and 220 µg/day respectively for pregnant women (86) 
(Table 2.3). 
During lactation, iodine is required to fulfil maternal thyroid function, and be secreted 
into breastmilk to ensure adequate iodine for optimal infant thyroid function. Studies 
have suggested that the mammary glands are able to concentrate 20-50 times more 
iodine than maternal blood due to the active NIS (108). The secretion of iodine into 
breastmilk is influenced by prolactin, oxytocin and oestradiol (108). A lactating 
woman may secrete 75-200 µg iodine a day via 0.5-1.11 L breastmilk daily up until six 
58 
 
months postpartum; thus, the daily iodine requirement is estimated at 225-350 µg/day 
(71). However, the NRVs from Australia and New Zealand suggested an extra 90 
µg/day secretion of iodine throughout breastmilk and suggest 190 µg/day as the EAR 
value for lactating mothers (86) and an RDI of 270 µg/day (Table 2.3). 
Breastfed infants depend on the iodine content in breastmilk for thyroid function and 
to build up reserves in their thyroid gland during the first six months of life (108). 
There are slight differences in the recommendations for adequate intake of infants 
aged 0-6 months among advice from the WHO (109), the Institute of Medicine (IOM) 
(110), and the NRVs from Australia and New Zealand. For example, the NRVs assume 
an average breastmilk intake of 0.78 L/day and an average iodine concentration in 
breastmilk at 115 µg/L, and this suggests that 90 µg/day is adequate to ensure a positive 
iodine balance in growing infants (86), when compared with the higher IOM 
recommendation of 110 µg/day (109, 110). 
For a population to have a very low prevalence of inadequate dietary intake, the 
mean/median intake should be above the RDI; while the percentage below the EAR 
approximates the proportion that is at risk of dietary inadequacy, according to the 
EAR cut-point method (111, 112).  
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Table 2.3 Dietary Reference Intakes for iodine (ug/day) by age or population group 
AI = Adequate Intake; RDA = Recommended Dietary Allowance.  
 
2.3.2.4 Assessment of iodine intake 
The following discussion highlights how iodine intake can be assessed by using several 
dietary assessment methods, including estimated/weighed food records (dietary 
diaries), food frequency questionnaires (FFQs) and repeated 24-hour dietary recalls.  
Food records are used to measure actual food intake at the time of consumption rather 
than relying on respondents’ memory. Weighed food records are commonly treated 
as a gold standard method to accurately assess the dietary intake and can be frequently 
used as a validation tool for other methods (113, 114). However, it adds a huge burden 
to respondents as they are required to record all food items including names, brands, 
preparation methods, and accurately measured quantities at the time of consumption 
over a specific given period (115). It is more expensive to administer since adequate 
measurement equipment needs to be used as well as hard copies of the food record 
instruction booklets. It can be difficult when respondents dine at restaurants, buy 
takeaways, or simplify the recording by altering their normal diet. Furthermore, 
motivated study subjects are more likely to collect precise dietary information. Most 
Age or population 
group 
NRVs  
Australia and NZ 
(86) 





Infant 0-6 months 90 (AI) 110 (AI) 90 
Infant 7-12 months 110 (AI) 130 (AI) 90 
Children 1-8 yr 65 (EAR) 90 (RDI) 65 (EAR) 90 (RDA) 120 
Children 9-13 yr 75 (EAR) 120 (RDI) 73 (EAR) 120 (RDA) 120 
Children 14-18 yr 95 (EAR) 150 (RDI) 95 (EAR) 150 (RDA) 150 
Adults >19 yr 100 (EAR) 150 (RDI) 95 (EAR) 150 (RDA) 150 
Pregnancy 160 (EAR) 220 (RDI) 160 (EAR)  220 (RDA) 250 
Lactation 190 (EAR) 270 (RDI) 209 (EAR) 290 (RDA) 250 
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recently, since the availability of mobile-based devices increased dramatically, new 
approaches have been developed to assess dietary record digitally, for example e-CA 
(an electronic mobile-based food record) (116). Such a tool has been suggested by 
researchers to reduce respondents’ burden and food data entry errors. However, 
further validation studies are required to assess and confirm their frequent usability. 
FFQs have been developed and validated to assess iodine habitual intake in a range of 
populations in different countries as it reduces burden on respondents and is less 
expensive to administer, when compared to dietary recalls and food records. High 
iodine content food items and foods containing iodine that are known to be frequently 
consumed by a certain population are included in the FFQ. Frequency is assessed by 
providing categories based on days, weeks, and months. Standard portion sizes are 
usually well-defined in a questionnaire so that total iodine intake per day can be 
estimated. FFQs are either administered by a personal interviewer or made available 
as a self-completion online or paper-based questionnaire. For instance, researchers 
have used iodine specific FFQs to assess dietary iodine intake among New Zealand 
school children (117) and adults (118), and pregnant women in Australia (113). However, 
information collected from FFQs relies heavily on respondents’ memory and cognitive 
ability to record retrospective data (115). Consequently, the overall accuracy of FFQs 
needs to be validated in conjunction with other more accurate dietary methods or 
biomarkers, for example, urinary iodine concentration or serum thyroglobulin 
The 24-hour recall is another dietary method carrying a low respondent burden and 
limited opportunity to change diet, especially if respondents are not pre-warned of 
the interview. However, this approach requires respondents having a good memory 
and some suitable ability to estimate portion sizes, along with an experienced 
interviewer to conduct the procedure. Extra assistance in estimating portion sizes is 
usually given by using photographs of foods, food models and providing household 
measuring cups, spoons and rulers which may all improve the quality of dietary data 
collected via 24-hour dietary recalls (119). This method has been often used with large 
representative population studies to assess average usual intake, for example, the New 
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Zealand National Nutrition Surveys (120) and the U.S. National Health and Nutrition 
Examination Survey (121). 
Despite the strengths and weaknesses of each dietary assessment method as described 
above, both under- and over-reporting remain of concern. To eliminate under-
reporting, the Goldberg cut-off method is commonly used to compare an individual’s 
energy intake with their basal metabolic rate based on age, weight, gender; excepting 
those who are purposely restricting food intake to manage body weight (122). Here, it 
is also important to note that adequate administration of any dietary assessment 
method and appropriate nutrient levels in an up-to-date food composition table is 
essential to achieve relatively adequate dietary intake data. 
It can be challenging to select an appropriate dietary assessment method which best 
suits the objectives of the study and a specific participant group, and to then balance 
the respondents’ burden with the required accuracy of the data collection. In the 
current study, FFQs were carefully selected to collect habitual iodine and selenium 
intake data. Weighed food records (dietary diaries) were used to evaluate participants’ 
current whole dietary intake, including iodine, selenium, and iron intake. The food 
records also may be used to validate the iodine-selenium specific FFQ which was 
adapted from one previously used in an Australian study (113). 
There are further challenges in estimating iodine intake. Due to a wide coverage of 
the iodised salt fortification programme, iodised salt may be a major contributor to 
overall iodine intake. However, it is difficult to accurately measure iodised salt 
consumption; accordingly, often a set amount is usually added. In New Zealand, 48 
µg iodine [equivalent to the consumption of 1 g discretionary iodised salt (48 mg 
iodine/kg salt)] was added to an individual’s daily dietary intake (118), for those who 
reported regular use of iodised salt at the table, or in cooking. Although the Concise 
New Zealand Food Composition Tables (12th Ed) has included iodine content in food 
items (90), the iodine content in bread has yet to be updated (91). In addition, this 
database has not been updated frequently to match the fast-changing food items more 
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recently available in the market and contains mostly data from the United Kingdom 
and the United States. Iodine content in those overseas databases may not accurately 
reflect local New Zealand food items. A call for a well-constructed iodine food content 
national database (including major dietary contributors from food, beverages, and 
supplements) has been made to improve the understanding of iodine intake patterns 
for both individuals and wider populations (90). 
2.3.2.5 Assessment of iodine status 
Measurement of urinary iodine 
Iodine absorbed through the diet is excreted mostly via urine, and the urinary iodine 
content reflects recent iodine intake. Iodine concentrations in spot urine (single void) 
samples (expressed as UIC µg/L) and a 24-hour urinary collection (expressed as UIE 
µg/day) can be measured to evaluate iodine status. Both measures may not be used as 
an indicator of an individual’ iodine status due to the variations of daily (123) and 
seasonal iodine intake (124). Iodine concentration in spot urine samples are also 
influenced by fluid intake (125, 126) and diurnal iodine secretion (127). Therefore, a 
single UIC value is limited in assessing an individual’s current iodine status. Ten 
repeated spot urine samples of UIC are needed to obtain an accurate measure of 
individual iodine intake (128). In comparison to spot urine iodine concentration, the 
24-hour urinary iodine excretion is not affected by diurnal and hydration variations 
over the day of measurement, but daily variation and seasonal difference of intakes 
remain. Obtaining a complete collection of urine over a single 24-hour period is 
challenging, due to the personal inconvenience for subjects and difficulty in ensuring 
accuracy, particularly in field research settings. Proving that compliance criteria have 
been fully met over a 24-hour period, urine sample collection is not easy to monitor, 
as subjects may unintentionally miss completing some collections. Spot urine samples 
are easier to obtain and cause less respondent burden during data collection. Recently, 
age and gender adjusted iodine creatinine ratio has been recommended for use by 
adults to allow correction for hydration status (129, 130). For example, in a Danish 
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pregnant and lactating women’s study, urine creatinine concentration was used to 
level out the fluctuations in the UIC caused by the timing of spot urine samples (131) 
and to estimate total 24-hour urinary iodine excretion (126). 
At population levels, UIC is a useful biomarker when specimens are collected from a 
large representative sample of a target group to lessen any inter- and intra-individual 
variations. The median value of UIC (MUIC) as µg/L is more commonly published, 
since most urinary iodine values are not normally distributed. In this respect, the 
World Health Organization, International Council for Control of Iodine Deficiency 
Disorders (ICCIDD), and the United Nations Children’s Fund (UNICEF) (2007) have 
summarised the epidemiological criteria for assessing iodine status based on the 
MUIC established for different subgroups [see Table 2.4, (132)]. Of note, lactating 
women, and children less than two years old, with MUIC less than 100 µg/L, will be 
classified as having insufficient iodine intake. 
Measurement of thyroid hormones 
As part of the body’s negative feedback system used to maintain homeostasis, 
decreased thyroid hormones (T3 and T4) trigger a higher secretion of TSH from the 
anterior pituitary gland directly into the blood. As inadequate iodine intake directly 
affects the thyroid function, thyroid hormone levels in serum are considered as 
functional measures. Increase or decrease in TSH, T3 and T4 are observed among 
iodine deficient populations, but concentrations can also overlap with the iodine 
sufficient populations, due to tight physiological homeostatic regulation (69). 
Therefore, serum T3, T4 and TSH are not considered sensitive indicators for assessing 
iodine status in adults (69). However, serum TSH has been suggested as a sensitive 




Table 2.4 Epidemiological criteria for assessing iodine nutrition for different groups (132) 
MUIC (µg/L)  Iodine intake 
Pregnant women 
< 150 Insufficient 
150-249 Adequate 
250-499 Above requirements 
≥ 500 Excessive 
Lactating womena 
< 100 Insufficient 
≥ 100 Adequate 
Children < 2 years of age 
< 100 Insufficient 
≥ 100 Adequate 
Children ≥ 6 years of age  Iodine intake Iodine Status 
< 20 Insufficient Severe iodine deficiency 
20-49 Insufficient Moderate iodine deficiency 
50-99 Insufficient Mild iodine deficiency 
100-199 Adequate Adequate iodine nutrition 
200-299 Above 
requirements 
A slight risk of more than adequate 
intake in the overall population. 





Although lactating women have the same requirement as pregnant women, the MUIC is lower because iodine is excreted in breastmilk. 
b 
The term “excessive” means in excess of the amount required to prevent and control iodine deficiency. 
 
Thyroglobulin (Tg) is a glycoprotein which plays an important role in the synthesis of 
thyroid hormones. Previously, the measurement of serum Tg has been used to 
monitor thyroid cancer treatment (133). A small amount of this protein (< 10 µg/L) is 
constantly present in the blood of healthy individuals with adequate iodine status. 
Serum Tg concentrations increase with enlarged or inflamed thyroid, or rising TSH 
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secretion (133, 134). Iodine supplementation studies suggest serum Tg responds 
rapidly to the changes in iodine supply (135, 136), which in turn indicates that serum 
Tg might be a more sensitive indicator than other thyroid hormone measurements 
(134, 137). Measuring serum Tg is acknowledged as being sensitive in assessing both 
iodine deficiency and excess at population levels (134, 137, 138). Measuring TgAb is 
recommended to avoid an underestimate of serum Tg (139). However, limitations exist 
in using serum Tg as a biomarker including the uncertain prevalence of TgAb in iodine 
deficiency, and large variations in assays for analysis and poor reproducibility which 
result in limited ability to establish normal ranges (140). 
Research has attempted to establish a reference cut-off of serum Tg (< 13 µg/L) for 
iodine status in school-aged children (141), and suggests iodine sufficiency if less than 
3% of the population have Tg > 40 µg/L. This cut-off has been validated in a 24-week 
supplementation study (150 µg/day) of an adult population in New Zealand (142). 
However, the effectiveness of the suggested cut-off for pregnant women remains 
unclear (143). For example, two recent observational cohort studies have investigated 
the use of serum Tg as a biomarker for iodine status among mildly iodine deficient 
pregnant women. One study in the United Kingdom of pregnant women (n = 230), 
reported a higher serum Tg (20 µg/L) in the group of women at 35 gestational weeks 
with the iodine-to-creatinine ratio < 150 µg/L, when compared to the others (16 µg/L); 
suggesting that serum Tg was a useful functional marker to evaluate iodine status 
during pregnancy (144). However, a study of 299 pregnant women in Greece did not 
support using serum Tg as a biomarker of iodine status during pregnancy, although 
serum Tg concentrations were weakly correlated to the UIC within mild iodine 
deficiency only in the third trimester, which suggests a possible stimulating effect 
from a decreased human chorionic gonadotropin (145). It remains debatable whether 
trimester specific serum Tg concentrations would be more useful in evaluating iodine 
status (143). No studies have investigated the value of Tg in evaluating the iodine 
status of lactating women. 
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Measurement of the thyroid gland 
Measurement of the thyroid gland size is another assessment method for evaluating 
iodine status. Palpation by experienced physicians is used to detect an enlarged 
thyroid gland (goitre). While palpation is non-invasive, the method is subjective and 
can result in a large inter-observer error. Palpation of goitre was considered insensitive 
and less specific in populations with mild iodine deficiency (140). Since the late 1990s, 
to improve diagnostic precision, ultrasound is used as a safe, quick and non-invasive 
technique in assessing thyroid gland size. However, ultrasound measurement on 
thyroid volume may introduce inter-observer variability due to subjective judgement 
being applied on finding and measuring the maximum diameters on the thyroid gland 
image, which indicates a standardisation of technique may increase the accuracy of 
sonographic measurement of thyroid volume (146). Possible intra-observer variations 
on the measure of children’s thyroid glands also have been reported, but the mean 
value was relatively smaller for intra-observer (8.4%) than the inter-observer (30%) 
errors (147), which may result in difficulties in comparing outcomes to other studies.  
There is often a long lag time taken to normalise the thyroid gland volume after 
adequate iodine intake is achieved (148). This is evident in the discrepancy shown in 
a normalisation of UICs and the remaining goitre rate after the introduction of the 
mandatory salt iodisation programme. A five-year consecutive study of children with 
moderate iodine deficiency in West Africa found that UICs were normalized within a 
year, with only an 8% reduction of the goitre rate; after four years, 29% of the children 
remained goitrous (148). A previous one-year study of South African children 
examined the short-term effectiveness of an iodised salt programme, and they found 
children achieved adequate intake based on the UIC, but the goitre rate assessed by 
palpation did not decline (149). Unlike UICs, which respond rapidly to changes in 
dietary iodine intake, thyroid volume changes primarily reflect historical iodine 
status. Therefore, when interpreting results from the measurement of thyroid volume, 
the current iodine status of the population should be taken into consideration. 
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The methods described above have been used in both observational and 
interventional studies to monitor iodine status among different population groups. In 
summary, the UIC values reflect recent iodine intake (within 24-hour periods), serum 
Tg displays a relatively slower response to dietary iodine intake, and the long-term 
iodine status being reflected in measuring thyroid volume.  
2.3.3 Iodine intake and status in postpartum women and their infants 
Iodine concentration in breastmilk is an additional indicator of iodine status/intake 
for lactating women and their breastfed infants. Breastfed infants rely on iodine from 
breastmilk to support their thyroid hormone synthesis, which is critical in their 
neurodevelopment (108). It is important that lactating mothers achieve adequate 
iodine intake. Hence, an increased expression of NIS raises iodide uptake by the 
mammary glands, culminating in an increased secretion of iodine in breastmilk (107). 
Maternal iodine intake needs to increase to allow for that secreted into breastmilk.  
Several factors may affect breastmilk iodine concentrations (BMIC), including the 
stages of lactation (150); the timing of breastmilk collection; maternal iodine intake; 
maternal fluid intake (126), and exposure to cigarette smoking (107). A 2018 systematic 
review of five longitudinal studies of BMICs in non-supplemented women 
summarised that the BMIC dropped from colostrum (200-400 µg/L) to mature milk 
(100-150 µg/L) (151), and continually decreased until nine months after birth (152). A 
New Zealand study between 2004 and 2005 observed a significant reduction of mean 
BMIC from week one (43 µg/L) to week 24 postpartum (25 µg/L) for breastfeeding 
women not consuming iodine-containing supplements (150). In addition, maternal 
fluid intake has less influence on breastmilk iodine than the urinary iodine 
concentrations (126). Importantly, smoking has been suggested to impair the NIS 
transporter in the mammary gland due to the presence of thiocyanate; smoking 
mothers showed a much lower level of BMIC when compared to non-smokers (107). 
Observational studies have been conducted on the iodine status of breastfeeding 
women among iodine-deficient and iodine-sufficient countries. A systematic review 
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included 42 published studies between 1964 and 2013 (153) and reported that iodine 
deficiency in lactating mothers remained irrespective of mandatory or voluntary 
fortification strategies implemented in their countries. For these reasons, authors 
supported the provision of 150 µg/day to pregnant and breastfeeding women (153). The 
table 2.5 summarises observational studies conducted in the past 10-year on 
postpartum women’s iodine status (2009-2020). As shown, most of the countries listed 
have implemented either mandatory or voluntary salt iodisation programmes, with 
levels of iodisation between 20 and 70 mg iodine/kg salt. Denmark introduced the 
mandatory fortification of bread with iodised salt (9-25 µg/100 g bread) from 2000 
(154); followed by Australia and New Zealand (14-28 µg/100 g bread) in 2009 (155). 
Bread fortification was projected to increase iodine intake to an average of 84 µg/day 
in New Zealand adults (156). Most studies recruited non-exclusive breastfeeding 
women (supplementing infants with formula or complementary foods), whereas some 
used data from exclusively breastfeeding women (infants solely fed from breastmilk). 
The timing of postpartum data varied from four days to 12 months, thus, the iodine 
concentration in breastmilk may reflect changes in the stages of lactation from 
colostrum to mature milk. 
The current cut-off for UIC for iodine adequacy in a population of lactating women is 
above 100 µg/L, and data from most countries (Table 2.5) indicated insufficient iodine 
intake. Based on the Global Scorecard of iodine nutrition in 2020 (72), iodine intakes 
stated from each country studied did not accurately reflect breastfeeding women’s 
iodine status, as the scores were based on the MUIC of school-aged children. The 
appropriate cut-off for BMIC has not yet reached a scientific consensus. Further study 
in examining BMIC and its relation to iodine status will be required in both iodine 
sufficient and insufficient regions. 
Some interventional studies have investigated the effects of mother and infant iodine 
supplementation on their iodine status. In regions of moderate to severe iodine 
deficiency (maternal MUIC as 30-37 µg/L), in Morocco, a randomised double-blinded 
placebo-controlled trial (n = 241 mother-infant pairs) compared the effectiveness of 
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using maternal supplementation, either with a single dose of 400 mg iodised oil or 
supplementing infants (aged ≤ 8 weeks) directly with a single dose of 100 mg (157). 
This study found that maternal supplementation is more effective in ensuring 
adequate infant iodine status and maintaining BMIC levels until at least six months 
postpartum (157). A recent randomised trial in Southern Ethiopia showed that 
continuous use for six months of iodine supplementation of 225 µg daily was equally 
effective at maintaining UIC and BMIC when compared to a household iodised salt 
programme (35 mg iodine/kg salt), as the median UIC/BMIC in the iodine 
supplementation group showed adequate iodine status (150 µg/L/104 µg/L)  and 110 
µg/L/111 µg/L in the iodised salt group (158). In the regions of moderate iodine 
deficiency (maternal MUIC as 42 µg/L), in New Zealand, prior to mandatory 
fortification of bread with iodised salt, a randomised double-blind placebo-controlled 
trial reported that maternal supplementation of 150 µg and 75 µg iodine daily for the 
first six months postpartum improved BMIC. It is important to note, however, that 
both dosages were not sufficient to enable achieving adequate iodine status for 
mothers and their infants (150). 
2.3.4 Iodine intake and status in New Zealand  
In New Zealand, soils contain low levels of iodine, resulting in low concentrations in 
the local food supply (88). Consequently, people living in New Zealand have a low 
dietary intake of iodine. Iodine deficiency was a concern in New Zealand in the early 
years of the 20th century, but its prevalence was mostly reduced through the 
introduction of iodised salt in the 1930s (85). However, since the 1990s, several studies 
in New Zealand have shown iodine deficiency has re-emerged within adults (159), 
pregnant and breastfeeding women (150, 160), school children (85) and breastfed 
infants and toddlers (161). To overcome iodine deficiency in New Zealand, two 
government initiatives were introduced: mandatory iodised salt in commercially 
made bread and bread products from September 2009 (5), and iodine 
supplementation (150 µg/day) for all pregnant and lactating women was 
recommended in 2010 (96). 
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Although recent studies suggested that adults (95, 118) and children (94) in New 
Zealand may now have adequate iodine intake/status, women aged 40 to 63 years with 
low bread intake (162), and both pregnant and breastfeeding women remain deficient 
(97). A pilot study of a small sample of self-selected highly educated pregnant (n = 34) 
and breastfeeding women (n = 36) assessed UIC, BMIC and serum Tg, and results 
suggested iodine deficiency (97). There is a need to investigate iodine status of a 
representative sample of postpartum women and their infants, after the establishment 
of government iodine interventions.
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Table 2.5 A summary of recent ten-year observational studies on postpartum women’s iodine status (2009-2020). 

























users Authors  
Australia 
MF of IS in 
bread 2009 50  
4  
days  46  81 84  n/a n/a 
Chan et al. 
2003 (163)  
Australia 
MF of IS in 
bread 2009 60  
6  
months  123  n/a n/a BF:45 
UIC:  
206 vs 97  
P=0.029 
Axford et al.  
2011(164) 
Australia 
MF of IS in 
bread 2009 
291 









Pre: 47  
Post: 90 
BMIC:  
pre: 100 vs 
105 P=0.93           
post: 195 vs 
137 P<0.001 
Huynh et al.  
2016(165)  
Australia 
MF of IS in 
bread 2009 55   
39  
days  n/a n/a 167  BF: 57 
BMIC:  
With IS: 272 
vs 156 




al. 2016(166)  
Australia 
MF of IS in 
bread 2009 538  
 3  
months 125  n/a 127  n/a n/a 
Huynh et al 
2017(167)  
Britain 
No IS  
168  
 26  
weeks  79  n/a n/a 28  
UIC:  
no difference  
P=0.600 




























users Authors  
China  
(Linfen) 





weeks 107  n/a n/a zero n/a 








 4  
months  177  n/a n/a n/a 
UIC:  
192 vs 174  
P<0.001 




MF of IS  
1993 88  
4, 8 and 12 
weeks  
*4 weeks  
152       
*8 weeks  
112         
 *12 weeks 
109           n/a 
mean 
4weeks   
222  
8weeks                  
175 
12weeks                           
148  n/a n/a 
Wang et al. 




No IS  
73  
Excl. 
12   
weeks 35   n/a 124  zero n/a 
Dold et al.  
2017 (169)  
Denmark 
MF of IS in 
bread 2000 
IS raised 
from 13 to 
20 mg/kg in 





72 n/a  83 BF: 47 
MUIC  
83 vs 65  
P =0.004  
BMIC  




































of fish and 
dairy in the 
adult 
Icelandic diet 







No IS  
128  
Excl. 
30 to 90  
days  185  n/a 230  n/a n/a 
Pal et al.  
2018(174)  
Iran (Gorgan) 
MF of IS  
1994 100   
30-180  
days  259 n/a 93   n/a n/a 
Azizi 
2007(175)  
Iran (Tehran) IS 1990 147   
4  
days 68  n/a n/a n/a n/a 
Nazeri et al. 
2016(176)  





BMIC < 100 
37 n/a 218 n/a n/a 








weeks  n/a n/a 




892  n/a n/a 









weeks  33  n/a 30 n/a n/a 
































had IS  500 
6.8  
months  230 n/a 250  n/a n/a 
Henjum et al. 
2018(179) 
Netherlands 
IS since 1945  
IS in bread 33 
4  





IS with 50 
mg Iodine/kg 
salt 175  11 weeks 64 n/a 68  29 
habitual 
users  
99 vs 60  
P<0.001 
used last 24h 
140 vs 61  
P<0.001 
Henjum et al. 
2017(181)  
Norway 
IS with 50 
mg Iodine/kg 
salt 133 
1 to 12 


















37                        
*6months 
25                          
*12months 
47  n/a n/a n/a n/a 
Thomson et 
al. 2001(183)  
New Zealand  












*Post:74        n/a 
Pre: 55 (48)  
Post: 63 
(44)  
Pre: 19  
Post: 36 
BMIC  
Post: 126 vs 
58 
P<0.001 




































weeks  89  n/a 185 zero n/a 
Dold et al. 
2017(169)  
South Africa 
IS, but a 
third lacks 
access  100 
3  
months  118 126  179 n/a n/a 

















63 n/a n/a n/a n/a 
































140 vs 71,  















42 3 n/a 
Andersson et 
al. 2010(190) 
BF: breastfeeding; BMIC: breastmilk iodine concentration; P: pregnancy; MF: mandatory fortification; IS: iodised salt; Pre: pre-fortification; Post: post-fortification; UIC: urinary iodine 
concentration. 
*samples used were 24-hour urinary collection. 




Selenium plays a key role not only in the synthesis of thyroid hormones, but also is 
involved in multiple areas of human health, including immune function, mental 
health, and infant neurodevelopment. There is a complex relationship between 
selenium intake and health outcomes, as both selenium deficiency and excess may 
result in adverse health outcomes (191). Numerous research studies have investigated 
selenium and human health, and endeavoured to understand the mechanisms 
involved (192). 
2.4.1 Selenium and health  
Through selenoproteins, selenium plays an antioxidant and anti-inflammatory role 
against oxidative stress and regulates the redox reactions of several micronutrients 
(192). Severe selenium deficiency results in clinical effects such as Keshan (an endemic 
disease of myocardium necrosis and fibrosis) and Kashin-Beck diseases (an endemic 
disease of osteoarthropathy) within populations living in selenium-deficient areas 
(193). Selenium status is associated with pregnancy-induced hypertension, 
preeclampsia, pre-term birth, and recurrent miscarriage. These topic areas have been 
extensively researched by Rayman’s group (192, 194, 195) and Barrington (196), both 
are based in the United Kingdom. Selenium supplementation has shown protective 
effects for some selected cancers, such as prostate cancer, but only among those 
presenting with low selenium status initially (192). Excessive intake also can be 
detrimental, for example the human selenosis outbreak (selenium intoxication, such 
as loss of hair and nails, and lesions of skin) which occurred in Enshi, China, between 
1961-1964 (197). Therefore, like many essential nutrients, selenium presents a U-curve 




Figure 2.4 U-shaped relationship between selenium status and disease risk [Winther, 
Rayman, Bonnema, and Hegedüs, 2020 (198)] 
Selenium plays an important role in normal brain development, although the exact 
mechanism is unclear. Two recent large cohort studies from Poland (n = 410) (199) 
and Spain (n = 490) (200) found maternal selenium status in the first trimester (mean 
serum selenium concentration in Polish mothers at 48.3 µg/L; in Spanish mothers at 
79.1 µg/L) was positively associated with neuropsychological development, which was 
measured by the Bayley Scales of Infants and Toddler Development at one year and 
two years of age (199), and the McCarthy Scales for Children’s Abilities (MSCA) at five 
years of age (197). A Norwegian study of 114 pregnant and lactating women and their 
infants examined the effect of maternal selenium status on infant neurodevelopment 
as measured by the Ages and Stages Questionnaire (ASQ), and reported that low 
maternal serum selenium concentration (< 71 µg/L) at 18 gestational weeks was 
associated with lower infant psychomotor scores (total, problem solving, personal-
social functioning and fine motor function) at six months of age (201). It should be 
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noted that infant neurodevelopment in relation to postnatal selenium intake and 
status will warrant ongoing investigation, as brain development continues up to two 
years of age (202). 
2.4.2 Selenium intake and status in postpartum women and their infants 
2.4.2.1 Selenium intake 
Most organic selenium occurs in human diets as selenomethionine and 
selenocysteine, which are absorbed and stored in pools to reserve selenium for the 
tissues (198). Inorganic forms selenite and selenate commonly used in dietary 
supplementation and infant formula may be less bioavailable than organic forms of 
selenium (198). The selenium content in food sources depends on the soils where 
plants are grown, and the nature of animal feed. Geographic variations of selenium in 
local soils are reflected in subsequent human dietary intake, with worldwide selenium 
intakes ranging from seven to 4990 µg/day, varying between deficient to toxic intakes 
(192). About 50-60% of selenium intakes are excreted into urine to maintain selenium 
homeostasis (203). 
Newborn infants are born with some selenium reserves; however, breastfed infants 
rely on continuous supplies from breastmilk to achieve optimal selenium status. 
Breastmilk is recommended as the best food for infants during the first six months of 
life (204). Selenium present in human breastmilk is significantly associated with 
maternal selenium intake (205, 206). Variation in dietary selenium intakes of people 
living in different geographic areas is widely reflected in breastmilk selenium 
concentrations (BMSC). For example, Shearer and Hadjimarkos observed that mature 
breastmilk from American women living in a high selenium area had a selenium 
concentration of 283 µg/kg, compared to only 2.6 µg/kg from women living in an area 
with endemic Keshan disease which indicates selenium deficiency (207). 
The assessment of selenium requirements for adults has been based on maximising 
plasma GPx activity, rather than the prevention of Keshan disease (208). During 
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lactation, selenium requirements are necessarily increased to meet the growing 
infants’ needs. The EAR for lactating women is at 65 µg/day to include an allowance 
of 12 µg/day selenium secreted into breastmilk and the RDI is 75 µg/day by assuming 
a coefficient of variation of 10% for the EAR (since insufficient data are available to 
determine the standard deviation). Final EAR and RDI recommendations are rounded 
up to the nearest 5 µg (86). The Upper Level of Intake (UL) is suggested as 400 µg/day 
for all women without amendment for lactation. Infants’ dietary intake is calculated 
from selenium concentration in human milk multiplied by the volume of breastmilk 
needed at different ages (86). Adequate Intakes (AI) for selenium are suggested to be 
12 and 15 µg/day for birth to six months, and seven to twelve months, respectively (86). 
UL for Infants are 45 and 60 µg/day for birth to six months, and seven to twelve 
months, respectively, based on a previous study of Shearer & Hadjimarkos (207). 
2.4.2.2 Selenium status 
Selenium status of postpartum women and infants have been examined. A 
comparative observation study from Levander et al. (1987) reported on plasma 
selenium from a small sample of 23 North American women at one, three and six 
months postpartum (136, 137, and 138 µg/L) (206). Although these concentrations did 
not change during the stages of lactation, they were lower than those in a non-
lactating group (151, 152, and 144 µg/L, above 110 µg/L to maximise expression of 
selenoprotein P )(203, 207). BMSCs of these American women at all three time points 
(20 µg/L, 15 µg/L, and 15 µg/L respectively) were found to be adequate to meet the 
needs of infants aged 0-6 months (10, 12 and 13  µg/day, based the US National 
Research Council recommendation 10-40 µg/day) (206). 
Recent studies examined both maternal plasma and cord blood selenium in 
postpartum women in Greek mothers along with Albanian mothers who had 
immigrated to Greece before birth (209), and Spanish mother-infant pairs (210). 
Maternal blood/plasma selenium concentrations were determined in labour, so, in 
consequence, they cannot be directly compared to the 1987 North American study. 
80 
 
Much lower serum selenium concentrations were observed in Albanian immigrant 
mothers (37 µg/L) compared to Greek women raised and living in the same region (68 
µg/L). Furthermore, Albanian infants showed much lower serum selenium (measured 
in the cord blood) when compared to Greek infants (34 vs 37 µg/L, P < 0.05). Authors 
suggested this phenomenon could be due to the low socioeconomic status of Albanian 
mothers who found selenium rich food unaffordable, particularly meat and fish (209). 
A cross-sectional study with 83 Spanish mother-infant pairs attempted to identify 
selenium varieties in maternal blood (during 24 hours before giving birth) and cord 
blood by measuring plasma selenium, selenoprotein P (SeP), serum GPx, and Se 
metabolites (SeMetab). Also reported was the low selenium status of these mothers to 
optimise GPx activity (< 70 µg/L) (210). Even though 25% of participating women 
consumed selenium-containing supplements during pregnancy, no differences in 
selenium measures were detected (median total plasma selenium 67.4 vs 69.7 µg/L, P 
= 0.54; SeP 41.4 vs 44.9 µg/L, P = 0.16; GPx 10.8 vs 11.6 µg/L, P = 0.43; SeMetab 4.4 vs 
3.2 µg/L, P = 0.18). This observation may be due to low dose of supplementation at 55 
µg/day as selenite, which is an inorganic form of selenium with less bioavailability. In 
addition, it would be useful to include supplement compliance when reporting results. 
Three clinical trials examined the effects of selenium supplementation on status. 
Common forms of selenium supplementations include selenium-Methionine (Se-
Met), yeast containing selenium (Se-yeast), together with inorganic form of selenite 
or selenate which may be less bioavailable than organic forms of selenium (198). In a 
randomised double-blind placebo-controlled trial, American women were 
supplemented 200 µg daily selenium as Se-Met or as Se-yeast at four weeks 
postpartum for four weeks (211). The participating women were followed at eight and 
twelve months postpartum. They found Se-Met significantly increased plasma 
selenium of lactating women (98.7 µg/L at four weeks, 194.3 µg/L at eight weeks 
postpartum), but a declined plasma selenium was observed in those lactating women 
who were in the placebo group (137.4 µg/L at four weeks, 119.3 µg/L at eight weeks 
postpartum) (211). This American study had a small sample size (31 lactating and 22 
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non-lactating), and even smaller numbers were allocated to each treatment group; 
breastfeeding patterns (exclusively or partially) were unreported. In addition, the 
baseline plasma selenium concentrations were statistically different between the 
control and Se-Met treatment group (137.4 vs 98.7 µg/L, P < 0.05). Such differences at 
baseline may suggest instability in the data (211). In a larger sample size interventional 
study (n = 167), 100 µg of selenite daily, or 100 µg of Se-yeast daily or no 
supplementation were randomly assigned to Finnish women who were exclusively 
breastfeeding (212). The participating women were followed at two, four and six 
months postpartum. The findings showed the Se-yeast, when compared to selenite, 
more effectively increased selenium in serum (increment of 86 µg/L vs 51 µg/L at four 
months of lactation) and breastmilk, which may have increased the infants’ selenium 
intake (11.5 vs 8.9 µg at age of six months based on 800 mL daily breastmilk 
consumption) (212). Authors suggested one of the available compounds in selenium 
yeast was Se-Met, therefore, organic forms of selenium supplementation showed clear 
effectiveness in improving maternal selenium status and infant selenium intake (212). 
In contrast, sub data generated from the Breastfeeding, Antiretrovirals and Nutrition 
study [randomised intervention with antiretroviral drugs (ARV), lipid-based nutrient 
(LNS) containing 75 µg selenite, LNS and ARV, and the control)] reported that the 
plasma selenium of HIV-infected Malawian mothers was unchanged after 
supplementing 75 µg selenite daily from birth till 28 weeks postpartum (213). Women’s 
HIV status may have had an impact on selenium uptake. The authors acknowledged 
selenite, as an inorganic form of selenium, is less readily absorbed, thus this may also 
have had a minimum impact on selenium status (213). Variable findings in these 
studies may be due to factors such as the type of selenium source, dosage, original 
selenium status before supplementation, or variable stages of lactating, so further 
research is needed to investigate the effects of selenium supplementation in 
improving maternal status. Interestingly, all three studies observed a similar decline 
of BMSC from early to later stages of lactation, despite appropriate supplementation. 
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It is thought that such gradual decreases of selenium in breastmilk concentrations 
may be a natural physiological process (the changing of needs of the infants) (210). 
2.4.2.3 Assessment of selenium intake and status 
Selenium intake can be assessed by dietary assessment methods, including 
estimated/weighed food records, food frequency questionnaires (FFQs), and repeated 
24-hour dietary recalls (see Section 2.3.2). Weighed food records is recognised as the 
gold standard measure of food and nutrient intake (119). However, this often presents 
challenges when estimating selenium intake solely from food records. Selenium values 
contained in the updated food composition data may not reflect regional variations of 
selenium in the food items consumed, since not all data bases may contain accurate 
selenium data. 
Methods used to assess selenium status for both breastfeeding women and their 
infants include urinary selenium excretion, blood and breastmilk selenium 
concentrations, and selenium concentrations obtained from hair/nail clippings. 
Urinary selenium excretion is the portion of absorbed selenium that has not been 
retained by body tissues. It is considered as a proxy measure reflecting short-term 
dietary selenium intake, since increased dietary intake results in raised urinary 
excretion of selenium (214). Historical data from China showed a 400 times higher 
urinary selenium excretion in people with selenosis compared to those living in an 
area of endemic Keshan disease (215). Urinary selenium excretion is commonly used 
to estimate daily dietary selenium intake for adults, based on 50-60% of the excretion 
rate. However, it is not possible to use the urinary selenium excretion rate to estimate 
selenium intake with lactating women, since selenium is also secreted into breastmilk. 
Selenium concentrations can be measured in both spot and 24-hour urine samples. 
Collecting 24-hour urine samples requires motivated participants and may not be 
practical in large studies. Diurnal variation and hydration status are the main 
challenges in evaluating selenium excretion in spot urine samples (215). Urinary 
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creatinine can correct for the changes in hydration status. In healthy Polish subjects 
(n = 199), the urinary selenium to creatinine ratio was positively correlated the whole 
blood selenium (216), which suggests the ratio may be a better method to estimate 
selenium status than urinary selenium excretion alone. 
Measuring the selenoproteins in blood, including selenoprotein P, GPx1(plasma GPx) 
and GPx3 (GPx in red blood cells) has been suggested, as these are useful functional 
markers for selenium status (200). Results may be misleading if only one of the 
selenoproteins is measured, due to the hierarchal arrangement of selenoproteins in 
body function. In a randomized double-blind trial in New Zealand in 1987, women 
aged 18-23 years were given either 200 µg Se-yeast enriched in Se-Met, or brewer’s 
yeast mixed with selenite, or a placebo for 32 weeks (217). At the conclusion of 
supplementation, plasma selenium in the Se-Met group (190 µg/L) was 1.7 times more 
than that in the selenite group (110 µg/L), both being effectively increased from the 
baseline values of 53 µg/L (217). A 2009 systematic review reported that plasma 
selenium was increased significantly by selenium supplementation (218). However, 
differences observed in gender, supplement type/dosage/duration, or the subject’s 
baseline selenium status, as well as an inconsistency of measurement assays raised 
difficulties in the meta-analyses of the results (218). The review found that plasma 
selenium is the most widely measured biomarker in the published supplementation 
studies, due to its effectiveness in reflecting levels of selenium intake (218).  
A range of plasma selenium values in adults has been suggested for optimal activity of 
iodothyronine 5’ deiodinases (65 µg/L) (208), nutritional adequacy (70 µg/L) (219), or 
maximal GPx activities (95 µg/L) (217), but no reference values are available at this 
time for plasma selenium to define adequate or deficient selenium status for lactating 
women. Furthermore, plasma selenium has been used to estimate selenium intake, as 
recorded from an extensive data analysis of Chinese studies, where a proposed formula 
was suggested to calculate selenium intake daily (log Y = 1.623 log X + 3.433; X = plasma 
selenium, mg/L; Y = selenium daily intake µg/day) (220). It is useful to compare such 
results to the estimated dietary intake from dietary assessment. 
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Measuring selenium concentrations in nail clippings is another established method of 
assessing selenium status (220, 221). Selenium is incorporated into hair or nails 
(keratinised tissues) and, as they grow slowly, this reflects long-term (up to 52 weeks) 
selenium status; however, hair and fingernails are easily contaminated by selenium-
containing shampoo or other environmental exposures, and toenails are recognised 
as having less exposure to these contaminants. Toenail clippings were used to 
determine selenium concentrations in large cohort or epidemiological studies, such 
as the risk of preeclampsia in pregnant women (195). In comparing selenium 
concentrations in toenails to other biomarkers including whole blood, serum and 
urine, twelve healthy American males were randomly assigned to either consuming 
two slices of study bread containing selenium at 206 µg/day, or 388 µg/day, or the 
control group over a one-year period; and their toenail clippings were collected for 
analysis at a twelve-week interval over a two-year period (222). The trial found toenail 
selenium concentrations started to reflect dietary change after the first three months, 
while whole blood and serum selenium increased after two weeks, and consequently, 
measuring selenium in nail clippings could be an important biomarker representing 
exposure up to 52 weeks (221, 222).  The advantages of measuring nail clippings include 
that collecting nail clipping samples are less invasive and convenient for participants 
(221). Additionally, measuring selenium concentrations in maternal toenail clippings 
after childbirth can be used to estimate fetal selenium exposure (222). 
2.4.3 Selenium intake and status in New Zealand 
In New Zealand, local food supply contains low levels of selenium. Historical data 
(1966-1986) collected by Robinson’s group reported low selenium intake in the New 
Zealand population, particularly those living in the South Island (223). Even after the 
importation of selenium-rich wheat from Australia (containing 10 times higher levels 
of selenium than that contained in New Zealand wheat), low selenium intake and 
status of people who live in the North and South Island continued to be present (53). 
Differing selenium intake between the two islands are due to  locally produced wheat 
being preferred for breadmaking in the South Island of New Zealand (83). 
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Based on self-reported 24-hour diet recall data from the 2008/09 New Zealand Adult 
Nutrition Survey, a median selenium intake of women aged 31-50 years old was 51.9 
µg/day, with 58% below the EAR, indicating the presence of inadequate intake (224). 
An increase in median selenium intake among females aged over 25 years from 2009 
(56 µg/day) to 2016 (68 µg/day) was observed in the 2016 New Zealand Total Diet 
Survey (percentages below the EAR were not reported) when compared to the 
previous national Adult Nutrition Survey (89). The authors suggested that the 
increased selenium intake was due to increased consumption of selenium rich food 
since selenium concentrations of key food contributors had remained constant (89). 
Low selenium intakes continue to be reported in New Zealand women of childbearing 
age (225), and postmenopausal women (226). Before the year of 2000, several research 
studies in New Zealand examined selenium status in adults, with serum or plasma 
selenium ranging from 43 to 69 µg/L, which was lower than the suggested minimum 
level of plasma selenium for nutritional selenium adequacy (70 µg/L) (227). It was 
clearly established that New Zealand adults had low selenium status. 
Pregnant and lactating women who live in low selenium areas remain of concern, 
owing to their increased requirement for meeting both foetal and infant growth. A few 
studies in New Zealand have investigated the selenium intake and status within these 
populations. An early double-blind supplementation study recruited thirty-five 
pregnant women from the South-Island of New Zealand (either receiving 50 µg 
selenomethionine daily, or a placebo) and they were followed up until 12 months 
postpartum, with the addition of 17 non-pregnant women who received a selenium 
supplement forming a positive control group (183). The focus of this South-Island 
study was to compare the responses of selenium supplementation for non-pregnant, 
pregnant and postpartum women. The data reported that levels of plasma selenium 
for postpartum women rose at three and six months postpartum but fell at 12 months 
postpartum. This confirmed an overall higher level of plasma selenium recorded for 
those women who received supplementation over the 12-month period, when 
compared to the non-supplemented pregnant group. Even so, the study, when 
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published, offered no detailed data report for the selenium status of these postpartum 
women, therefore their selenium status remained inconclusive (183). 
Between May 1998 to March 1999, an observational study by McLachlan et al. was 
conducted on infants aged 6-12 months, toddlers aged 12 to 24 months, and their 
postpartum mothers in the South Island of New Zealand (228). The study measured 
maternal plasma selenium and children’s serum selenium, and maternal dietary 
intake from three-day weighed food records. The mean selenium plasma 
concentration in lactating women (72.9 µg/L), was close to that of non-pregnant/non-
lactating women (73.5 µg/L, P = 0.055). Estimated dietary selenium intake was 
significantly higher in lactating women (46 µg/day) than non-pregnant/non-lactating 
women (36 µg/day, P = 0.004), despite their similar plasma selenium status. The loss 
of selenium in breastmilk may account for this difference. However, this study did not 
examine selenium concentration in breastmilk, therefore the total intake for breastfed 
infants was unable to be firmly established. 
More recent reported data was from a cross-sectional study of 53 exclusively 
breastfeeding mother-infant pairs at eight weeks postpartum in Dunedin, New 
Zealand between 2012 and 2013 (229). Results showed mean selenium intake was 47 
µg/day based on the three-day weighed food records; and mean maternal serum 
selenium concentration at 75 µg/L with 39% lower than 70 µg/L, suggesting 
suboptimal selenium status. However, the sample size was small, and the information 
as to the use or not of selenium-containing supplements during pregnancy or lactation 
was not forthcoming. To our knowledge, there have been no recent studies in New 
Zealand investigating selenium status in breastfeeding women. 
2.5  Iron 
Iron deficiency, one of the most common nutritional disorders, affects individuals of 
all ages and ethnicities in the world, although, infants, children, and women of 
childbearing age are disproportionately affected (230). For example, based on a 
published 2013 analysis of 257 surveys (232 nationally representative sources) from 190 
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countries categorised into 11 regions, anaemia prevalence decreased in pregnant 
women (43% to 38%), in non-pregnant women aged 15-49 years (33% to 29%), and in 
children aged less than five years (47% to 43%) through the years 1995 to 2011. 
However, eight hundred million women and children remained affected by anaemia 
globally in 2011, with iron deficiency contributing to at least 50% of anaemia in women, 
and 42% in children (230). According to the Global Health Observatory data 
repository, in 2016, 40% of pregnant women, 33% women of childbearing age were 
anaemic (231), and 42% of children younger than 5 years (232). 
Women of childbearing age are disproportionally affected by iron deficiency without 
anaemia (ID)/iron deficiency anaemia (IDA) (114), since low iron intake is probably 
the major cause. Failure to compensate for iron loss through heavy menstrual bleeding 
and failure to reach an increased iron requirement during pregnancy may play a part 
in developing ID/IDA in women (233). A cross-sectional study examined the 
prevalence of ID and IDA with women aged 18 -35 years living in the state of New 
South Wales in Australia (n = 300), where the prevalence of ID and IDA were 14% and 
6% respectively (234). In New Zealand, results from the 2008/2009 Adult Nutrition 
Survey found the highest prevalence of ID and IDA were observed among females aged 
31 to 50 years old, measured at 12% and 6% respectively (224). 
2.5.1 Iron and health 
Iron is a principal component of haemoglobin (Hb) and myoglobin (oxygen reserve in 
muscles) (20). The balance of the body’s iron presents as iron-containing enzymes 
which are involved in cellular respiration, cell proliferation and differentiation, 
optimal immune function, and hormone synthesis (20). The primary function of iron 
is erythropoiesis (formation of red blood cells), and this process is well protected, even 
if the iron store becomes depleted. Impaired iron status presents in discrete stages, 
from an early stage of iron storage depletion, tissue iron deficiency, then moving on 
to the last stage of impaired Hb production [Figure 2.5, (235)]. People with depleted 
iron stores usually do not show any noticeable clinical symptoms (235). When iron 
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deficiency occurs, Hb production is initially compensated for by drawing on stored 
iron. Concurrently, other iron functional roles are compromised in order to maintain 
erythropoiesis. If deficiency continues, this not only affects Hb formation, but may 
also cause abnormal red blood cells to form. Individuals then exhibit IDA, which may 
present as clinical symptoms, varying from fatigue, to hair loss, or spoon-shaped 
fingernails in more severe cases (235). 
 
Figure 2.5 Spectrum of Iron deficiency and diagnosis [Coad and Pedley, 2014 (235)] 
Iron deficiency may negatively impact on both the physical and mental health of 
reproductive aged women, including reduced work capacity, impaired cognitive 
function and adverse mental health (236). A recent cross-sectional study assessed 
cognitive function of women aged 18-35 years living in the state of New South Wales, 
Australia (n = 300), in relation to their iron status [iron replete (IR), ID, and IDA] 
(234). The results showed significant reduced attention in women with IDA but not 
observed in women with ID or IR after controlling the body mass index, inflammation 
and physical activity, despite the five cognition domains assessed (impulsivity, 
attention, information processing, memory and executive function) using the online 
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computer-based questionnaire. Authors suggested cognition is less likely affected at 
early stages of iron deficiency (234). 
Several interventional studies have examined iron status in relation to physical fitness, 
general mental health, and cognitive functioning. A randomised placebo-controlled 
trial of a group of 22 non-anaemic iron deficient (SF< 16 µg/L and Hb > 120 g/L) 
American women aged 18-33 years has shown improved fitness levels (measured by 
the VO2 max – the maximum rate of oxygen consumption) after correcting iron 
deficiency by a six-week daily supplementation (50 mg FeSO4) (237). Moreover, 
reduced fatigue and marginal improvement of general mental health were observed 
from a randomised controlled study of iron deficient Australian women aged 18 to 50 
years, after consuming a high iron diet (providing 2.25 mg absorbed iron daily) or iron 
supplements (350 mg FeSO4) over a 12-week trial period (238). Another placebo-
controlled stratified intervention study investigated the improved iron status on the 
accuracy of cognitive function (attention, memory and learning) among American 
women aged 18-35 years (239). According to the iron status, women were classified 
into three groups: one control (iron sufficient, n = 43), and two treatment groups (ID, 
n = 75; and IDA, n = 34).  Women in each group were given either 160 mg FeSO4 daily 
or a placebo for 16 weeks. Results showed that slower information processing was 
observed in women with ID when compared with others with normal iron status, and 
the iron supplementation led to an improvement in both cognitive performance and 
the timing required to complete the tasks (239). Strengths of this trial include detailed 
cognitive performance tasks (from Detterman’s Cognitive Abilities Test) at baseline 
and 16 weeks after treatment, and iron status was treated as continuous data to enable 
detection of subtle cognitive changes. Research shows that the developing brain is 
sensitive to iron depletion, which explains the link between iron deficiency and 
impaired neuronal functioning, more specifically, with cognitive function (attention 
and memory) and related psychological effects (240). 
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2.5.2 Iron physiology and intake patterns 
Dietary iron intake is required to meet the balance of losses from skin, urine and the 
gastrointestinal tract, and the loss of menstrual blood in women of childbearing age. 
However, iron balance is regulated by the amount of iron absorbed. In total, only 1-2 
mg of iron is absorbed from the 10-20 mg of iron consumed from food daily. The 
amount absorbed is mostly regulated by the divalent metal ion transporter 1 (DMT-1), 
and transferrin (the major iron transport protein) transports iron in the blood 
circulation (235). In addition, iron is recycled from the breakdown of red blood cells 
via macrophages into the circulating iron pool. The remainder is stored in bone 
marrow and the liver. Iron is stored as ferritin predominantly in hepatocytes, and a 
small amount of ferritin is present in serum which can be detected. Therefore, serum 
ferritin acts as a good indicator for assessing current iron storage. Figure 2.6 provides 
a visual representation of iron balance in the body (235). 
Most dietary iron, initially present as non-haem iron consumed in the ferric form, is 
reduced to ferrous iron before being absorbed and transported by DMT-1 expressed 
by enterocytes which line the intestine. Other metal ions, such as zinc and manganese 
compete for the DMT-1, which may limit iron absorption (20). The amount of iron 
entering the blood circulation is regulated by the secretion of hepcidin, a peptide 
hormone from the liver, which causes sequestration of iron by the enterocytes and 
macrophages. For example, when iron deficiency is present, hepcidin release is 
reduced to maximise iron absorption into the blood. Dietary haem iron from animal 
products, such as meat, fish, and poultry is more readily bioavailable for absorption 
(possibly by using haem carrier protein and haem oxygenase, Figure 2.7) than non-
haem iron(235), as well as being less likely to be influenced by meal composition (241). 
However, the detailed mechanism as how haem-iron is absorbed is less understood 




Figure 2.6 Iron balance in the body [Coad and Pedley, 2014 (235)] 
 
Figure 2.7 Mechanisms of intestinal iron absorption [Milman, 2020 (243)] 
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Moreover, several enhancers and inhibitors impact on non-haem dietary iron 
absorption. Ascorbic acid, alongside citric acid and lactic acid is one of the most 
recognised iron absorption enhancers, mostly evident from single meal consumptions 
rather than from a complete diet (244).  The possible mechanism is due to its ability 
to increase iron solubility in the small intestine and to reverse the negative effects of 
tea/coffee/phosphate. In addition, the “meat-fish-poultry” factor is also responsible 
for an increase in iron absorption (244, 245, 246), although a single mechanism is yet 
to be clearly identified. In contrast, many dietary factors inhibit iron absorption, 
including polyphenols derived from tea or coffee, phytates found in whole grains and 
legumes, or oxalic acid from spinach, berries, or chocolate. 
Iron balance in the human body is complex and influenced by dietary intake, 
metabolic processes, and physiological stages of life. When evaluating iron intake or 
status, dietary intakes, or enhancers and inhibitors in the diet, other non-dietary 
factors need to be considered. Most commonly, dietary assessment methods are used 
to estimate iron intake, as for example, weighed food records. Detailed selection of 
dietary assessment methods has been discussed in a previous section (2.3.2). However, 
dietary assessment of iron intake is more difficult than for other nutrients, as the 
complexity of a person’s diet contains both enhancers and inhibitors for iron 
absorption. Thus, in recent years, new approaches have been developed to consider 
the whole diet and to include food combinations in the diet (dietary pattern analysis) 
to evaluate iron-related nutrition. A food frequency questionnaire has been developed 
and validated in New Zealand to identify dietary patterns in relation to iron status 
(114). Subsequently, dietary patterns such as ‘meat and vegetable” or “milk and 
yoghurt” have been identified, which may reduce or enhance the likelihood of there 
being suboptimal iron status among young New Zealand women (247). In the MINI 
study, this validated FFQ is used to explore iron-related dietary patterns among 
postpartum women, and the relation of these patterns to their iron status.  
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2.5.3 Iron status and its assessment 
IDA is usually confirmed by a combination of lower serum ferritin (SF) and Hb; 
however, the diagnosis of ID is more complicated due to a wider selection of 
biomarkers and the lack of standards. SF is the most effective and recommended 
indicator to assess the adequacy of iron stores individually. SF below 12 ug/L indicates 
a depleted iron store (248). Interpretation of results from SF is complicated by acute 
and chronic inflammation and infection. Therefore, to avoid an underestimated iron 
deficiency, C-reactive protein (CRP) is measured. An increased CRP (with a cut-off 
range of 10-30 mg/L) may indicate that the high SF result is unreliable (140).  In 
contrast, elevated serum soluble transferrin receptors (sTfR) can confirm functional 
iron deficiency independently of inflammatory state. A recent meta-analysis 
suggested the ratio between sTfR, and the log value of SF may offer a better sensitivity 
and specificity to indicate IDA (249). The other commonly used biomarker is zinc 
protoporphyrin, where a value above 8 µg/L in red blood cells indicates ID (250). If 
feasible, assessing Hb and SF (provided inflammation is excluded), either zinc 
protoporphyrin or sTfR together is the best combination to measure iron status (140). 
2.5.4 Iron intake and status in postpartum women 
Postpartum mothers should have a lower risk of developing ID or IDA, when 
compared to other women at reproductive ages (248). The low risk results from a 
period of amenorrhoea, low levels of iron in breastmilk, and possible increased 
absorption of iron from the small intestine (251).  
To estimate postpartum anaemia prevalence, data collected from over 46,000 German 
postpartum women between 1993 and 2008 were analysed and the study reported that 
22% of women at the second day after delivery were anaemic (Hb < 100 g/L) (251).  
This figure may be slightly overestimated since water balance regulation changes 
between 24 to 48 hours after childbirth. However, this large sample size enabled 
exploration of attributable risk factors contributing to immediate postpartum 
anaemia, and blood loss during childbirth (> 500 mL) was identified as the most 
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important determinant (251). A similar dataset from the United States determined the 
prevalence of postpartum anaemia. Bodnar examined nearly 60,000 low-income 
American women four to 26 weeks postpartum and identified 27% as being anaemic 
(Hb < 120 g/L) (252). After assessing a range of potential determinants, the researchers 
identified prenatal anaemia as a key contributing factor to postnatal anaemia (252). A 
protective effect of breastfeeding status through the presence of amenorrhoea was 
also suggested. Both studies were inconclusive as to whether anaemia status was due 
to iron deficiency, or perhaps other nutrient deficiencies such as vitamin B12, given 
the absence of any further measurement of nutrient status, especially iron (251). 
With regard to ID and IDA, based on the analysis of data collected for the National 
Health and Nutrition Examination in the United States from 1988-94, a 16% ID (SF <15 
µg/L) and around 4% IDA (SF < 12 g/L, Hb < 120 g/L) among women from childbirth 
to six months postpartum (253). After controlling confounding variables, early 
postpartum women from low income groups presented a four times higher risk of IDA 
than their non-pregnant counterparts, and such heightened risks continued for those 
between 7-12, and 13-24 months postpartum (253). A cross-section study of Nepali 
lactating women [only 7% (33/465) < three months postpartum including exclusive 
and partial breastfeeding] reported that over 70% of studied women presented with 
inadequate iron intake (≤ 23.4 mg), but only 5% were identified as being ID (plasma 
ferritin < 15 µg/L) (254). There was a possibility of overestimation of inadequate intake 
since an EAR value of over three months postpartum was used. Low prevalence of ID 
and IDA was, perhaps, due to protective effects from amenorrhoea and over six-month 
consumption of iron supplements during pregnancy.  
Supplementation during later pregnancy may lower the prevalence of postpartum 
anaemia (255) and enhance iron status (256). An earlier double-blinded placebo 
pregnancy supplementation trial (28 gestation weeks, receiving 100 mg elemental Fe 
daily) in Niger also found that at three months postpartum there was less prevalence 
of ID among women from the supplementation group (12%), compared to the placebo 
group (34%) assessed by serum ferritin levels (< 12 µg/L) (257). The 2016 WHO 
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guideline recommends oral iron supplementation may be provided to women at six 
to twelve weeks postpartum where a prevalence of gestational anaemia is higher than 
20% and emphasised this was conditional due to low quality evidence (258). 
In New Zealand, a recent study from the Massey research group (unpublished data 
from the Mother and Baby Study in 2011) found the median iron intake met the RDI 
and no individual intake was below the EAR level, confirming that iron intake was 
adequate in these studied postpartum women. Although iron intake was estimated 
from repeated 24-hour dietary recalls, iron status itself was unexamined. Iron storage 
and Hb levels of postpartum women in New Zealand are rarely examined routinely, 
unless higher than usual levels of blood loss during childbirth are recorded (259), thus, 
research concerning iron intake and status of postpartum women is limited. 
2.6 Postnatal Depression (PND) 
Postnatal depression (PND) is one of the major maternal health issues to arise and can 
exacerbate negative health effects on their newborns (poorer growth, higher risk of 
diarrhoea) and children (delayed motor development and behavioural problems) (257, 
259). Its onset begins six weeks to six months after childbirth. Most women will 
recover over time from PND, though approximately one quarter of affected women 
report being depressed when their infant reaches their first birthday (260). It has been 
established that minor depressive symptoms during the postpartum stages may 
increase the risk of recurrence of depression throughout the reproductive years (261). 
Of additional concern, is that mothers with newborns are often reluctant or unable to 
seek help when they experience symptoms of PND (262). Such under-diagnosed and, 
at times, untreated mental health conditions affect both the mother and their 
children’s ongoing cognitive, emotional, and behavioural development (263). 
A meta-analysis from 59 studies globally suggested the prevalence of PND was 
approximately 13% among women after partition (264). Using the Edinburgh 
Postnatal Depression Scale (EPDS), the prevalence of PND in New Zealand was 
around 8% in 1994, and 16% in 2006. In the 2015 New Mothers’ Mental Health Survey, 
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the prevalence was estimated to be 14% (262), and it is now regarded as the most 
common disorder for mothers in their first postpartum year (265). 
Despite other instances of social and psychological aetiology of depression, potential 
risk factors have been extensively explored, including hormonal factors and the 
micronutrients status of birth mothers. 
2.6.1 Thyroid antibodies and thyroid hormones 
Endocrinological factors have been suggested to play a significant role in the 
development of PND, since women experience dramatic hormonal changes (such as 
progesterone) after parturition (264, 265, 266). In attempts to seek predictive factors, 
studies have measured antenatal thyroid function to evaluate risk of PND. They have 
found that pregnant women with low total and fT3 (267) or total T4 (268), and low 
fT3 and fT4 (269) may indicate increased risk of developing PND. However, other 
cofounding factors can also play a role in these studies, such as prepartum depression, 
or subjects being single mothers. Since thyroid dysfunction and depression were 
experienced concurrently by some postpartum women, some researchers have 
investigated their associations. A follow-up study from the Netherlands found that 
even though thyroid function was normal during pregnancy, 7% (n = 21) of women 
developed thyroid dysfunction after giving birth, with 38% (8/21) developing 
depression (270). In contrast, a Spanish observational study of pregnant women with 
follow-up at 1, 3, 6, 9 and 12 months postpartum, detected no cases of PND among a 
group of women with thyroid dysfunction, and no statistically significant depression 
scores (as measured by  Beck Depression Inventory) between healthy women and 
those with thyroid dysfunction (271). 
A double-blinded comparison study in Wales recruited a cohort of postpartum 
women with TPOAb positive (n = 145) and negative (n = 229), and found that women 
with positive antibodies (43%) were more likely to be depressed, when compared to 
similar women with negative antibodies (28%) (272). Such associations were also 
reported by Breese McCoy et al. (2008, n = 51) at four weeks postpartum (273) and Le 
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Donne et al. (2012, n = 74) at day three of postpartum (274), although only relatively 
smaller sample sizes were studied. In contrast, other studies of 57 Greek women (one 
and six weeks postpartum) and 1053 Spanish women (at eight and 32 weeks 
postpartum) have reported no associations between positive thyroid antibody status 
and risk of PND (based on EPDS scores) (267, 273). However, based on the possible 
effects of thyroid antibodies, only one known randomised control trial was conducted 
by supplementing 100 µg thyroxine daily (n = 167) or placebo (n = 174) to women with 
thyroid antibody positive from six weeks to six months postpartum (275). Even so, no 
significant effect on PND (measured by the Montgomery and Asberg Depression 
Rating Scale) was found to exist. 
In addition, individual thyroid hormones have been examined in relation to their 
association with PND. In a small sample observational study (n = 51), a high plasma 
TSH at four weeks postpartum has been found to increase the risk of depression of 
American women at the same time, however, only one person in the cohort showed 
abnormally high TSH (273). A larger sample of Swedish women’s study (n = 365) 
reported a high TSH (> 4 mIU/L, measured at childbirth) increased the risk of PND at 
six months postpartum (2). The specificity (69.4%) and sensitivity (76.2%) of using 
serum TSH at childbirth to predict PND at six months postpartum were examined, 
suggesting serum TSH can be used as a routine screening test for PND (2). However, 
a 2003 prospective study examined 57 breastfeeding British women and did not find 
any association between TSH examined at one and four weeks postpartum and the 
risk of PND (EPDS scores ≥ 10) at six months after birth (276). Further, a large 
observational Spanish study (n = 1053) reported thyroid function indicators (TPOAb, 
fT4, and TSH), measured immediately after childbirth, did not predict later postnatal 
depression risks examined at eight weeks and 32 weeks postpartum (277). 
Overall, it must be stated, that inconsistent results on the relationship between 
thyroid function on the risks of PND were more often reported. Further studies will 
be required using a standardised measure of postnatal depression scales to evaluate 
its predictive factors. 
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2.6.2 Selenium status  
Selenium is suggested to offer increased protective effects on impaired mental health. 
Lower dietary selenium intake has been associated with an increased risk of de novo 
major depressive disorder among women (278), whereas adequate dietary intake of 
selenium has been shown to improve the mental outlook among the general 
population (279), including young adults living in New Zealand (280). 
Results from a longitudinal Canadian study (Alberta Pregnancy Outcomes and 
Nutrition, APrON) found that women who used selenium supplementation during 
their pregnancy presented with a lower risk of having depressive symptoms at 12 weeks 
postpartum (281). Micronutrient supplementation in the APrON study was measured 
repeatedly by a self-reporting questionnaire, though selenium status was not 
measured and dietary intake from food was not included in the analysis. In contrast, 
a randomised clinical trial of supplementing selenium (100 µg/day as selenium yeast) 
to Iranian women early in primigravid pregnancy (n = 83) through to childbirth 
provided supportive evidence that prenatal supplementation may itself prevent PND 
(based on the EPDS), when compared to the placebo group (n = 83) (282). The mean 
EPDS scores in the selenium treatment group was 8.8, which is significantly lower 
than 10.7 in the placebo group, at eight weeks postpartum (P < 0.05). Such study 
outcome remained after adjusting for multiple confounders, including education, job 
and social support scores, and excluded subjects with existing depression (Beck 
Depression Inventory Test scores ≥ 31) (282). These results have demonstrated that 
prenatal selenium supplementation can impact positively on women’s postnatal 
mental health. However, there have been limited published studies which examine 
postpartum women’s selenium status in relation to the risk of postnatal depressive 
symptoms, particularly where continuous measurements were taken from childbirth 
to the end of the first postpartum year. 
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2.6.3 Iron status  
Research shows an association between iron status and cognitive performance among 
women of childbearing age. American women (n = 37) from Pennsylvania, with a low 
Hb (< 120 g/L, analysed by HemoCue device) at the first week of postpartum, had an 
increased risk of developing PND 28 days after childbirth (based on the Centre for 
Epidemiological Studies-Depressive Symptomatology Scale, 16.4 vs 6.9, P = 0.001) 
(283). This American cohort observational study suggested those postpartum women 
with symptoms of anaemia may benefit from iron supplementation (283). 
Unfortunately, iron status (serum iron or ferritin levels) was not measured in this 
study, neither was thyroid dysfunction screened. 
Two well-designed interventional studies have also investigated the relation between 
iron status and postpartum women’s emotion and cognition. A randomised six-month 
double-blind placebo-controlled trial was conducted by Beard et al. in 2005 (284). Low 
income postpartum South African mothers were allocated into three groups: 
nonanemic controls, anaemic mothers receiving placebo of the combination of 10 µg 
folate and 25 mg vitamin C, and anaemic mothers receiving 125 mg FeSO4 in 
conjunction with 10 µg folate and 25 mg vitamin C (284). Their iron status (Hb, mean 
corpuscular volume, and transferrin saturation), cognitive and behavioural variables 
were measured at six weeks and nine months postpartum. The researchers observed 
a strong relation between IDA and depression and anxiety (measured by the Raven's 
Progressive Matrices test) at nine months postpartum, suggesting an accumulative 
effect of IDA on maternal cognition. Another more recent randomised placebo-
controlled trial in 2017 was implemented on 70 Iranian mothers at seven days 
postpartum diagnosed with PND (EPDS score ≥11 and confirmation from further 
psychiatric interviews) (285). This was a six-week interventional study, non-anaemic 
women with PND were given 50 mg elemental iron daily starting from one week after 
childbirth. Reduced EPDS scores from 12 to 9 (P < 0.001) was observed in the iron 
supplementation group, while non-significant changes from 13 to 12 (P = 0.13) in the 
placebo group. The results highlighted that early iron supplementation had led to a 
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positive reduction in the EPDS scores, together with 43% of women from the 
treatment group having negative psychiatric interviews (285). It was noted also that a 
higher percentage of women with depletion of iron stores (serum ferritin < 15 µg/L) 
continuously presented with postnatal depression (27%) when compared to women 
with sufficient iron stores (4%, P = 0.02) (285). These results suggested iron may play 
a critical role in the aetiology of PND. 
Further, similar lowering effects of EPDS scores was reported in Italian women (n = 
424) at one month postpartum after daily supplementing with iron-containing 
multiple-mineral and vitamins (Elevit), particularly evident among women with a 
baseline EPDS score higher than 12. Unsurprisingly, no significant changes were found 
among women (n = 428) in the control group with dual supplementation of 500 mg 
calcium and 400 IU vitamin D3 (286). However, it was unclear the amount of iron 
which was supplemented in the treatment group. The researchers concluded iron 
mixed with vitamins played a favourable role in improving postnatal depression (286). 
In respect of the studies described above, iron status at different timing and stages of 
postpartum was measured, also their chosen screening scales and cut-offs varied, and 
some appear to have used follow-up psychiatric interviews to further diagnose PND. 
Therefore, it is inconclusive whether, and to what degree, unfavourable iron status 
contributes to the risk of depression or at which defined stages of postpartum. 
Although some high-quality control trials revealed a positive contribution of 
improving iron status towards postpartum women’s mental health (287), PND is a 
multifactorial condition. Further research is required to better identify risk factors, 
and to understand the role of  ID and IDA in relation to depression. 
2.7  Summary of the literature review 
Postpartum thyroiditis is one of the thyroid dysfunctions occurring in the first year 
after parturition, and even subclinical forms may develop into permanent thyroid 
dysfunction. However, as far as can be ascertained, there are no current available 
research data regarding the prevalence of postpartum dysfunction in New Zealand. 
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Previous literature has suggested that iodine, selenium, and iron are important in the 
synthesis of thyroid hormones. However, limited research has investigated the 
interaction of these three nutrients simultaneously within the thyroid function. 
Iodine deficiency affects all ages and stages of human life, especially postpartum 
women and their infants. Studies conducted to date support the importance of early 
gestational iodine status in infants’ neurodevelopment, which enables children to 
reach their optimal cognitive potential and academic performance in later years. 
Accordingly, the first 1000 days of life remain an important window of opportunity for 
optimal growth and development. Further research is required to investigate maternal 
postpartum iodine status in relation to early infant development. Re-emerging iodine 
deficiency has continued be a concern in New Zealand since the 1990s, so in an 
attempt to overcome such a deficiency, two government initiatives were introduced: 
1) mandatory fortification of bread and bread products with iodised salt from 
September 2009, and 2) the provision of iodine supplementation (150 µg/day) for all 
pregnant and lactating women in 2010. Subsequent studies have reported that most 
adults and children in New Zealand may now have reached adequate iodine 
intake/status, but further research is needed to examine more widely iodine intake 
and status of postpartum women and their infants in New Zealand. 
Selenium plays an important role as an antioxidant involved in thyroid function, 
mental health, and child development. New Zealand soils continue to provide low 
selenium to local food supplies. Low selenium intake has been reported in women of 
childbearing age and postmenopausal women, however, few research studies on 
breastfeeding women and their infants have been published. Given recent changes in 
dietary habits (excluding animal-products, such as chicken), increased food product 
availability and changing agricultural practices, the continual monitoring and 




Postpartum women are known to pose a low risk of developing ID and IDA. However, 
unless significant blood loss during childbirth, iron status is not routinely monitored 
during the postpartum period. Despite possible negative effects on maternal-infant 
interactions and infant development, there has been insufficient recent research 
concerning postpartum women’s iron status in New Zealand. 
Lastly, PND is one of the major maternal health issues to arise and can often 
exacerbate negative health effects for mothers and their newborns. Previous literature 
has indicated possible biological contributors to PND are suboptimal thyroid 
hormones, and low selenium and iron status, but results published to date are 
inconclusive. Further opportunities of investigating iodine (the major component of 
thyroid hormone), selenium and iron together may provide additional evidence on 
their potential influence on the risk of postnatal depression. 
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Chapter 3 Selenium intake in iodine-deficient pregnant and 
breastfeeding women in New Zealand 
 
Historically, insufficient selenium intake exists in the New Zealand population, and 
numerous studies have investigated selenium intake during the decade of 1980-1990. 
However, limited studies have monitored selenium intake/status in recent years, 
especially in pregnant and breastfeeding women (noted in Chapter 2).  
This chapter reports the results of a secondary data analysis arising from the Mother 
and Baby pilot study over the 2009 and 2011 period (Study 1). It explores the selenium 
intake in a sample of iodine-deficient pregnant and breastfeeding women residing in 
Palmerston North, in the North Island of New Zealand. Ethics approval was obtained 
from the Massey University Human Ethics Committee (Southern A 08/32 and 10/54). 
The main findings suggest suboptimal dietary selenium intake continues to be of 
concern for both pregnant and breastfeeding women and their breastfed infants in New 
Zealand. Inadequate intake of selenium for pregnant women was not followed up, as it 
is not within the scope of this PhD thesis. The focus of this thesis is on a cohort of 
breastfeeding women; it is pivotal to measure their actual selenium status by assessing 
plasma selenium. As selenium has numerous roles, it is also necessary to investigate any 
effects of low intake on other health outcomes during the perinatal period, specifically 
postnatal depression. The research gaps arising from this pilot study predominantly 
contributed to form the basis of the Mother and Infant Nutrition Investigation (MINI) 
study research questions and final design. 
 
This chapter has been published as: 
 Jin Y, Coad J, Weber J, Thomson J, Brough L. Selenium intake in iodine-deficient 






Selenium plays a role in antioxidant status and, together with iodine, in thyroid 
function. Iodine deficiency exists in New Zealand during pregnancy and lactation, and 
selenium deficiency may further affect thyroid function. 
Objective 
This study investigated selenium intakes of pregnant and lactating women, in 
Palmerston North, in the North Island of New Zealand. 
Methods 
Dietary intake was estimated using three repeated 24-hour dietary recalls. Dietary 
intake in pregnancy was also estimated from 24-hour urinary excretion of selenium. 
Selenium concentrations were determined in urine and breastmilk using inductively 
coupled plasma mass spectrometry. 
Results 
Median (p25, p75) selenium intakes based on dietary data were 51 (39, 65) µg/day in 
pregnancy and 51 (36, 80) µg/day in lactation, with 61% and 68% below estimated 
average requirement (EAR). Median daily selenium intake in pregnancy based on 
urinary excretion was 49 (40, 60) µg/day, with 59% below EAR. Median selenium 
concentration in breastmilk was 11 (10, 13) µg/L and estimated median selenium intake 
for infants was 9 (8, 10) µg/day, with 91% below the Adequate Intake of 12 µg/day. 
Conclusions 
These pregnant and breastfeeding women were at risk of dietary selenium inadequacy. 
Further research is required to assess selenium status in relation to thyroid function 




The intake of selenium worldwide ranges from 7 to 4990 µg/day and varies greatly 
from deficient to toxic intakes (1). New Zealand soils contain low levels of selenium, 
leading to low levels in the food supply (2). The most recent New Zealand Total Diet 
Survey suggested dietary selenium intake was inadequate throughout the New 
Zealand population, putting them at risk of deficiency (3). Recent New Zealand studies 
have shown low selenium intakes in women of childbearing age and older women 
based on urinary selenium excretion (4, 5). 
Selenium is essential in human health to produce selenoproteins, which have 
antioxidant and anti-inflammatory roles, and for production of thyroid hormones (6). 
Selenoproteins (iodothyronine deiodinases) are required for generating the active 
thyroid hormone T3 (triiodothyronine) from the inactive T4 (thyroxine) form (7). 
Selenium is also an essential cofactor for glutathione peroxidase, a potent antioxidant, 
which protects thyroid cells from damage due to any excessive hydrogen peroxide 
generated from the synthesis of thyroid hormones (8). 
Selenium has been suggested to play an important role in normal brain development, 
although the mechanism is not clear. Two recent large cohort studies from Poland 
and Spain found selenium status in the first trimester was adversely associated with 
neuropsychological development assessed at one year and two years of age by the 
Bayley Scales of infants and Toddler development (9), and five years of age by the 
McCarthy Scales for Children’s Abilities (MSCA) (10). Varsi et al. (2017) investigated 
the effect of maternal selenium status on neurodevelopment of infants and reported 
that low serum selenium concentration in pregnancy was negatively associated with 
infant psychomotor score at six months of age (11). 
The interaction between selenium and iodine in thyroid hormone synthesis is of 
particular concern in New Zealand due to dietary insufficiency of both selenium and 
iodine. Iodine deficiency has historically been a health problem in New Zealand (12) 
and the mandatory fortification of all bread (except organic and unleavened) with 
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iodised salt was introduced in September 2009 (13). Since mandatory fortification, 
most adults (14) and school-aged children (15) in New Zealand have adequate iodine 
intakes. Despite an iodine supplement being recommended and available to all 
pregnant and lactating women in New Zealand, this population group still has 
insufficient intakes and low status (16). Selenium deficiency could potentially 
exacerbate the consequences of mild iodine deficiency in this vulnerable group (12). 
During pregnancy and lactation, there are increased selenium requirements for the 
growing fetus and newborn (3). Low maternal serum selenium concentrations are 
associated with adverse pregnancy outcomes such as pre-eclampsia (17), other types 
of pregnancy-induced hypertension (18) and preterm birth (19). Human milk is critical 
for an exclusively breastfed infant’s optimal selenium status. A study in the South 
Island of New Zealand (1998–1999) showed postpartum women and breastfed infants 
had low plasma selenium, suggesting suboptimal status (20). Since then, no data 
about selenium intakes have been collected for this population. Given changes in 
dietary habits, food product availability and agricultural practices, continual 
monitoring of selenium intake in this vulnerable population is essential. 
This study aimed to assess current maternal selenium intake during pregnancy and 
lactation and estimate infant selenium intake in a sample of women in Palmerston 
North, North Island, New Zealand. 
3.3 Materials and methods 
3.3.1 Study population 
Pregnant and breastfeeding women were recruited from January to July 2009 and 
January to September 2011 via local health professionals who work closely with 
pregnant and breastfeeding women, as described previously (16). Volunteers were 
aged 16 years and older, in their third trimester of pregnancy (greater than 26 weeks 
of gestation), or at least three weeks postpartum and breastfeeding. Women who had 
medical complications during their pregnancy were excluded. Women had to actively 
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volunteer for this study and no data were kept from women who did not meet the 
selection criteria (16). Ethical approval was obtained from the Massey University 
Human Ethics Committee (Southern A 08/32 and 10/54). Written consent was 
obtained from all participants. 
3.3.2 Dietary data collection 
A 24-hour dietary recall was conducted based on the US Department of Agriculture 
Automated Multiple-Pass Method but excluded the Forgotten Foods List (21). A 
photographic food atlas was provided to estimate portion sizes (22). Participants were 
also asked to include any dietary supplements taken, including the brand name and 
the amount. Two subsequent recalls were collected via telephone interviews over the 
following two weeks, ensuring a weekend day was included; food portion sizes were 
estimated using household measures. Previous research has found no difference in 
energy intakes when comparing 24-hour dietary recalls collected in person versus via 
the telephone (23). Dietary data were analysed using Foodworks 2009 (Xyris Software, 
Brisbane, Australia) based on the New Zealand food database (24). Dietary 
supplements used by participants were included in dietary data analysis.  
The estimated average requirement (EAR) cut-point method can be used to assess 
population nutrient intake providing nutrient requirements are normally distributed 
(e.g., selenium); the percentage below the EAR approximates the proportion that is at 
risk of dietary inadequacy (25). For a population to have a very low prevalence of 
inadequate dietary intakes, the mean/median intake should be above the 
recommended daily intake (RDI) (25). Current intakes based on diet and urine data 
were compared to Australian and New Zealand recommendations; the EAR and RDI 
for selenium for pregnant women are 55 and 65 µg/day, and for lactating women are 
65 and 75 µg/day, respectively (3). 
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3.3.3 Sample collection and selenium analysis of urine and breastmilk 
All participants were asked to collect a 24-hour urine sample and provided with an 
insulated box containing two polythene bottles for urine storage and frozen silica pads 
to keep the sample cool. Lactating women were also requested to provide a breastmilk 
sample (around 30 mL) and provided with a breast pump if required; timing of 
collection of breastmilk samples was not standardized, since no significant differences 
have been found in selenium concentrations between hind-milk and fore-milk (26). 
The concentration of selenium in breastmilk varies most significantly during the first 
21 days from the transition from colostrum to mature milk (26), thus breastmilk 
samples were collected after three weeks postpartum. All samples were brought 
immediately to the Human Nutrition Research Unit for processing after collection. 
The total volume of urine collected over 24 hours was measured for each participant. 
Samples were stored without preservative at −20 ◦C, prior to analysis. Urine samples 
were defined as inaccurate if urine volume was below 1 L and urinary creatinine below 
5 mmol/day, or extreme outliers of creatinine (> 3 standard deviation) (27). However, 
no study samples were classified accordingly. 
Selenium concentrations of urine and breastmilk samples were determined by Hill 
Laboratories, Hamilton, New Zealand, using inductively coupled plasma mass 
spectrometry (28). Quality Control procedures included analysis of blanks, analytical 
repeats and spiked samples in order to ensure accuracy and precision. Calibration 
standards and checks were undertaken on every run with the limit of detection at 
0.002 mg/kg.  Dietary selenium intake was estimated for pregnant women, based on 
a urinary excretion of 55% of selenium intake (29). However, it was not possible to 
estimate dietary selenium intake for lactating women via urine, as we were unable to 
determine the daily loss of selenium from breastmilk. Creatinine was measured using 
the Jaffe Method Flexor E (Vital Scientific NV, 6956 AV Spankeren/Dieren, Rheden, 
Gelderland, The Netherlands) at the Massey University Nutrition Laboratory. 
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3.3.4 Statistical analysis 
Data were analysed using IBM SPSS (Statistics Package for the Social Sciences, IBM, 
Armonk, NY, USA) version 20. Data were tested for normality using Shapiro-Wilk’s 
test. Non-parametric data were expressed as median (25th, 75th percentile) and 
parametric data expressed as mean (± standard deviation; SD). Bivariate correlations 
were tested using the nonparametric Spearman’s rho correlation coefficient. Scatter 
plots were generated for suspected bivariate correlations and visually inspected for 
verification. Fisher’s exact test was used to detect associations between dietary and 
biological methods in assessing dietary intake. 
3.4 Results 
Fifty-nine pregnant and 68 lactating women were recruited. The mean age was 31.6 ± 
5.7 and 31.3 ± 5.0 years for pregnant and breastfeeding women, respectively (Table 3.1). 
The ethnicities of participants were Caucasian (80%, 81%), Maori (12%, 9%), Asian 
(5%, 2%) and other (3%, 8%). Participants were predominantly educated at tertiary 
level (86% pregnant and 68% breastfeeding), with approximately half being pregnant 
with or breastfeeding their first infant. 
Table 3.1 Description of pregnant and breastfeeding participants. 
n (%) Pregnant (n = 59) Breastfeeding (n = 68) 
Age, years (Mean ± SD) 31.6 ± 5.7 31.3 ± 5.0 
Tertiary Education 51 (86) 46 (68) 
Ethnicity (Caucasian)  47 (80) 56 (81) 
Ethnicity (Maori)  7 (12) 6 (9) 
Ethnicity (Asian) 3 (5) 1 (2) 
Ethnicity (Other) 2 (3) 5 (7) 
Nulliparous 31 (53) - 
First time lactation  - 36 (53) 




Median selenium intake based on dietary assessment among pregnant women was 51 
(39, 65) µg/day, below both the RDI (65 µg/day) and EAR (55 µg/day), with 61% below 
the EAR (Table 3.3). Median urinary selenium for pregnant women was 14.1 (9.1, 18.2) 
µg/L (Table 3.2) and median selenium intake based on urinary excretion was 49 (40, 
60) µg/day (Table 3.3); below both the RDI, with 59% below the EAR. Dietary and 
urinary data both suggest inadequate selenium intakes among pregnant participants. 
Only four of the 59 pregnant and six of the 68 lactating women were taking selenium-
containing supplements. 
Table 3.2 Selenium and creatinine in 24-hour urine samples and selenium in breastmilk. 
Median (p25, p75)  Pregnant  Breastfeeding 
Numbers of participants (n) 59 68 
Urine volume (L) 2.2 (1.5, 3.0) 1.8 (1.2, 2.5) 
Urinary selenium concentration µg/L  14.1 (9.1, 18.2)  12.1 (7.8, 19.9) 
Measured 24-hour urinay selenum µg/day  27.1 (22.0, 32.9) 21.2 (14.5, 29.9) 
Urinary creatinine g/L  0.5 (0.4, 0.7) 0.7 (0.5, 1.1) 
Urinary creatinine g/day 1.2 (1.0, 1.5) 1.3 (1.2, 1.4) 
Selenium: creastinine µg/g 22.8 (17.7, 28.7) 16.5 (12.3, 23.8) 
Selenium in breastmilk µg/L - 11.3(10.0, 13.3) a 
a 
n= 64 for breastmilk samples. 
 
Based on dietary assessment the median selenium intake for breastfeeding women 
was 51 (36, 80) µg/day (Table 3.3), also below both the EAR (65 µg/day) and RDI (75 
µg/day), with 68% below the EAR. Median selenium concentration in breastmilk (n = 
64) was 11 (10, 13) µg/L (Table 3.2). Using an estimated daily breastmilk intake of 750 
ml (30), the median estimated selenium intake for infants was 9 (8, 10) µg/day; 70% 
(45/64) were below the daily minimum of 10 µg/day suggested by Levander (31), and 
91% (58/64) below the Adequate Intake of 12 µg/day (32). 
For breastfeeding women, selenium concentration in breastmilk was weakly, 
positively correlated with 24-hour selenium excretion in urine as µg/day (r = 0.269, P 
= 0.032, see Appendix 16.2). Pregnant participants’ dietary selenium intake based on 
dietary assessment was not associated with selenium excretion as either µg/L (r = 
0.053, P = 0.692) or µg/day (r = 0.230, P = 0.079). However, the classification of intakes 
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as either above or below the EAR were associated for the two methods of assessing 
dietary intake (P = 0.016, Fisher’s Exact Test). 
Table 3.3 Estimated selenium intake in pregnant and breastfeeding women, infants and 
comparison to recommendations. 
Selenium Intake 
Pregnant  
(n = 59)  
Breastfeeding  
(n = 68) 
Infant 
(n = 64) 
Estimated selenium intake; median (p25, p75) 
Based on 24-hour urine, µg/day 
 
49 (40, 60) 
  
Based on 24 hour dietary recalls, µg/day  51 (39, 65)  51 (36, 80)  - 
Below EAR (55 µg/day) (n, %) 




Based on 24-hour dietary recalls 36 (61) 45 (68) - 
Estimated selenium intake; median (p25, p75) 
Based on 750 ml breastmilk per day  
- - 9 (8, 10) 
Below (10 µg/day) (n, %) - - 45 (70) 
Below (12 µg/day) (n, %) - - 58 (91) 
a EAR = estimated average requirement, 55 µg/day for pregnant women and 65 µg/day for breastfeeding women. 
3.5 Discussion 
This study found 59–61% of pregnant and 68% breastfeeding participants had 
estimated selenium intakes below the EAR, suggesting this vulnerable group is at risk 
of an inadequate selenium intake. This supports the latest New Zealand Adult 
Nutrition Survey 2008/2009, which estimated that 44–72% of women aged 19–50 years 
had inadequate selenium intakes (33). Previous research shows that low selenium 
status is associated with an increased risk of thyroid enlargement, which may indicate 
compromised thyroid function (34). Iodine deficiency has previously been reported in 
both pregnant and breastfeeding women in New Zealand in the same cohort 
investigated in this study (16), and selenium deficiency could further compromise 
thyroid function. 
In the present study, dietary intake was assessed by three 24-hour dietary recalls, due 
to its low participant burden and good compliance. Under- or over-reporting is a 
concern for dietary assessment. As energy expenditure was not recorded, we were 
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unable to determine if participants had misreported dietary intake. A large daily 
variation of selenium intake was reported in an earlier study of American pregnant 
and postpartum women using duplicate-plate food and drink composites and dietary 
recalls (35). Single 24-hour recalls do not consider day-to-day variation, therefore 
repeated 24-hour dietary recalls are frequently used to estimate usual intake (36). 
In the current study, 24-hour urinary selenium excretion was used to estimate 
selenium intake. It is estimated that 50–60% of dietary selenium is excreted in urine 
(29), and selenium intake determined in this manner is suggested to be more accurate 
than dietary assessment data (37). However, collecting 24-hour urine samples requires 
motivated participants and is not practical for all populations or large studies. Urinary 
selenium has been shown to be a valid method to assess recent selenium intake in 
populations that live in selenium-deficient areas (37, 38). Research has shown that 
serum selenium and glomerular filtration rate increase in pregnancy, and studies have 
shown an increase in selenium in urine during pregnancy (39). Thus, the selenium 
excretion of 55% could be overestimated, so actual selenium intakes could be even 
lower than estimated values. A previous New Zealand study found selenium intake 
determined from a Food Frequency Questionnaire was associated with 24-hour urine 
excretion in pregnant women (39). Although the current study found no such 
association in pregnant women, the classification of intakes as either above or below 
the EAR was associated for the two methods of assessing dietary intake. 
Median intake of selenium for pregnant women in the current study was 51 µg/day 
based on dietary intake and 49 µg/day based on urine excretion. In previous studies 
of New Zealand pregnant women, Watson and McDonald found median intakes 
ranging between 33.5 µg/day excluding dietary supplements to 67 mcg/day including 
dietary supplements (40), however, these data were based on dietary assessment with 
no verification using biomarkers. The median selenium intake of 51 µg/day for 
breastfeeding women was higher than previously reported (46 µg/day) in the 1998–
1999 study of lactating mothers from the South Island of New Zealand (20). This was 
not unexpected, as selenium intake is typically lower in the South Island of New 
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Zealand, where bread is made from local wheat, compared to the North Island, where 
bread is manufactured from wheat imported from Australia, which has higher levels 
of soil selenium (12). It could also be due to changes occurring in diet in the last 20 
years. Even though selenium intake is higher among breastfeeding women in the 
current study than previously reported, many current intakes are still below the EAR, 
thus suggesting a risk of dietary inadequacy. 
Breastmilk selenium concentration is associated with maternal selenium intake 
and/or status. Selenium is generally higher in colostrum (26 µg/L), and then decreases 
to nadir levels in mature milk (1–3 months, 15 µg/L) (31). Median selenium breastmilk 
concentrations (11.3 µg/L) in the present study were similar to those reported in the 
South Island in 1992 (13.4 µg/L) (41) and also a recent study in the North Island (14 
µg/L) (42). Adequate selenium concentrations in breastmilk have been observed to 
maintain optimum selenium status in both preterm and term infants (26). For 
exclusively breastfed infants, breastmilk is the only source of selenium; in the current 
study, 70% of infants would not have achieved the 10 µg/day suggested as adequate by 
extrapolation from adults (31) and 91% did not achieve the Adequate Intake of 12 
µg/day (18). This suggests infants in the present study are at risk of selenium 
deficiency. 
The inadequate selenium intakes in this vulnerable population are of concern. Studies 
in rats have previously shown that in utero selenium deficiency can impair neonatal 
lung development (43). Maternal selenium status in French women was negatively 
associated with risk of wheezing in children aged 1–3 years; this could potentially lead 
to asthma later in life (44). Low selenium status in childhood in New Zealand has also 
been associated with increased risk of wheeze (45), for which New Zealand has a high 
incidence (46). Low maternal selenium status in Norwegian women has been 
associated with an increased risk of neonatal infections in the first 6 weeks of life and 
lower psychomotor score at six months (11). Adequate dietary intake of selenium has 
been suggested to be beneficial in improving mental outlook among the general 
population (47). Lower dietary selenium intake has also been associated with an 
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increased risk of de novo major depressive disorder among women (48). Selenium 
supplementation during early pregnancy has been found to reduce postnatal 
depression (49), which has a 7.8% to 16% prevalence in New Zealand (50). 
Determining selenium concentrations in blood (whole, plasma or erythrocyte), 
plasma selenoprotein P or GPx activity in blood (whole, plasma or platelet) are 
considered more reliable markers of selenium status (51, 52) However, urinary 
selenium excretion is associated with both plasma selenium and dietary intake in 
populations with low selenium intake (12).  A limitation of the current study is not 
measuring selenium or GPx activity in blood, however, determining daily urinary 
selenium excretion serves as a proxy measure for selenium intake and indicates the 
need for further research. 
This study included a small sample of pregnant and breastfeeding women who were 
predominantly well educated and more likely to be affluent, thus the sample is not 
representative of the New Zealand population. However, women who volunteer for 
health studies tend to be interested in health and motivated towards a healthy 
lifestyle, thus it is of concern that these women are at risk of selenium deficiency. 
Further, we would not expect such women to have a poorer health status than less 
affluent women. The age spread of infants may indicate that some infants were not 
exclusively breastfed, and consuming complementary food may impact on infant 
selenium intake.  
Additionally, supplement intakes could contribute to participants’ dietary selenium 
intake; however, only a small proportion of participants consumed selenium-
containing supplements. Thus, we were not able to meaningfully investigate the 
potential impact of supplement intake on other measures. 
3.6 Conclusions  
This current research suggests dietary selenium intake is a concern for pregnant and 
breastfeeding women and their infants in New Zealand. Further research is required 
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to assess selenium status among these groups by measuring biomarkers such as 
plasma selenium or GPx activity in blood selenium. Further investigations should also 
include all socioeconomic groups. It is essential that we assess whether suboptimal 
intake of selenium adversely affects thyroid function in this already iodine deficient 
population. As selenium is a nutrient with numerous roles, it is also necessary to 
investigate any effects of low intake on other health outcomes potentially related to 
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Chapter 4 Study Protocol: Mother and Infant Nutrition 
Investigation in New Zealand (MINI Project): An Observational 
Longitudinal Cohort Study 
 
Chapter 4 describes the study protocol followed in the Mother and Nutrition 
Investigation (MINI) study. Ethics approval was obtained from the Health and 
Disability Ethics Committee (15/NTA/172) in December 2015. The study was registered 
with the Australian New Zealand Clinical Trials Registry (ACTRN12615001028594). This 
manuscript presents information on the research participant recruitment; the 
questionnaires used to collect data; methods used to estimate dietary intake; and 
maternal and infant anthropometry measurements. In addition, it details the process of 
biological sample collection and biomarker analysis of urine, breastmilk, blood, and nail 
clipping samples. It provides information on the study outcome measures, including 
iodine, selenium and iron intake and status; maternal thyroid function; longitudinal 
assessment of maternal mental health and infant neurodevelopment. 
A large volume of data has been collected in this observational longitudinal cohort 
study. Only certain data analyses are reported in this thesis, including data collected 
from the maternal questionnaires; weighed four-day dietary diary, maternal and infants’ 
anthropometric measures; thyroid gland volume determined via ultrasound; biological 
sample analysis of iodine, selenium and iron status; and thyroid hormone 
concentrations. Also, the thesis contains the results from assessing maternal mental 
health using the Edinburgh Postnatal Depression Scale. 
 
This Chapter has been published as: 
Jin Y, Coad J, Zhou SJ, Skeaff S, Benn C, Kim N, Pond RL, Brough L. Mother and Infant 
Nutrition Investigation in New Zealand (MINI Project): Protocol for an Observational 






Thyroid dysfunction is associated with cognitive impairment, mood disturbance, and 
postnatal depression. Sufficient thyroid hormone synthesis requires adequate intake 
of iodine, selenium, and iron. Iodine deficiency was historically a problem for New 
Zealand, and initiatives were introduced to overcome the problem: (1) mandatory 
fortification of all bread (except organic and unleavened) with iodized salt (2009) and 
(2) provision of subsidised iodine supplements for pregnant and breastfeeding women 
(2010). Subsequent to these initiatives, most adults and children have adequate iodine 
status; however, status among breastfeeding women and their infants remains 
unclear. This paper outlines the methodology of the Mother and Infant Nutrition 
Investigation (MINI) study: an observational longitudinal cohort study of 
breastfeeding women and their infants. 
Objectives 
This study will determine women’s iodine intake and status between supplement 
users and nonusers; women’s intake and status of iodine, selenium, and iron relating 
to thyroid function; associations between women’s selenium status, thyroid function, 
and postnatal depression; and infants’ iodine and selenium status relating to first year 
neurodevelopment. 
Methods 
Breastfeeding women aged over 16 years with a healthy term singleton infant were 
recruited from Manawatu, New Zealand. Participants attended study visits three, six, 
and twelve months postpartum. Maternal questionnaires investigated supplement use 
before and after birth, iodine knowledge, and demographic information. Dietary 
assessment and urine, blood, and breastmilk samples were taken to measure iodine, 
selenium, and iron intake/status. The Edinburgh Postnatal Depression Scale was used 
repeatedly to screen for postnatal depression. Thyroid hormones (free 
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triiodothyronine, free thyroxine, thyroid stimulating hormone, thyroglobulin, 
antithyroglobulin antibodies, and thyroid peroxidase antibodies) were measured in 
blood samples, and thyroid gland volume was measured by ultrasound at six months 
postpartum. Infant iodine and selenium concentrations were determined in urine. 
The Ages and Stages Questionnaire was used to assess infant development at four, 
eight, and twelve months. 
Results 
Data collection was completed. Biological samples analysis, excluding nail clippings, 
is complete. Data analysis and presentation of the results will be available after 2020. 
Conclusions 
This study will provide data on the current iodine status of breastfeeding women. It 
will also provide a greater understanding of the three essential minerals required for 
optimal thyroid function among breastfeeding women. The prospective longitudinal 
design allows opportunities to examine women’s mental health and infant 





Postpartum women experience abnormalities in thyroid function at twice the 
prevalence of the general population (1). Thyroid hormone is essential in maintaining 
the human body’s metabolism, temperature (thermoregulation), and psychological 
mood (2). In a developing brain, thyroid hormone is responsible for adequate 
myelination, neuron cell maturation, and central nervous system development (3). 
Optimal thyroid function relies on adequate biosynthesis of thyroid hormones, which 
depends on three dietary minerals: iodine, selenium, and iron (4, 5). Pregnancy 
increases thyroid hormone turnover; women with limited thyroidal reserve or 
marginal iodine deficiency are at increased risk to develop thyroid dysfunction after 
birth (6), which is one of the most common endocrine disorders that postpartum 
women experience (7). 
Iodine is the major component of thyroid hormones and a regulator for the synthesis 
and secretion of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). 
Selenium, as a component of the selenocysteine-containing proteins glutathione 
peroxidase, protects the thyroid gland from oxidative damage (5). Selenoproteins are 
required to convert T4 to T3, the active form of thyroid hormone. Iron is required for 
haem-dependent thyroperoxidase activity, which is required for the synthesis of 
adequate thyroid hormone. Selenium deficiency and iron deficiency anemia may 
negatively affect thyroid hormone synthesis by impairing selenium- and iron-
dependent enzyme activities, even if iodine status is adequate (5). Previous research 
has investigated iodine, selenium, and iron intake/status separately or a combination 
of any two of them among women of childbearing age (8) and postmenopausal women 
(9). However, further research is needed to explore all three micronutrients together, 
acknowledging their close relationship in thyroid hormone synthesis. 
Thyroid dysfunction is a significant health issue in New Zealand, with women 
diagnosed at five times the prevalence in men (10, 11). Concerning adequate thyroid 
function, iodine, selenium, and iron play important roles. In New Zealand, soils 
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provide low levels of available iodine and selenium, resulting in low concentrations in 
the food supply (12), hence in the diet (13). Iodine deficiency in early life is associated 
with impaired neurodevelopment (14). Iodine deficiency was a concern in New 
Zealand in the early years of the 20th century, but its prevalence was mostly reduced 
through the introduction of iodized salt in the 1930s. However, since the 1990s, a 
number of studies in New Zealand have shown iodine deficiency has reemerged in 
adults (15), pregnant and breastfeeding women (16, 17), school children (18) and 
breastfed infants and toddlers (19). To improve iodine status in New Zealand, two 
government initiatives were introduced: mandatory iodized salt in commercially 
made bread and bread products from September 2009 and the provision of iodine (150 
µg/day) supplementation for all pregnant and lactating women in 2010 (20). Although 
recent studies suggested that adults (21, 22) and children (23) in New Zealand may 
now have adequate iodine intake/status, both pregnant and breastfeeding women 
remain deficient. A pilot study of a small sample of self-selected highly educated 
pregnant and breastfeeding women assessed urinary iodine excretion, breastmilk 
iodine concentration, and blood thyroglobulin and suggested iodine deficiency (24). 
There is a need for a more robust investigation into the iodine status of postpartum 
women and their infants from a wide range of socioeconomic backgrounds. 
Low selenium status in New Zealand has been partially reversed by increased 
consumption of imported flour from Australia (which generally has higher selenium 
concentrations than flour produced in New Zealand) (25, 26). In addition, both 
pregnant and breastfeeding women have an increased requirement for dietary 
selenium due to the demands from the fetus and breastfed infants. Previous research, 
which investigated selenium status among postpartum women and their infants in 
New Zealand 20 years ago (27), measured urinary selenium excretion and plasma 
selenium and indicated that such women were at risk of selenium deficiency. To our 
knowledge only one small study of breastfeeding women, by our research group, 
assessed dietary selenium, urinary selenium excretion, and breastmilk selenium 
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concentration and suggested selenium inadequacy was still a concern (28). Research 
investigating selenium status among postpartum women and their infants is limited. 
Health professionals closely monitor the iron status of women during pregnancy. 
However, after birth, management of iron status can be inconsistent. Results from a 
UK multicentre study reported only 50% of postpartum women had hemoglobin levels 
checked after delivery (with 30% of those women confirmed as anemic), while the 
overall iron stores of participating women remained unexamined (29). Generally, 
postpartum women’s iron status recovers as a consequence of cessation of menstrual 
bleeding since conception or a minimal secretion of iron via breastmilk if 
breastfeeding (30). However, if women have suffered iron deficiency before and/or 
during pregnancy and/or have experienced significant blood loss during childbirth, 
their iron status may not reach optimal levels even if an intervention subsequently 
occurs. A New Zealand study of 186 women found 77% of women were not tested for 
hemoglobin levels after childbirth. Further, out of those most at risk (with low iron 
status during late pregnancy and high blood loss, exceeding 500 mL, during 
childbirth), few women were then retested for their iron status after 10 days 
postpartum (31). Iron status of postpartum women remains largely underreported. 
Low serum selenium has been identified as an independent risk factor for depression 
(32) and selenium supplementation has been observed to reduce postnatal depression 
(33). Postnatal depression is one of the main disorders women experience postnatally, 
its onset being timed at six weeks to six months after birth (34). Most women will 
recover from postpartum depression, though approximately one-quarter of affected 
women report being depressed when their infant reaches their first birthday (34). 
Using the measured criteria of postnatal depression on the Edinburgh Postnatal 
Depression Scale (EPDS), the prevalence of postnatal depression in New Zealand was 
about 8% in 1994 and 16% in 2006 (35). In the 2015 New Mothers’ Mental Health Survey 
(36), the prevalence was 14% and is now recorded as the most common disorder for 
mothers in their first year after childbirth (37). 
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Of additional concern, mothers are often reluctant or unable to seek help when they 
experience symptoms of postnatal depression (36). Such underdiagnosed and 
untreated mental health conditions affect both the mother and their children’s 
ongoing cognitive, emotional, and behavioral development (38). Despite other social 
and psychological etiology of depression, potential links between micronutrient 
status, thyroid hormone, and the risk of postpartum depression need to be further 
explored. This may help develop new preventive approaches to lower the risks of 
postpartum depression. 
4.3 Study objectives  
The study’s primary outcomes include investigating breastfeeding women’s iodine 
intake and status among supplement users and nonusers following the 
implementation of two government initiatives to improve iodine status; examining 
maternal iodine, selenium, and iron intake status; and exploring iodine, selenium, and 
iron status in maternal thyroid function. 
In addition, the study provides preliminary data on possible associations between 
women’s selenium status, thyroid function, and postnatal depression over a one-year 
period and infants’ iodine and selenium status in relation to neurodevelopment 
during their first year of life. Ultimately, this research will inform a future larger study 
of potential variables impacting maternal thyroid function and the risk of postnatal 
depression, together with early infant neurodevelopment. 
4.4 Methods 
4.4.1 Study design and overview 
The MINI study is an observational longitudinal cohort study spanning the first 
postpartum year. It was approved by the Health and Disability Ethics Committee 
(15/NTA/172) in December 2015. The study’s ethics approval was registered with the 
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Royal New Zealand Plunket Ethics Committee in June 2016. The MidCentral District 
Health Board in New Zealand also approved the study. 
The study is being conducted in the Human Nutrition Research Unit at Massey 
University, Palmerston North, New Zealand. The first study visit for participants is at 
approximately three months postpartum (3MPP), and follow-up assessments take 
place at six months (6MPP) and twelve months postpartum (12MPP) (Appendix 7). 
4.4.2 Selection criteria 
The target population for the study were healthy breastfeeding women aged over 16 
years who had birthed a healthy term singleton infant three months prior. Women 
were excluded if they developed significant health problems, such as metabolic 
disease or cancer. Women were excluded if they had been diagnosed or treated at any 
time for hyperthyroidism or hypothyroidism. Participants were required to live within 
or near the local Palmerston North area and be able to attend Massey University for 
scheduled study visits. Women of any ethnic and socioeconomic status were eligible. 
4.4.3 Recruitment and participation 
Posters to promote the study were placed at selected sites (General Practitioner 
surgeries, midwifery clinics, pharmacies, antenatal classes, ultrasound clinics, 
maternal wards in hospitals, local community playgroups, and early childhood 
centres, etc.). Local newspapers and social media sites were used to publicise the 
study. Local midwives, childbirth educators, and lactation consultants were asked to 
raise awareness of the MINI study to their clients. An effort was made to recruit 
women from a wide range of socioeconomic backgrounds and ethnic groups, 
including Maori, Pacific Islanders, and Asian women. Potential participants 
responded by recording an expression of interest online or via telephone or email. 
Prospective participants were provided with a study information sheet. Interested 
participants then completed a screening questionnaire to ensure eligibility. Written 
informed consent was obtained from all participants before their enrolment in the 
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study. Mothers also gave written content to their infants’ participation in the study. 
After providing informed consent, participants were assigned a unique identifier code 
and scheduled for their first study visit. 
4.4.4 Sample size calculation 
The main outcome measure was iodine excreted per day, and the sample size was 
calculated using G*Power 3.1 (Heinrich Heine University) based on data (mean and 
standard deviation) from a preliminary study of breastfeeding women (24). 
Calculation used one-way analysis of variance with two groups (95% power, 𝛼 = 0.05, 
two-tailed) and three repeat measures; 80 participants were needed, using expected 
mean daily urine iodine concentrations of 140 and 100 µg/L for iodine supplement 
users and nonusers, respectively, and a standard deviation of 60. 
4.4.5 Outcome measures 
4.4.5.1 Questionnaires 
At the initial visit, general baseline questions were asked about salt and supplements 
use, nutrition knowledge of iodine, tobacco and alcohol use, breastfeeding patterns, 
general health, and demographic information (including age, ethnicity, educational 
attainment, household size, and income). Potential changeable information including 
tobacco and alcohol use, breastfeeding patterns, and general health was also sought 
at the second and third visits. 
Participants were assessed about their general health and that of their infants by 
online questionnaire when infants reached six months and twelve months of age. 
During the postpartum period, stress may negatively affect immunity, and the 
occurrence of infection symptoms can be an estimated measurement of postpartum 
immune function. The Carr Infection Symptom Checklist, which has been validated 
for use with postpartum women (39), was used to measure the symptoms of infection 
experienced by the mother since the childbirth. The Infant Symptom Checklist (which 
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reports the frequency of symptoms of common illnesses in young infants) was used to 
measure the health of infants (39). 
The 10-item EPDS was completed online by participating women to assess any 
symptoms of depression and anxiety over the previous seven days. Women recorded 
severity of symptoms on a 4-point scale (40). Specified anxiety disorders were 
evaluated using the EPDS-3A, a cluster of selected question items numbered three, 
four, and five from the original EPDS (41). This is a validated tool to screen for 
probable anxiety and depression during the postpartum period. A cut-off point of 13 
or above was used to define high levels of depressive symptoms (36). Any woman 
whose score equalled 13 or above was advised to see her general practitioner for further 
evaluation as well as being provided with an information sheet containing postnatal 
depression services in New Zealand. Only study participants with the correct link 
supplied via emails could complete these questionnaires. All questions were answered 
in the same order. Participants could not go back to change their answers once the 
questionnaire was completed. Answers from incomplete questionnaires may be used 
for analysis. 
The first year of infant neurodevelopment was assessed using a parent-completed 
Ages and Stages Questionnaire (ASQ) when the infant was aged four, eight, and twelve 
months (42). These questionnaires were self-administered and completed in hard 
copies. This screening tool uses parent observation to assess child development and 
behaviour and records results in five developmental domains: communication, gross 
motor, fine motor, problem solving, and personal-social. There are six questions in 
each domain, with answers of yes, sometimes, or not yet. A yes indicates reaching the 
achievement with ten points awarded, a sometimes indicates partial achievement with 
five points awarded, and a not yet indicates not achieved with 0 points awarded. The 
sum score of each domain was calculated and compared with the cut-off scores 
reached, which were derived empirically by subtracting two standard deviations from 
the mean for each area of development (42). A score below the cut-off point indicates 
a fail on the ASQ. The questionnaires were used to assess the relationship between 
151 
 
maternal and infant iodine and selenium status, maternal iron status, and recorded 
early child neurodevelopment. 
4.4.5.2 Dietary Intake 
To assess participant dietary intake including nutrients that may be associated with 
mental health and child development including iodine, selenium, and iron intake, 
participants were asked to complete a weighed four-day diet diary within two weeks 
of the initial study visit. All four days were consecutive and included one weekend 
day. Each participant was requested to record food items, brands, amount consumed, 
and the content of the nutritional information panel if applicable. All food and 
beverage items consumed were weighed and measured with a QM-7288 electronic 
kitchen scale (Digitech), and household measurement cups and spoons were 
provided. The Digitech scale can weigh up to five kilograms with an accuracy to one 
gram; all women were shown how to use the scale to quantify food items. All 
participants received both written and oral instructions on how to complete the 
record, which included a written example of a one-day food record. Women were also 
asked to include dietary supplements consumed. When eating or dining out, 
participants were asked to estimate the portion size of all food eaten. The food record 
and equipment were collected, or return posted two weeks after the initial visit. 
A 69-item self-administrated semiquantitative iodine- and selenium-specific food 
frequency questionnaire, adapted from an Australian study of pregnant women (43), 
was used to estimate habitual maternal iodine and selenium intake at the first and 
third study visits. An iron-specific food frequency questionnaire, validated by other 
female population groups in New Zealand, was used to assess women’s iron-related 
dietary patterns (44) at the second study visit. Within two weeks of this visit, 
participants also completed a three-day estimated food dietary record for their infants 
to enable assessment of infant nutrient intakes at weaning periods. 
All dietary data were entered into Foodworks 9 Professional (Xyris Pty Ltd) online and 
analyzed using data sets from the New Zealand Foodfiles 2016 to estimate nutrient 
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intake. When food items were not included in Foodfiles 2016, new food items were 
created based on the information directly provided by participants (i.e. food packages) 
or from appropriate international databases from Australia and the United States. 
Estimates for iodine concentrations of categories of bread (e.g. white, fiber white, 
fruited, mixed grain) were based on data from the Ministry of Primary Industries (22), 
since iodine content has not been determined for all commercially made bread in New 
Zealand after the mandatory fortification of bread with iodized salt. It was difficult to 
quantify the amount of discretionary salt added to food. However, for women who 
reported using iodized salt, 48 µg of iodine (equivalent to one gram of salt) was added 
to their iodine intakes (21). Dietary supplements used by participants were entered 
into Foodworks as a new food item based on nutritional information obtained from 
the manufacturers. To ensure accuracy and completeness, a registered nutritionist 
(YJ) checked all dietary data and then transferred the data to SPSS Statistics (IBM 
Corporation) version 23 for statistical analysis. 
4.4.5.3 Anthropometry 
Maternal and infant anthropometry measurements were obtained at each study visit. 
Women’s weight was measured using the same annually calibrated weighing scale 
with a capacity of 150 kilograms (Detecto). Before standing on the scale, participants 
were asked to remove their shoes and to wear minimum clothes. Body weight was 
recorded to the nearest 0.1 kilogram. Height was measured by using a Toledo 
stadiometer and recorded to the nearest millimeter (45). Maternal body composition 
was determined using both bioelectrical impedance analysis (InBody230, InBody Co) 
and air displacement plethysmography (BodPod, COSMED SRL). Measurements were 
completed under the following conditions: minimal clothing, wearing swimming cap, 
before midday, after urination, normal room temperature (20℃ to 25℃), with no 
exercise, eating, drinking, or bathing/showering within two hours prior to 
measurement (preferably completing the measurement after breastfeeding the baby). 
On the day of the test, quality control steps for BodPod were carried out by following 
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the manufacturer’s instructions, with acceptance criteria being volume ±100 mL of 
actual volume and standard deviation ≤ 75 mL. 
Infant recumbent length was measured crown to heel using an infant length board 
and recorded to the nearest millimeter. Infant weight (without clothing and diapers) 
was measured using a baby weighing scale (Nagata Scale Co Ltd) and recorded to the 
nearest 10 grams. Infant head circumference was measured over the most prominent 
part on the back of the head (occiput) and just above the eyebrows (supraorbital 
ridges) by using a flexible non-stretch tape (45) and recorded to the nearest even 
millimeter. 
4.4.5.4 Ultrasound measurement of thyroid volume 
A portable ultrasound (uSmart 3200T Ultrasound System, Teratech Corp) equipped 
with a linear transducer (7 to 15 MHz) was used for the thyroid measurement. Women 
were examined in a supine position (an adequate neck extension was achieved by 
placing pillows under the shoulders). Longitudinal and transverse scans were 
performed. Measurements of anteroposterior diameter and width (mediolateral 
diameter) were obtained with electronic calipers on a transverse image. The maximum 
lobe length was measured on a longitudinal width. The total volume of each thyroid 
gland was the sum of the volumes of left and right lobes, excluding the volume of the 
isthmus but including any nodules and/or cystic areas. The formula used to calculate 
the volume for each lobe is anteroposterior diameter × width × length × 0.479 (46). A 
total volume greater than 18 mL was defined as thyroid enlargement based on the 
normative thyroid volume in iodine sufficient populations (47). Any participant with 
observed abnormalities was referred to clinical health professionals for further 
assessment. 
4.4.5.5 Biomarker analysis 
During each study visit, spot urine samples from each participating woman and her 
infant were collected to assess iodine, selenium, and creatinine excretion. All maternal 
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spot urine samples were collected in the morning and immediately frozen and stored 
at –20℃. Infant urine was collected using a 100 mL pediatric urine bag placed inside 
the diaper and checked every 10 minutes. The collected urine was frozen and stored 
at –20℃ for later analysis. Spot urine samples can be used to estimate iodine status of 
a population but not for individual iodine deficiency diagnosis (48). As creatinine 
output is relatively constant, the adjusted iodine/creatinine ratio (µg iodine per gram 
creatinine) can be used as a proxy measure of iodine excretion (49). However, the total 
dietary iodine and selenium intake for lactating women cannot be estimated from 
urinary output because some of the iodine and selenium is diverted to breastmilk.  
Lactating women were asked to provide a breastmilk sample (approximately 30 to 50 
mL) at each visit using an Allegro electric breast pump (Unimom NZ) if required. All 
breastmilk samples were collected before noon on the study visit day, and timing of 
breastmilk collection was not standardized. Breastmilk samples were analyzed for 
iodine and selenium concentration, allowing for estimations of infant intake of iodine 
and selenium based on 750 mL/d of milk production (50). 
Iodine and selenium concentration in both urine and breastmilk samples were 
determined by an accredited commercial laboratory (Hill Laboratories) using 
inductively coupled plasma mass spectrometry (ICP-MS) (51). Quality control 
procedures included analysis of blanks, analytical repeats, and certified reference 
material to ensure accuracy and precision. The Massey University Nutrition 
Laboratory measured creatinine using the Jaffe method in a Flexor E (Vital Scientific) 
biochemistry analyser. 
To assess further selenium status, toenail clippings from women and nail clippings 
from infants were collected. Toenail clippings have been used to determine selenium 
concentrations in large cohort or epidemiological studies, such as for the preeclampsia 
risk in pregnant women (52). The instruction for sample collection was explained to 
participants during each study visit and nail clippings were self-collected by 
participating women at home, with the collected samples brought back by the 
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participants at the following study visit. All toenail clippings were stored at room 
temperature prior to analysis. Nail clipping samples will be prepared by using the 
method adapted from nail zinc analysis (53). This involves washing all nail clipping 
samples by using five minutes contact with 25 mL portions in the order of acetone, 
water, acetone, water, and water (54). Selenium concentration will be measured by 
ICP-MS. 
During the second study visit, to assess blood hemoglobin concentrations, the 
handheld Hemocue Hb 201+ device (HemoCue America) was used, a standard in 
hemoglobin point-of-care testing (55, 56). It requires a finger prick and wicking of 
capillary blood into a pretreated microcuvette for analysis. Quality tests using 
external, liquid controls were necessary for each day of instrument use prior to sample 
analysis. 
A qualified and experienced phlebotomist collected non-fasting maternal venous 
blood samples (22 mL) at the second study visit. Samples were centrifuged and 
aliquoted into microcentrifuge tubes prelabeled with participant unique sample 
identification number and then stored at –80℃. In conjunction with the hemoglobin 
results, collected maternal venous blood samples were used to determine iron status 
by measuring soluble transferrin receptors and serum ferritin [using the 
chemiluminescent microparticle immunoassay (CMIA) method], which reflects iron 
storage, but if serum ferritin levels are increased during infection or inflammation, it 
may mask any iron deficiency results (57). Therefore, an inflammatory marker, C-
reactive protein, was measured [tested by an immunoturbidometric method analyzed 
on an Abbott C Series analyzer (Abbott Labs)]. 
Venous blood samples were assayed for hormonal biomarkers: free T3, free T4, and 
thyroid stimulating hormone via CMIA method; thyroglobulin (Tg, Beckman Coulter 
Access method); and antithyroglobulin antibodies (anti-Tg, CMIA method) at 
Canterbury Health Laboratories. Serum thyroglobulin has been suggested as an 
alternative method to assess individual iodine status reflecting a period of months 
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(58); to avoid potential underestimation of thyroglobulin, anti-Tg and thyroid 
peroxidase antibodies (TPOAb) were measured. Selenium status was assessed by 
determining the biomarker plasma selenium via ICP-MS method (59). 
Details of data and biological samples collected from both mothers and infants 
throughout the study period are summarized in Tables 4.1 and 4.2. 
Table 4.1 Summary of outcomes collected from participating women and their infants. 
Outcome Visit 1 Visit 2 Visit 3 
Dietary intake 
   
 
Maternal 4-day dietary diary x 
  
 














   
 
Maternal weight and height x x x 
 
Maternal body composition via BodPod and BIA x x x 
 
Infant weight, height, and head circumference x x x 
Biochemistry 
   
 
Maternal spot urine samples x x x 
 
Maternal breastmilk samples x x x 
 
Maternal toenail clipping samples x x x 
 










Infant spot urine samples x x x 
 
Infant nail clipping samples x x x 
Others 
   
 





Maternal Edinburgh Postnatal Depression Scale results x x x 
 
Maternal self-reported health questionnaire x x x 
 
Maternal iodine nutritional knowledge questionnaire x 
  
 
Infant health questionnaire reported by mothers x x x 
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Table 4.2 Analysis from biological data collected at each study visit  
Samples Visit 1 Visit 2 Visit 3 
 
Mothers Infants Mothers Infants Mothers Infants 
Spot urine 
      
 
Iodine x x x x x x 
 








Breastmilk (if available) 




































   
Nail clippings for selenium 
      
 










Iodine status: testing thyroglobulin and antithyroglobulin. 
b
Selenium status: testing plasma selenium. 
c
Iron status: testing hemoglobin, serum ferritin, soluble transferrin receptors, and C-reactive protein. 
d
Thyroid function: testing serum free triiodothyronine, free thyroxine, thyroid stimulating hormone, and antithyroid peroxidase. 
 
4.4.6 Statistical analysis 
Statistical analysis will be performed using SPSS Statistics version 23. The Shapiro-
Wilk test will be used to test for data normality. Nonparametric data will be expressed 
as median (25th, 75th percentile), and parametric data will be expressed as mean and 
standard deviation. Bivariate correlations will be tested using the nonparametric 
Spearman 𝜌 correlation coefficient. Repeated-measures analysis of variance will be 
used to calculate continuous variables between groups. Nonparametric Mann-
Whitney U test (2-tailed) will be used to examine iodine intake and status between 
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supplement users and nonusers. Multiple regression model analysis will be used to 
determine the associations between iodine, selenium, iron status, and thyroid 
function, as well as considering confounding factors. Multivariate analysis will be used 
to examine possible associations between women’s selenium status, thyroid function, 
and postnatal depression and infant first year neurodevelopment. 
4.5 Results 
Recruitment traversed the 19-month period between June 2016 and December 2017, 
and a sample of 91 women-infant pairs was enrolled (Figure 4.1). Data collection has 
been completed. Biological samples analysis, excluding nail clippings, is complete. 
Data analysis and presentation of the results will be available after 2020. 
4.6 Discussion  
A unique aspect of this study is that it will investigate all three micronutrients 
responsible for adequate thyroid hormone synthesis concurrently, rather than each 
separately in isolation. This observational longitudinal cohort study will measure the 
iodine and selenium status of women repeatedly in their first year after childbirth, 
which provides an evaluation of their nutritional status. Iodine status among 
supplement users and nonusers will provide up-to-date data on this postpartum group 
in New Zealand around eight years after government interventions. Results will 
explore whether maternal iodine and selenium status could be used as a proxy 
measure of infant status. It provides an opportunity to examine the association of 
maternal iodine and selenium with infant neurodevelopment during their first year. 
This study explores selenium status using both short-term and long-term measures in 
relation to neurodevelopment at six months and twelve months of age, which has not 
been reported previously. Furthermore, the study results will add preliminary data on 
iron status of women at six months postpartum. 
Importantly, the study will investigate overall thyroid function of women at six 
months postpartum with respect to the risk of postnatal depression. Measurement of 
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thyroid hormones, thyroid stimulating hormone, TPOAb, Tg, and anti-Tg in serum as 
well as measuring thyroid gland volume via ultrasound will provide an overall picture 
of maternal thyroid function after childbirth. This is an opportune time to check 
thyroid status, especially as women with limited thyroidal reserve or iodine deficiency 
in pregnancy may develop postpartum thyroid dysfunction, one of the most common 
endocrine disorders women experience (6, 60). 
Additionally, there will be longitudinal assessment of mothers’ mental health via 
repeated screening by using the EPDS. The results may add to the literature in 
postpartum mental health status. Their offspring’s growth and neurodevelopment will 
be followed during the first postpartum year. The findings from this study have the 
potential to inform future public health policy and practice regarding postpartum 
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Chapter 5 Prevalence of thyroid dysfunction in postpartum 
women with suboptimal iodine and selenium and adequate 
iron status 
 
This chapter is the first of four articles (published and forthcoming) presenting the 
research findings from the MINI study, each, in turn, describing different features 
obtained from the analysis of data collected from the participating postpartum women 
and their infants. Despite the critical roles of iodine, selenium, and iron in synthesising 
thyroid hormones, limited research has investigated the interaction of these three 
nutrients simultaneously within the thyroid function (noted in Chapter 2).  This 
forthcoming article focuses on research objectives which investigate the roles of iodine, 
selenium, and iron status in maternal thyroid function, and explore maternal iron status 
at six months postpartum. It reports on postpartum women’s thyroid function including 
the prevalence of thyroid dysfunction; and maternal thyroid volumes which were 
compared to data from other countries. In addition, maternal status of all three 
nutrients are reported. This article presents further examination of the extent to which 
iodine status (urinary iodine concentration, breastmilk iodine concentration, serum 
thyroglobulin), selenium status (plasma selenium), and iron status (serum ferritin and 
soluble transferrin receptors) were likely to relate to maternal dysfunction among a 
cohort of women at six months postpartum. 
This forthcoming publication addresses hypothesis 1: Suboptimal iodine, selenium or 
iron status will impede maternal thyroid function at six months postpartum; and 
hypothesis 7: High prevalence of iron deficiency and iron deficiency anaemia exist in 
women at six months postpartum. 
 
 
This chapter has been submitted for publication to the Clinical Endocrinology 





Postpartum women experience thyroid dysfunction at twice the prevalence of the 
general population. Optimal thyroid function relies on adequate biosynthesis of 
thyroid hormones, which depends on three trace elements: iodine, selenium, and iron. 
Objective 
This study aimed to investigate thyroid dysfunction within a cohort of women at six 
months postpartum in relation to iodine, selenium, and iron status. 
Methods 
This cross-sectional study was part of an observational longitudinal cohort Mother 
and Infant Nutrition Investigation; data obtained at six months postpartum are 
reported. Thyroid hormones [free triiodothyronine, free thyroxine, thyroid 
stimulating hormone (TSH)] and thyroid peroxidase antibodies were measured. 
Urinary iodine concentration, breastmilk iodine concentration, serum thyroglobulin, 
plasma selenium, serum ferritin, and serum soluble transferrin receptors were 
determined. 
Results 
Mother-infant pairs (n = 87) were recruited at three months postpartum and followed 
up at six months postpartum (n = 78). Overall, 18% of women had thyroid dysfunction, 
and 4% of women had iron deficiency without anaemia. Median urinary iodine 
concentration was 85 (43, 134) µg/L, median breastmilk iodine concentration was 59 
(39, 109) µg/L, and median serum thyroglobulin at 11.4 (8.6, 18.6) µg/L, indicating 
iodine deficiency. Women with marginally lower plasma selenium were 1.14 % times 






There was a high prevalence of thyroid dysfunction. Plasma selenium was the only 
significant predictor of the likelihood that women had thyroid dysfunction within this 
cohort, who were iodine deficient and mostly had adequate iron status. Future 





Thyroid dysfunction has been associated with anxiety, depression, cognitive deficit 
(1), and adverse effects on reproductive health (2). Thyroid dysfunction occurring in 
the first year after parturition is defined as postpartum thyroiditis (PPT). In 2017, the 
American Thyroid Association reported from different cohorts of studies the 
prevalence of PPT ranged from 1.1% to 16.7% (3). Most women initially diagnosed with 
PPT have normal thyroid hormones concentrations by the end of their first 
postpartum year (3). However, longitudinal follow-up studies have reported that 
between 12% and 30% of women developed permanent hypothyroidism three to five 
years after the original episode of PPT (4). Maternal thyroid dysfunction has been 
linked to the development of postnatal depression (5, 6), is weakly associated with 
reduced breastmilk production and milk-ejection reflex (“let-down”) (3) and may 
impact on infant neurodevelopment (7). 
Iodine, selenium and iron are essential for the synthesis of thyroid hormones (8, 9). 
Iodine is an integral component of thyroid hormones, thyroxine (T4) and 
triiodothyronine (T3). Selenium is a component of the selenocysteine-containing 
protein, glutathione peroxidase (GPx), which protects cells from damage by 
neutralising the excessive hydrogen peroxide generated during thyroid hormone 
synthesis (10,11). The deiodinases, which convert biologically inactive T4 into active 
T3, are selenoproteins (10). Furthermore, the activity of thyroid peroxidase, a haem-
dependent enzyme required for adequate synthesis of thyroid hormones, is impaired 
in iron deficiency (11). 
The interaction between selenium and iodine in synthesising thyroid hormones is of 
particular concern within New Zealand due to dietary insufficiency of both nutrients 
(12). Two New Zealand government initiatives aim to improve iodine status: the 
mandatory fortification of bread with iodised salt, introduced in 2009, and the 
provision of iodine supplements for all pregnant and lactating women introduced in 
2010 (13). Despite these initiatives, this population group continues have suboptimal 
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iodine intake and status (14). Selenium deficiency could potentially aggravate the 
negative consequences of mild iodine deficiency in this vulnerable group (15). Further, 
the iron status of postpartum women in New Zealand is rarely clinically determined, 
except in women who had significant blood loss during childbirth (16). 
This study aimed to investigate thyroid dysfunction in a cohort of women at six 
months postpartum in relation to maternal iodine, selenium, and iron status. 
5.3 Methods 
The Mother and Infant Nutrition Investigation (MINI) study was approved by the 
Health and Disability Ethics Committee, New Zealand (15/NTA/172) in December 2015 
(ACTRN12615001028594). Prior written consent was obtained from all participants. 
Infants’ participation was consented to by their mothers. 
5.3.1 Study design and participants 
The MINI study was an observational longitudinal cohort study spanning the first 
postpartum year in Palmerston North within the North Island of New Zealand. Data 
from six months postpartum are reported here, since biomarkers for iodine, selenium 
and iron status, and thyroid hormone concentrations were only determined at this 
time point. Women aged 16 years and older, who had given birth to a healthy term 
singleton infant aged less than three months of age, were invited to join the study. 
Women were excluded: 1) if they had pre-existing or developed significant health 
problems, such as metabolic disease and cancer; 2) if they had been diagnosed or 
treated at any time for hyperthyroidism or hypothyroidism. The full study protocol is 
published (17). 
5.3.2 Data collection  
5.3.2.1 Assessment of thyroid hormones and thyroid volume 
Thyroid hormone biomarkers [serum free T3, free T4, and thyroid stimulating 
hormone (TSH)] were measured using the chemiluminescent microparticle 
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immunoassay (CMIA) method at Canterbury Health Laboratories, New Zealand which 
is accredited with International Accreditation New Zealand (IANZ). The adult 
reference ranges of these biomarkers were used due to the absence of reference ranges 
specifically for lactating women. Thyroid peroxidase antibody (TPOAb) concentration 
above 10 IU/mL was regarded as indicative of a potential autoimmune disorder. 
Reference ranges for euthyroid are: TSH, 0.40 - 4.00 mIU/L; free T4, 10 - 24 pmol/L; 
and free T3, 2.5 - 6.0 pmol/L. These reference ranges were used to calculate the 
prevalence of thyroid dysfunction including subclinical hypothyroidism (TSH > 4.00 
mIU/L and normal free T4), overt hypothyroidism (TSH > 4.00 mIU/L and free T4 < 
10 pmol/L), subclinical hyperthyroidism (TSH < 0.40 mIU/L and normal free T4), and 
overt hyperthyroidism (TSH < 0.40 mIU/L and free T4 > 24 pmol/L) (18). 
Thyroid volume was measured by a portable ultrasound (Terason uSmart3200TTM, 
Terason Corporation, USA) equipped with a linear transducer (7 - 15 MHz). The 
measurements of anteroposterior diameter and width (mediolateral diameter) were 
obtained with electronic calipers on a transverse image. The total volume of the 
thyroid gland was the sum of the volumes of left and right lobes, excluding the volume 
of the isthmus, but including any nodules and/or cystic areas. The formula used to 
calculate the volume for each lobe was: Anteroposterior diameter x Width x Length x 
0.479 (19). A total volume greater than 18 mL was defined as thyroid enlargement, 
based on the normative thyroid volume in an iodine sufficient population (20,21). Any 
participant with observed abnormalities was referred to clinical health professionals 
for further assessment. 
5.3.2.2 Assessment of iodine, selenium, and iron status 
Maternal non-fasting spot urine samples (approximately 120 mL) were collected to 
measure maternal urinary iodine concentration (UIC, µg/L) and creatinine 
concentration to determine maternal urinary iodine creatinine ratio (µg/g). Women 
were asked to provide a breastmilk sample (approximately 30-50 mL) using an electric 
breast pump, if needed, and breastmilk iodine concentration (BMIC, µg/L) was 
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determined. The timing of breastmilk collection was not standardised, although all 
samples were collected before 12 noon on the study visit day. All samples were stored 
without preservative at -20°C prior to analysis. Non-fasting maternal venous blood 
samples (22 mL) were collected by a phlebotomist, and separated into plasma and 
serum samples before storage at -80°C. 
Iodine concentrations in urine and breastmilk samples were determined by Hill 
Laboratories, Hamilton, New Zealand, using inductively coupled plasma mass 
spectrometry (22). Quality control procedures included analysis of blanks, analytical 
repeats, and spiked samples in order to ensure accuracy and precision. Calibration 
standards and checks were undertaken on every run with the limit of detection at 
0.002 mg/kg. Each batch (25 samples) of urinary samples was analysed together with 
an external reference standard (Seronorm Trace Elements Urine, L-2, Norway) giving 
a mean ± SD iodine concentration of 286 ± 12 µg/L, with a coefficient of variance (CV) 
of 4.2% (n = 14). Creatinine was measured in maternal urine using the Jaffe Method 
Flexor (Randox Assayed Multisera levels 2&3) at Massey University Nutrition 
Laboratory in Palmerston North. Each batch of breastmilk samples was analysed 
together with an external reference standard (Skimmed milk powder, Elements in 
organic matrix, European) giving a mean ± SD iodine concentration of 1.603 ± 0.029 
mg/kg, with a coefficient of variance (CV) of 4.9% (n = 6). 
Serum thyroglobulin (Tg) was measured by the Beckman Coulter Access method and 
anti-thyroglobulin antibodies were determined by the CMIA method, at Canterbury 
Health Laboratories, Christchurch, New Zealand. Serum Tg has been suggested as a 
biomarker to assess individual iodine status reflecting a period of weeks or months 
(23, 24); if anti-thyroglobulin antibodies were detected positive (≥ 10 IU/mL), Tg 
concentrations were disregarded. 
Plasma selenium concentration was assessed by the inductively coupled plasma 
spectrometry method at Canterbury Health Laboratories, New Zealand (25). A plasma 
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selenium concentration of 95 µg/L has been suggested to saturate GPx activity (26), 
this was used as a cut off for the current study. 
Hemoglobulin (Hb), serum ferritin (SF), and soluble transferrin receptor (sTfR) 
concentrations were determined to evaluate maternal iron status. Hb concentrations 
were measured using a handheld Hemocue Hb 201+ device (HemoCue® Hb 201+, 
Sweden) (27). sTfR (using the Nephelometry method) was measured to determine iron 
demand versus iron supply. Serum ferritin (using the CMIA method) and C-reactive 
protein (CRP) were determined (using an immunoturbidimetric method analysed on 
an Abbott c series analyser), and, if CRP ≥ 8 mg/L (indicating inflammation), the 
serum ferritin concentration was disregarded (28). The iron status of participants was 
defined using the following definitions: sufficient iron stores: SF ≥ 12 µg/L and Hb ≥ 
120 g/L; anaemia without iron deficiency: SF ≥ 12 µg/L but Hb < 120 g/L; iron deficiency 
without anaemia (ID): SF < 12 µg/L and Hb ≥ 120 g/L; iron deficiency anaemia (IDA): 
SF < 12 µg/L and Hb < 120 g/L (29). 
5.3.3 Data analysis 
All data were analysed using IBM SPSS (Statistics Package for the Social Sciences, IBM, 
Armonk, NY, USA) version 20 and R statistical programme (Vienna, Austria. 
https://www.R-project.org/) (30). 
Data were tested for normality using the Shapiro-Wilk test. Non-parametric data were 
expressed as median (25th, 75th percentile), and parametric data expressed as mean (± 
standard deviation; SD). Bivariate correlations were tested using either the parametric 
Pearson correlations or the nonparametric Spearman’s rho correlation coefficient, as 
appropriate. Differences in categorical variables were tested by Fisher’s exact t-test. 
Plasma selenium concentrations were split into two categories (≥ 95 µg/L or < 95 µg/L) 
for comparison with the biomarkers; independent t-test was used for parametric data 
after natural log transformation (including UIC, urinary iodine creatinine, BMIC, Hb, 
SF, free T3:T4), biomarkers which were unable to be transformed into parametric data 
(including serum Tg, sTfR and TSH) were tested by Mann Whitney U test. A logistic 
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regression model was employed to consider factors likely to influence abnormal TSH 
concentrations. The dependent variable was binary, with the value of one being 
abnormal TSH concentration and the value of zero being normal TSH concentration. 
Age, parity and iodine status have been suggested as risk factors for maternal thyroid 
disease (31). Selenium is involved in thyroid autoimmunity (32) and iron deficiency 
impairs the synthesis of thyroid hormones (9). Therefore, age of participants; parity 
(categorical variable); UIC; BMIC; plasma selenium; and sTfR were selected as 
covariates to enter the logistic regression model simultaneously (Table 5.1). Average 
marginal effects are less sensitive to changes in the specification of the logistic 
regression model when compared to odds ratios (33). Therefore, average marginal 
effects were calculated to illustrate the effect of small changes in covariates on the 
binary dependent variable (TSH concentration). 
Table 5.1 Description of the variables entered the logistic regression model. 
Variables Description  Definition 
Dependent variable    
TSH  0 - Normal (0.4-4 mIU/L) 
1- Abnormal (< 0.4 mIU/L or > 
4.0 mIU/l) 
Abnormal TSH concentrations indicate 
thyroid dysfunction. 
Covariates    
Age of participants Continuous (Years) Age of participants in years 
Parity 1 – Primiparity 
0 - Multiparity 
The number of childbirths; single or 
multiple 
UIC Continuous (µg/L) Indicator for iodine status 
BMIC Continuous (µg/L) Indicator for iodine status  
Plasma selenium  Continuous (µg/L) Indicator for selenium status 
sTfR Continuous (mg/L) Reflection of functional iron status 
5.4 Results 
A total of 87 breastfeeding mother-infant pairs were recruited at three months 
postpartum, nine participating pairs dropped out from the study at six months 
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postpartum (n = 78). A description of characteristics of breastfeeding women and their 
infants at enrolment are shown in Table 5.2.  At six months postpartum, 31% (24/78) 
were exclusively breastfeeding, 4% (3/78) had stopped breastfeeding, with the 
remainder providing partial breastfeeding. Iodine, selenium, and iron containing 
dietary supplements were used by nine, one and six women, respectively. 
Table 5.2 Description of breastfeeding participants and their infants at recruitment. 
Maternal characteristics n % 
Maternal age, years (Mean ± SD) 31.5 ± 4.2  
Tertiary Education 67  77 
Ethnicity (Maori) 9  10 
Ethnicity (Caucasian) 66  76 
Ethnicity (Asian) 9  10 
Ethnicity (Other) 3  4 
Annual household income (Above median)* 54  62 
Primiparity 38  44 
Caesarean delivery 19  22 
Gestational ages at birth, weeks (Mean ± SD) 39.4 ± 1.5  
Age of infants at recruitment, days (Mean ± SD)  88.5 ± 14.8  
Infants birth weight, kilograms (Mean ± SD) 3.6 ± 0.6  
* Median annual household income based on Statistics New Zealand is 75,995 New Zealand dollars for the year ended June 2016 (36) 
5.4.1 Thyroid hormones and thyroid volume 
The median (p25, p75) maternal total thyroid volume was 6.1 (4.4, 8.4) mL, ranging 
from 2.2 to 15.2 mL, with none above 18 mL which is the suggested cut-off of thyroid 
enlargement for women (21). Based on maternal thyroid function markers, 18% (13/74) 
had thyroid dysfunction, with 8% (6/74) having positive TPOAb indicating 
autoimmune thyroid disorders (Table 5.3). Positive TPOAb was correlated with 
abnormal TSH (r = 0.261, P = 0.025). Total thyroid volume was weakly, positively 
associated with serum free T4 (r = 0.314, P = 0.006).  
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Table 5.3 Thyroid function biomarkers and thyroid dysfunction prevalence (n = 74). 
Thyroid markers Median (p25, p75) 
TSH, mIU/L 0.96 (0.69, 1.33) 
free T4, pmol/L 12 (11, 12) 
free T3, pmol/L 3.8 (3.6, 4) 
free T3:T4 ratio 0.33 (0.31, 0.36) 
 n (%) 
TPOAb (+)a 6 (8) 
Subclinical hypothyroidismb 0 (0) 
Overt hypothyroidismc 2 (3) 
Subclinical hyperthyroidismd 11 (15) 
Overt hyperthyroidisme 0 (0) 
a
TPOAb ≥ 10 IU/mL indicates positive. 
b
Subclinical hypothyroidism: TSH > 4.0 mIU/L and 10 < free T4 < 24 pmol/L. 
c
Overt hypothyroidism: TSH > 4.0 mIU/L and free T4 < 10 pmol/L 
d
Subclinical hyperthyroidism: TSH < 0.4 mIU/L and 10 < free T4 < 24 pmol/L 
e
Overt hyperthyroidism: TSH < 0.4 mIU/L and free T4 > 24 pmol/L. 
 
5.4.2 Iodine, selenium, and iron status  
The WHO (2007) defines iodine deficiency in a population by using the median UIC 
and suggests a cut-off for deficiency in non-pregnant women below 100 µg/L (34). 
Maternal median UIC was 85 (43, 134) µg/L, indicating deficiency (35). Median BMIC 
was 59 (39, 109) µg/L, below 75 µg/L which has been suggested as the index of 
sufficient infant iodine intake (36). After excluding nine women with positive Tg 
antibodies, median Tg was 11.4 (8.6, 18.6) µg/L, above the suggested cut-off of 10 µg/L, 
and suggests iodine deficiency (37, 38, 39). All three biomarkers indicated iodine 
deficiency in this cohort of postpartum women. Median maternal plasma selenium 
was 105.8 (95.6, 115.3) µg/L; with 23% (17/74) below 95 µg/L, suggesting inadequate 
status as this concentration is required to saturate GPx activity (26). 
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During childbirth, 17% (13/78) of women experienced severe blood loss (> 500 mL), 
46% (6/13) received an iron transfusion and 15% (2/13) had a blood transfusion. Six 
women reported taking iron-containing supplements of either 60 mg (5/6) or 5 mg 
(1/6) daily. Mean Hb was 132.5 ± 9.00 g/L. Median SF was 41 (27, 78) µg/L after 
excluding three women with elevated CRP. Median sTfR was 1.12 (1.00, 1.26) mg/L, 
with 4% having elevated values suggesting iron-deficient erythropoiesis (40). In total, 
90% (64/71) of women were classified as having sufficient iron stores. Four 
participants were classified as having anaemia without iron deficiency. Only three 
women were classified as being ID, and no participants were classified as having IDA. 
Women who had a plasma selenium concentration below 95 µg/L had a significantly 
lower urinary iodine creatinine ratio, SF and TSH, and a higher serum Tg, compared 
to women with an adequate plasma selenium concentration (≥ 95 µg/L) (Table 5.4). 





(< 95 µg/L) 
n = 17 
Plasma Se 
(≥ 95 µg/L) 




UIC µg/La 58 (38,116) 89 (42, 159) 0.318 
Urinary iodine creatinine 
µg/ga 
99 (63, 159) 145 (93, 208) 0.024 
BMIC µg/La 56 (38, 90) 62 (39, 114) 0.769 
Hb g/La 133 (123, 139) 132 (126, 140) 0.865 
SF µg/La 29 (17, 50) 48 (30,81) 0.024 
free T3:T4 a  0.33 (0.32, 0.35) 0.33 (0.30, 0.36) 0.996 
   Mann-Whitney U 
test P value 
Serum Tg µg/Lb 23.6 (10.6,34.0)  10.2 (8.6, 15.8) 0.017 
Serum sTfR mg/Lb 1.18 (1.11, 1.35) 1.10 (0.97, 1.25) 0.063 
TSH mIU/Lb 0.62 (0.04, 1.17) 1.02 (0.77, 1.50) 0.005 
a 
Data become normally distributed after natural log transformation 
b 




5.4.3 Iodine, selenium and iron status and thyroid hormone concentrations  
All women using iodine-containing supplements (9/74) had normal TSH 
concentrations, while 20% (13/65) who did not use iodine-containing supplements 
had abnormal TSH concentrations. The proportion of women with thyroid 
dysfunction was higher in those who had plasma selenium concentrations below 95 
µg/L compared with women who had plasma selenium concentrations of 95 µg/L or 
above (41% vs. 10.5%, P = 0.008). 
The logistic regression showed a negative but statistically significant coefficient of 
plasma selenium, and the marginal effect suggests women with lower plasma 
selenium were 1.14 % times more likely to have abnormal TSH concentrations. 
However, none of other covariates had a significant effect when entered the model 
(Table 5.5). Although UIC was weakly correlated with BMIC, the variance impact 
factor was close to one, thus no correction was needed for the multicollinearity. 
No significant correlations were observed between biomarkers for iron status (Hb, SF 
and sTfR) and thyroid hormone concentrations. There were no statistically significant 
differences in iron status observed between women with abnormal and normal TSH 
concentrations. 
Table 5.5 Logistic model of factors affecting abnormal TSH concentrations (n = 69) 
 Coefficients  P > [z]  Marginal effect 
Age of Participants 0.117 0.185 0.01356 
UIC ug/L 0.004 0.181  0.00048 
 BMIC ug/L -0.000 0.973 -0.00003 
Plasma Se ug/L -0.103 0.001 -0.01144 
Parity -0.323 0.761  -0.02516 




This cross-sectional study of 78 women at six months postpartum found thyroid 
dysfunction in 18%, including 3% with overt hypothyroidism, and 15% with subclinical 
hyperthyroidism. This was higher than a previous study of Australian women (n = 748) 
which detected 11.5% with thyroid dysfunction at six months postpartum (41). In New 
Zealand (2006/2007), 4.8% of adults aged from 18 to 80 years old registered with 
General Practices had thyroid dysfunction (42), however, the prevalence in women of 
childbearing age was not determined. Median thyroid volume (6.1 mL) in the MINI 
study was similar to that estimated in a study of Cuban women (6.4 mL) aged 18-50 
years who lived in iodine sufficient areas (43). There was no obvious thyroid 
enlargement observed in the current study, however, ultrasound echogenicity of the 
thyroid gland was not examined, which has been suggested as a predictor in thyroid 
dysfunction development (44). A follow-up study in the United Kingdom has 
suggested that women experiencing PPT may present hypoechogenicity (structural 
changes revealed in ultrasound images) during the first postpartum year, but most 
were improved by the 77-81 month-follow-up (45). 
In the MINI study, low selenium status was the only significant predictor of the 
likelihood that women had thyroid dysfunction. Women with a plasma selenium 
concentration below 95 µg/L had a higher likelihood of experiencing thyroid 
dysfunction (41.2%), compared to only 10.5% in women with a plasma selenium 
concentration above 95 µg/L. This aligns with the results of a large Chinese 
observational study (n = 6152) which reported a higher prevalence of thyroid disease 
in people living in a low selenium region  compared to those living in an adequate 
selenium region  (31% vs 18%, P < 0.001) (46). The authors suggested low selenium 
may result in inadequate expression of selenoproteins, hence less protection of the 
thyroid gland from oxidative damage. In the current study, women with a plasma 
selenium concentration below 95 µg/L had a significantly lower TSH and SF, but 
higher serum Tg, compared to women with adequate plasma selenium 
concentrations. Although, median TSH and SF concentrations in the low versus high 
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selenium groups were significantly different, these were still within the normal range. 
However, median serum Tg in women with low selenium status was double the 
suggested normal concentration of 10 µg/L, indicative of iodine deficiency. Similar 
dietary sources contribute to the intake of iodine and selenium. Low selenium may 
exacerbate the consequences of iodine deficiency in this group of postpartum women, 
due to the requirement for both selenium and iodine for the synthesis of thyroid 
hormones (12). 
Iodine status (UIC or BMIC) was not a predictor of thyroid dysfunction in the current 
study, which was not entirely unexpected as UIC has high intraindividual variation (10 
-15 urine samples are suggested for assessing habitual status) (47). This could also be 
due to a small number of women who had abnormal thyroid hormones, and that 
thyroid hormones may remain in the normal range even in a mild-to-moderate iodine 
deficient population (35). In contrast, a cross-sectional study of Australian women at 
six months postpartum (n = 149) found a lower median UIC was significantly 
associated with TSH above normal concentrations (48). The current study found 
women using iodine-containing supplements (9/74) presented with normal TSH 
concentrations, while 20% (13/65) of women not using iodine-containing supplements 
were found to have abnormal TSH concentrations. This suggests there is a beneficial 
effect from iodine supplementation on thyroid function. However, it is inconclusive 
since the numbers using iodine-containing supplements were too small. 
It was unexpected that most women at six months postpartum achieved adequate iron 
status, with only 4% being iron deficient without anaemia (ID). The low rate of ID in 
the current study could be due to the protective effects of six-months’ lactational 
amenorrhoea. However, a previous study of American women up to six months 
postpartum (n = 220) reported that 12.7%  were ID, and women up to six months 
postpartum from low income groups had a fourfold increased risk of ID compared to 
than their non-pregnant counterparts (49). In the current study, 62% reported a 
household income above the median New Zealand household income (50). Although 
iron status in the current cohort was mostly adequate, further research is required to 
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ascertain the iron status of low-income postpartum women in New Zealand, who are 
known to consume a diet having lower iron bioavailability (51). 
Iron status in the current study was not associated with thyroid hormone 
concentrations, which may be due to the predominantly adequate iron status of the 
women. However, a nationally representative study of pregnant Swedish women, who 
lived in an area of iodine deficiency (median UIC at 139 µg/L), reported that lower iron 
status (sTfR to SF ratio) predicted elevated levels of TSH (≥ 4.0 mU/L) and lower 
concentrations of T4 (< 100 nmol/L). The authors suggested that a low iron status 
blunts the activity of the haem-dependent enzyme (thyroid peroxidase) which results 
in a reduction of thyroid hormone synthesis (52). 
To the best of our knowledge, the MINI study was the first study to examine iodine, 
selenium and iron concurrently in relation to thyroid function of postpartum women. 
It is one of a few studies to investigate the prevalence of thyroid dysfunction in a New 
Zealand postpartum cohort. One of the strengths of this study is the comprehensive 
range of biomarkers used to measure iron, iodine, and selenium status. Measuring SF 
is a well-established method to assess iron storage (53), but it does not indicate the 
severity of iron depletion. Increased serum sTfR would indicate functional iron 
deficiency without being confounded by inflammation. Changes in the reciprocal 
relationship between these measures would provide a better understanding of iron 
status and allow early detection of ID before the occurrence of IDA (40). Iodine status 
was determined by measuring UIC and BMIC to reflect recent iodine intake and serum 
Tg which is a sensitive biomarker (23).  Plasma selenium reflects short-term status and 
was used because it is the most used biomarker in other published research which 
would allow comparison. A potential limitation of this study is not determining 
functional selenium status by measuring plasma or platelet GPx (54) to assess 
nutritional deficiency. Measuring selenium in nail clippings may be another useful 
assessment of selenium status over a long-term exposure time (up to 52 weeks) (55). 
Other limitations of the study include the small sample size, and the participants were 
predominantly well-educated and may not have been representative of the wider New 
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Zealand population. Less educated women are under-represented, thus their thyroid 
function, and their iodine, selenium, and iron status may require further investigation. 
Few participants reported the use of selenium-containing supplements; therefore, this 
study has insufficient statistical power to examine the effects of such supplementation 
on thyroid function. 
5.6 Conclusion  
A high prevalence of thyroid dysfunction (especially subclinical hyperthyroidism) was 
observed, and low plasma selenium significantly increased the risk of thyroid 
dysfunction within this group of iodine deficient postpartum women who 
predominantly had adequate iron status. Future studies are required to provide a 
greater understanding of the role of selenium status, when combined with other 
micronutrients, in optimal thyroid function. Measuring long-term selenium status via 
nail clippings, could identify the risk of selenium deficiency and its impacts on thyroid 
function. Strategies may be required to improve both iodine and selenium status, 
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Chapter 6 Use of iodine supplements by breastfeeding mothers is 
associated with better maternal and infant iodine status 
 
Although maternal iodine status did not predict thyroid dysfunction, the use of iodine-
containing supplements showed some beneficial effect (noted in Chapter 5). Despite the 
establishment of two government initiatives, continually monitoring iodine intake and 
status is essential (see Chapter 2). 
Chapter 6 is the second article (published) derived from the analysis of the MINI study 
data. It concentrates on the research objective to compare breastfeeding women’s iodine 
intake and status between iodine-containing supplement users and non-users. In 
addition, this article records the participant’s levels of iodine knowledge, including the 
importance of iodine in health; good dietary sources of iodine; the two New Zealand 
government initiatives to improve iodine status; and the behaviour related to iodine. 
Finally, the effects of maternal use of iodine-containing supplements on the iodine 
status of mothers and infants are discussed and implications for future research and 
practice are considered. 
This published article addresses hypothesis 2: Breastfeeding women who used iodine-
containing supplements will achieve better iodine status for themselves and their 
breastfed infants. 
 
This chapter has been published as: 
Jin, Y, Coad, J, Zhou, JS, Skeaff, S, Benn C, Brough L. Use of iodine supplements by 
breastfeeding mothers is associated with better maternal and infant iodine status. 





Adequate iodine status during conception, pregnancy and lactation is essential for 
supporting infant neurodevelopment. Iodine status in adults and children was 
improved after two New Zealand government initiatives, but the status of 
breastfeeding women is unknown. 
Objectives 
This study aimed to investigate the iodine intake and status of lactating mother-infant 
pairs at three months postpartum, and to assess maternal iodine knowledge and 
practice. 
Methods 
Iodine intake was estimated by a weighed four-day diet diary (4DDD). Maternal 
urinary iodine concentrations (UIC) in spot urine, breastmilk iodine concentrations 
(BMIC), infant UIC were measured. Questions about iodine specific knowledge and 
practice were asked. 
Results 
In 87 breastfeeding mother-infant pairs, maternal iodine intake was 151 (99, 285) 
µg/day, 58% had an intake below the Estimated Average Requirement (EAR) of 190 
µg/day. Maternal median UIC (MUIC) was 82 (46, 157) µg/L indicating iodine 
deficiency (i.e. < 100 µg/L). Women who used iodine-containing supplements had a 
significantly higher MUIC (111 vs 68 µg/L, P = 0.023), and BMIC (84 vs 62 µg/L, P < 
0.001) than non-users. Infants fed by women using iodine-containing supplements 
had a higher MUIC (150 vs 86 µg/L, P = 0.036) than those of non-users. 66% (57/87) 
of women had no or low iodine knowledge. The iodine knowledge score was a 
statistically significant predictor of consuming iodine-containing supplements [(beta 





Despite a decade of initiatives to increase iodine intakes in New Zealand, iodine 
knowledge was low, iodine intake and status of these lactating women were 
suboptimal, but women who used iodine-containing supplement were more likely to 





Iodine is an essential trace element for thyroid hormone synthesis. Adequate thyroid 
hormone is required for the myelination of the central nervous system during the early 
postnatal period (1). Severe iodine deficiency may result in iodine deficiency disorders, 
such as goitre, and may negatively affect infant growth and mental development (2, 
3), even at mild to moderate iodine deficiency (4). 
During lactation, an adequate iodine intake is required for maternal thyroid function, 
and iodine is also secreted into breastmilk (5). Breastfed infants depend on the iodine 
content in breastmilk to ensure their optimal thyroid function during the first six 
months of life (3, 6). Therefore, it is essential that lactating women have adequate 
iodine status for their own health and that of their newborns. In countries with low 
iodine intake from dietary sources, supplementation is recommended for 
breastfeeding mothers (5). 
In New Zealand, soils provide low levels of available iodine, resulting in low 
concentrations in the food supply (7), and hence the diet (8). Iodine deficiency was a 
concern in New Zealand in the early 20th century, but its prevalence was mostly 
reduced through the introduction of iodised salt after the 1930s (9). However, mild 
iodine deficiency re-emerged in the 1990s (9, 10, 11, 12, 13). To improve iodine status, 
two New Zealand government initiatives were introduced: mandatory fortification of 
bread with iodised salt in 2009, and the provision of a subsidised iodine supplement 
(150 µg) for all pregnant and lactating women in 2010 (14). Subsequent studies have 
demonstrated that most adults (15, 16) and children (17) in New Zealand have achieved 
adequate iodine intake and status, but the status of pregnant and breastfeeding 
women is unknown. A pilot study assessed a small sample of self-selected highly 
educated breastfeeding women before (n = 25 and 32; 2009) and after (n = 34 and 36; 
2011) these initiatives, by testing their urinary iodine excretion, breastmilk iodine 
concentration and blood thyroglobulin; the results suggested iodine deficiency (18). 
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Globally, personal knowledge empowers people to make optimal decisions in dietary 
practices, including choice of food and use of supplements. Good general nutrition 
knowledge by women during pregnancy has been reported in the United Kingdom 
(19). However, researchers remained concerned about very low awareness of iodine-
specific recommendations for pregnant women (19). Poor knowledge of important 
food sources of iodine for women of reproductive age living in the UK/Ireland has 
been reported (20). Breastfeeding women from Norway and Australia had low 
knowledge of the importance of iodine in normal child growth and development, or 
sources of iodine, which may have contributed to their iodine deficiency (21, 22, 23). 
Overall, very few studies investigating iodine knowledge, practice, intake and status 
of breastfeeding women have eventuated.  
The aims of this study were: to evaluate iodine intake and status of breastfeeding 
women at three months postpartum; and to assess current iodine knowledge and 
practice of breastfeeding women in New Zealand. 
6.3 Materials and methods 
6.3.1 Participants and recruitment 
The Mother and infant Nutrition Investigation (MINI) followed a cohort of women 
from three months postpartum over the first year postpartum (24). This paper reports 
on data from three months postpartum. Healthy breastfeeding women were recruited 
from June 2016 to December 2017. Participants were required to live within or near the 
local Palmerston North area and be able to attend scheduled study visits. Women aged 
16 years and older, who had given birth to a healthy term singleton infant at around 
three months old were invited to join the study. Women were excluded: 1) if they had 
pre-existing or developed significant health problems, such as metabolic disease 
including uncontrolled diabetes and cancer; 2) if they had been diagnosed or treated 
at any time for hyperthyroidism or hypothyroidism. Written consent was obtained 
from all participants, mothers provided consent for their infants. 
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6.3.2 Data collection at three months postpartum 
6.3.2.1 Assessment of iodine status 
Non-fasting maternal (approximately 120 mL) and infants’ spot urine samples 
(approximately 20 mL) were collected to measure urinary iodine concentrations. 
Women were asked to provide a breastmilk sample (approximately 30-50 mL) 
expressed by hand or with an electric breast pump if needed. Timing of breastmilk 
collection was not standardised. All biological samples were collected between 0900 
and 1200 on the study visit day. Samples were stored without preservative at –20°C 
prior to analysis. 
Iodine concentrations in maternal and infant urine and breastmilk samples were 
determined by Hill Laboratories, Hamilton, New Zealand, using inductively coupled 
plasma mass spectrometry (25). Quality Control procedures included analysis of 
blanks, analytical repeats and spiked samples in order to ensure accuracy and 
precision. Calibration standards and checks were undertaken on every run with the 
limit of detection at 0.002 mg/kg. Each batch (25 samples) of urinary samples was 
analysed together with an external reference standard (Seronorm Trace Elements 
Urine, L-2, Norway) giving a mean ± SD iodine concentration of 286 ± 12 µg/L, with a 
coefficient of variance (CV) of 4.2% (n = 14). Creatinine was measured in maternal 
urine using the Jaffe Method Flexor (Randox Assayed Multisera levels 2&3) at Massey 
University Nutrition Laboratory in Palmerston North. Each batch of breastmilk 
samples was analysed together with an external reference standard (Skimmed milk 
powder, Elements in organic matrix, European) giving a mean ± SD iodine 
concentration of 1.603 ± 0.029) mg/kg, with a coefficient of variance (CV) of 4.9% (n 
= 6). 
6.3.2.2 Assessment of iodine intake and practice 
Iodine intake was estimated from a weighed four-day diet diary (4DDD). Participants 
were asked to complete the food record within two weeks of the initial study visit. The 
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four days were consecutive and included one weekend day. Detailed food items, 
brands, amount consumed, and the content of the nutritional information panel if 
applicable were recorded. All food and beverage items consumed were weighed with 
an electronic kitchen scale (Digitech, QM-7288), or measured using household 
measurement cups and spoons, which were provided. All participants received both 
oral and written instructions as to how to complete the record, which included a 
written example for one day. Women were also asked to include any dietary 
supplements consumed each time, including the brand and dose. When eating or 
dining out, participants were asked to estimate the portion size of all food eaten. All 
dietary data were entered in Foodworks 9 Professional (Xyris software, Brisbane, 
Australia), and analysed using data sets from the New Zealand Foodfiles 2016 to 
estimate nutrient intake. Where food items were not included in Foodfiles 2016, new 
food items were created based on the information directly provided by participants 
(i.e. food packages), or from appropriate international databases from Australia and 
the United States. To ensure accuracy and completeness, a registered nutritionist (YJ) 
checked all dietary data. Iodine-containing supplement use 24 hours prior to the 
biological sample collection was also collected via a separate question at the study 
visit day. This was also used in statistical analysis of biological variables to compare 
supplement users with non-users. 
Iodine related practice was investigated via a self-administered online questionnaire. 
Participants reported on the type of salt they usually used individually at the table or 
in cooking, and on their habitual use of iodine-containing supplements in pregnancy 
and lactation together with the brand, dose, and duration of consumption. Women 
were asked to give reasons if they chose not to take any supplements at any stage. 
Iodine contribution from discretionary iodised salt was added as 48 µg/day to 
individual’s dietary intake (15), for those who had reported regular use of iodised salt 
at the table or in cooking. 
For a population to have a very low prevalence of inadequate dietary intake, the 
mean/median intake should be above the Recommended Daily Intake (RDI); while 
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the percentage below the Estimated Average Requirement (EAR) approximates the 
proportion that is at risk of dietary inadequacy, according to the EAR cut-point 
method (26, 27). Current intakes based on the 4DDD were compared to Australian 
and New Zealand recommendations; the EAR and RDI for iodine for lactating 
women,190 and 270 µg/day, respectively (28). 
6.3.2.3 Assessment of iodine knowledge 
Iodine knowledge was assessed in two parts. Firstly, four questions examined iodine 
knowledge: Q1 and Q3 (each has only one correct answer); Q2 (four correct answers) 
and Q4 (three correct answers) (Appendix 9). One point was awarded to each correct 
answer given, and a maximum of nine points were generated (Table 6.1). Secondly, 
participants were asked to identify good or poor food sources for iodine from a list of 
12 food items (Appendix 9). Two points were awarded to each correctly identified good 
food source (high contribution of iodine to a normal New Zealand diet, e.g. fish and 
milk); one point was awarded to each correctly identified poor food source (19). If all 
parts were answered correctly, a maximum 17 points were generated. Those who 
gained more than 14 points from the second part of the questionnaire were awarded 2 
points towards their final knowledge score, while those gaining between 10-13 points 
were awarded one point towards their final knowledge score. Total iodine knowledge 
scores were determined from the two parts ranging from 0 to 11 and categorised as 
follows: no knowledge (0-2 points), low knowledge (3-5 points), medium knowledge 
(6-8 points), and high knowledge (9-11 points) (Table 6.4). 
6.3.2.4 Other assessments  
Sociodemographic characteristics of the mothers including age, ethnicity, educational 
attainment, smoking status, household size and income were collected on the initial 
study visit. Information on infants’ birth was collected from the “Well Child Tamariki 
Ora” book (New Zealand child health record) provided by participants, including 
gestational age at birth, birth weight, and date of birth which was used to calculate 
the ages of infants at the day of study visit. 
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Table 6.1 Iodine knowledge score calculation and number (%) of participants. 
Questions Correct choices Points  n (%) 
1) Why iodine is 
important 
Need iodine for thyroid gland 1 64 (74) 
2) Health issues 
associated with  
iodine deficiency 
Goitre 1 42 (48) 
Birth defects 1 33 (38) 
Mental retardation  1 23 (26) 
Impaired physical development during 
childhood 
1 28 (32)  
3) Awareness of iodine 
deficiency in NZ 
Yes 1 42 (48) 
4) Awareness of NZ 
government initiatives 
Mandatory iodised salt fortification of 
bread 
1 18 (21) 
Recommended routine taking iodine 
supplements – pregnant 
1 78 (90) 
Recommended routine taking iodine 
supplements – breastfeeding 
1 49 (56) 
5) Identify good food 
source for iodine 
   
 Poor  0 68 (77) 
 Some  1 16 (18) 
 Good  2 3 (3) 
 Maximum Total  11  
 
6.3.3 Data Analysis 
All data were analysed using IBM SPSS (Statistics Package for the Social Sciences, IBM, 
Armonk, NY, USA) version 20. Data were tested for normality using the Shapiro-Wilk 
test. Non-parametric data were expressed as median with interquartile range (25th,75th 
percentile) and parametric data expressed as mean (± standard deviation; SD). 
Bivariate correlations were tested using the nonparametric Spearman’s rho correlation 
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coefficient. Mann-Whitney U test was used to examine iodine status between 
exclusively breastfeeding and mixed feeding (providing breastmilk and infant 
formula) women and their infants. Differences in iodine status between iodine-
containing supplement users and non-users were tested with a nonpaired t-test after 
log transformation of these variables. Logistic regression was used to predict the 
likelihood of using iodine-containing supplements based on all variable(s) entered 
simultaneously: education attainment, parity, household income, and iodine 
knowledge scores. Logistic regression was fitted to examine the likelihood of a higher 
iodine knowledge score (> 5), based on all variable(s) entered simultaneously: 
educational attainment, habitual use of iodised salt, habitual use of iodine-containing 
supplement during this pregnancy. Chi-square tests were used to examine whether 
women with higher education (tertiary or lower than tertiary) or higher income 
(above or below the median income of New Zealand population) were more likely to 
habitually use iodine-containing supplements during this pregnancy and lactation 
(iodine practice). 
6.4 Results 
In total, 87 breastfeeding mother-infant pairs were recruited at three months 
postpartum. The mean age of the women was 32 years, and 83% were exclusively 
breastfeeding (no other food or drink, not even water, except breastmilk) at three 
months after childbirth (Table 6.2). Compared with the 2013 New Zealand Census data 
among women aged 30-34 years, this sample had a lower proportion of Māori (10% vs. 
13%), a higher percentage of Caucasians (76% vs 60%), and a similar proportion of 
Asians (10% vs. 8%) (29), a higher proportion of women who achieved a tertiary 
qualification (77% vs. 61%) (30), and 38% reported an annual household income below 
the national median for 2016 ($NZ75995) (31). In addition, 23 women reported that 
they had been smoking but most stopped after becoming pregnant, apart from one 
woman who continued. Further, three women stopped smoking during this 
pregnancy, but started again after the birth. 
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Table 6.2 Description of breastfeeding participants and their infants. 
Maternal characteristics n % 
Maternal age, years (Mean ± SD) 31.5 ± 4.2  
Tertiary Education 67  77 
Ethnicity (Māori) 9  10 
Ethnicity (Caucasian) 66  76 
Ethnicity (Asian) 9  10 
Ethnicity (Other) 3  4 
Annual household income (Above median)* 54  62 
Primiparity 38  44 
Caesarean birth 19  22 
Gestational ages at birth, weeks (Mean ± SD) 39.4 ± 1.5  
Age of infants, days (Mean ± SD)  88.5 ± 14.8  
Infants birth weight, kilograms (Mean ± SD) 3.6 ± 0.6  
* Median annual household income based on Statistics New Zealand is 75,995 New Zealand dollars for the year ended June 2016 (31). 
6.4.1 Iodine status  
Iodine deficiency in a population is defined by the median urinary iodine 
concentration (MUIC); the WHO guidelines (2007) currently recommend the cut-off 
as 100 µg/L for lactating women (32). Maternal MUIC (25th, 75th percentile) in the 
current cohort was 82 (46, 157) µg/L below 100 µg/L (32), which indicated iodine 
deficiency in this population of breastfeeding women (Table 6.3). Infant MUIC of 115 
µg/L was lower than the suggested cut off for infant MUIC of 125 µg/L based on the 
Estimated Average Requirement of 72 µg/day of infants aged two to five months 
derived from a Swiss study of infants (33). The MUIC of women who were exclusively 
breastfeeding was not significantly different from those who were mixed feeding (78 
vs. 117 µg/L, P = 0.511); the MUIC of infants who were exclusively breastfed was not 
significantly different from those who were mixed breastfed (111 vs. 134 µg/L, P = 
0.280). Median breastmilk iodine concentration (BMIC) of 69 µg/L was below 75 µg/L 
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which has been suggested as an index of sufficient iodine intake (34). Women who 
used iodine-containing supplements achieved significantly higher MUIC (111 vs 68 
µg/L), maternal urinary iodine creatinine ratio (197 vs 96 µg/g) and BMIC (84 vs 62 
µg/L) than non-supplement users (P < 0.001). Infants from women who used iodine-
containing supplement attained a higher infant MUIC of 150 (97, 193) µg/L, above the 
recommended cut-off of 125 µg/L, while infant MUIC from infants of non-users was 
86 (53, 171) µg/L (P = 0.036). 
The iodine knowledge score was statistically significant predictor of consuming 
iodine-containing supplements [(beta = 1.321, P = 0.008)], while educational 
attainment, parity, household income, breastfeeding patterns were not predictors. 
Although educational attainment and household income was weakly correlated, the 
variance impact factor equals to one, thus no correction was required for the 
multicollinearity. 














Numbers of participants (n) 
87 35 52 - 
a Maternal MUIC µg/L 82 (46, 157) 111(46, 240) 68 (44, 123) 0.023 
Maternal urinary creatinine 
g/L 0.6 (0.3, 1.1) 0.6 (0.2, 0.9) 0.7 (0.3, 1.3) 0.131 
Maternal urinary iodine 
creatinine ratio µg/g 124 (77, 231) 197 (129, 335) 96 (69, 169) <0.001 
bInfant MUIC µg/L 115 (69,182) 150 (97, 193) 86 (53, 171) 0.036 
cBMIC µg/L 69 (52,119) 84 (68, 167) 62 (47, 81) <0.001 
a
 Maternal MUIC cut-off is 100 µg/L (32); 
b
 Infant MUIC cut-off is 125 µg/L (33); 
c
 BMIC cut-off is 75 µg/L (34). 
1




6.4.2 Iodine intake and practice 
Median estimated iodine intake including iodine supplements based on 4DDD was 151 
(99, 285) µg/day below the RDI of 270 µg/L, with 58% below the EAR of 190 µg/day 
(Table 6.4). Median iodine intake for women using iodine-containing supplements 
was 289 µg/day, significantly higher than for non-users (120 µg/day, P < 0.001). For 
women using iodine-containing supplements, median iodine intake was above the 
RDI with only 10% (3/30) below the EAR, whereas median intakes for non-users were 
below the RDI with 89% (42/47) below the EAR. 
Table 6.4 Maternal iodine intake based on 4DDD. 















Below the EAR of 190 µg/day 
n (%) 45 (58) 3 (10) 42 (89) 
 
Despite iodised salt being available in New Zealand for over 80 years, only 51% (44/87) 
reported using iodised salt at the table or in cooking. Median consumption of fortified 
bread with iodised salt was 56 (36, 105) g/day, which is about 1.5 slices (based on 38g 
per slice of bread) (15), and iodine obtained from fortified bread was 23 (15, 41) µg/day. 
Median contribution of fortified bread to the total iodine intake was 15% (7%, 27%). 
Eighty-six percent (75/87) of women took iodine-containing supplements (ranging 
from 150 to 270 µg iodine per day, with 79% (59/75) consuming the government 
subsidised iodine of 150 µg/day) during pregnancy but this reduced to 46% (40/87) 
during lactation (ranging from 100 to 250 µg iodine per day, with only one person 
consuming a supplement containing less than 150 µg/day iodine, and 58% (23/40) 
consuming the government subsidised iodine). Habitual iodine-containing 
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supplement use during pregnancy was moderately correlated with education 
attainment (r = 0.434, P < 0.001), but not household incomes. Further Chi-square test 
showed during pregnancy, women with a tertiary education were more likely to use 
iodine-containing supplements than those who has not obtained tertiary education 
(94% vs 58%, P < 0.001). During lactation, habitual iodine-containing supplement use 
was not associated with either educational attainment or household incomes. The 
reasons for not taking iodine supplement during lactation included: 1) never being 
advised to do so by health professionals (31%, 16/87); 2) believing adequate nutrient 
intake was achieved from their overall diet (24%, 12/87); and 3) not remembering to 
take supplements daily (22%, 11/87). 
6.4.3 Iodine knowledge and its related iodine intake/status 
The median iodine knowledge score was 5 (3, 6), and 66% (57/87) of women had no 
or low iodine knowledge (Table 6.5). Forty-eight percent (42/87) of women identified 
that goitre was related to iodine deficiency (Table 6.1). When considering two 
government initiatives to combat iodine deficiency, only 21% (18/87) of women 
reported being aware of iodine fortification of bread. Although 90% (78/87) knew that 
iodine supplementation is recommended during pregnancy, the figure dropped to 
56% (49/87) for awareness that iodine supplementation is also recommended for 
breastfeeding women. Overall, the iodine knowledge score was moderately correlated 
with the estimated iodine intake (r = 0.304, P = 0.007). The iodine knowledge score 
was weakly correlated with iodine status determined by the maternal urinary iodine 
creatinine ratio (r = 0.250, P = .026), but not associated with maternal UIC (r = -0.026, 
P = 0.811) or BMIC (r = - 0.009, P = 0.931). The habitual use of iodised salt was a 
statistically significant predictor of a higher iodine knowledge score [(beta = 0.975, P 
= 0.042)], while educational attainment and habitual iodine-containing supplement 




Table 6.5 Categorised total iodine knowledge scores (n = 87). 
Categories of scores (points) Indicators n (%) 
0-2 No knowledge  18 (21) 
3-5 Low knowledge 39 (45) 
6-8 Medium knowledge 24 (27) 
9-11 High knowledge 6 (7) 
6.5 Discussion 
6.5.1 Iodine intake/status of iodine-containing supplement users and non-
users 
The MINI study found iodine deficiency was present in this sample of New Zealand 
breastfeeding women, despite the implementation of two government initiatives to 
improve iodine status. The maternal MUIC for current study participants (82 µg/L), 
was below the WHO cut-off suggesting deficiency, although it was similar to that 
reported among lactating women (74 µg/L) in the pilot study carried out in the same 
region one year after the government initiatives had been implemented (18). Although 
lower than reported among Australian breastfeeding women (125 µg/L) from a post-
fortification study (35), this was not unexpected due to a relatively higher iodine 
content in the Australian food supply in comparison to that in New Zealand (36). In 
the current study, there was not a significant difference in maternal and infant MUIC 
between women who were exclusively breastfeeding and those who were mixed 
feeding (providing breastmilk and infant formula) (78 vs 117 µg/L, P = 0.511; 111 vs 134 
µg/L, P = 0.280), although both maternal and infant MUIC from  women who were 
mixed feeding were higher than the suggested cut-offs of 100 µg/L (32) and 125 µg/L 
(33) respectively for iodine adequacy. Careful interpretation of this result is needed as 
the lack of statistical power from the low numbers of mixed feeding women (n = 11) in 
this study. Potentially supplementing breastfeeding with infant formula may increase 
UIC for both mothers and their infants in this study cohort. The overall iodine status 
of breastfeeding women remained deficient, which raises concern regarding the long-
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term effectiveness of the present strategies in establishing iodine sufficiency. Further 
studies on the long-term effects on infants’ neurodevelopment are required to 
determine definitions of the levels of iodine deficiency, as there for other population 
groups. 
In the present study, maternal and infant MUIC, BMIC, and maternal urinary iodine 
creatinine ratio were all significantly higher for women who used iodine-containing 
supplements compared to non-users. Median values for women who used iodine-
containing supplements were higher than recommended cut-offs suggesting 
adequacy; this was not observed for non-users. Similarly, an Australian post-
fortification study of 60 breastfeeding women reported a significantly higher MUIC 
from iodine supplement users (206 µg/l) than non-users (97 µg/L) and identified 
iodine deficiency among breastfeeding women who did not consume iodine 
supplements (23). This finding was consistent with the results from a supplementation 
trial in an iodine deficient area, in Morocco, where maternal supplementation of one 
dose of 400 mg iodine in early lactation effectively provided adequate iodine for their 
breastfed infants up until the age of six months (37). Our results suggest that 
appropriate supplementation of iodine during breastfeeding will effectively improve 
iodine status for both women and their breastfed infants. 
The estimated median iodine intake of lactating women in the current study based on 
the 4DDD suggested an inadequate intake. However, the median intake in women 
who used iodine-containing supplements was 289 µg/day above the RDI, with only 
10% below the EAR compared to median intake of 120 µg/day in the women who did 
not take supplements with 89% below the EAR. The inadequate iodine intake in this 
vulnerable population is of concern. Significant differences of the median iodine 
intake between iodine-containing supplements users (139 µg/day) and non-users 
(126µg/day) was reported in a Danish adult study (DanThyr), where only 34% of the 
participants used iodine supplements ranging from 50-150µg/day (38). However, the 
median iodine intake in both groups were below the RDI for adults at 150 µg, which 
may due to low levels of iodine supplementation. An observational study of 
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Norwegian pregnant women also reported an improvement of median iodine intake 
among supplement users [122 µg/day with 28% below the Nordic Nutrition 
Recommendations (NNR) of 175 µg/day], compared to non-users [116 µg/day with 80% 
below the NNR], however, the percentage of those using iodine-containing 
supplements was not reported (39). 
6.5.2 Iodine knowledge and iodine intake/status 
In the current study only 56% of breastfeeding women were aware of the 
recommendation of iodine supplementation during lactation, although 90% were 
aware of the need during pregnancy. This was reflected in 86% of current study 
participants reporting using iodine-containing supplements during pregnancy, which 
is compatible to 81% reported in a large pregnancy cohort study (n = 783) in Australia 
(40), but only 46% during breastfeeding which is lower than 57% of lactating women 
(41) who reported using iodine-containing supplements in an Australian study. A 
previous study in 2011 in Palmerston North, New Zealand indicated that there was a 
low awareness of the need for iodine supplements for breastfeeding women, with only 
35% reporting use of any iodine-containing supplements (18). Recently, low use of 
iodine-containing supplements among both pregnant and lactating women was also 
found in the United States (42). Currently, iodine-only supplements (government 
subsidised) and a suitable range of dietary supplements containing iodine are known 
to be available within New Zealand. Consumers, however, may become confused as to 
which may be the most desirable for their own personal circumstances. Women on a 
tight budget cannot afford the cost of government subsidised iodine-only 
supplements outside the free antenatal care period (six weeks after birth) from their 
registered general practitioners (GPs). A New Zealand study reported that 13% of 
women who received prescriptions for iodine supplements did not fill their 
prescription (43). In the current study, iodine knowledge score was the largest 
predictor for the use of iodine containing supplements by breastfeeding women, but 
educational attainment and household income were not predictors. Whereas, a 
previous large multicentred study of pregnant women in New Zealand (n = 968) 
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suggested low use of iodine-containing supplements among women with low 
education and income, despite the New Zealand Government subsiding the cost (44). 
The present study also found women with a tertiary education were more likely to 
consume iodine-containing supplements during pregnancy, but household income 
did not play a significant role in iodine-containing supplement use. This finding could 
be useful for targeting future educational interventions around iodine. 
The lack of awareness of the need for iodine supplementation during lactation is 
concerning. In New Zealand pregnant women are most reliant on midwives and GPs 
for their postnatal health advice. A 2014 Australian study investigating antenatal care 
(45), reported that even GPs could not correctly identify the best dietary food sources 
of iodine, and had expressed limited knowledge of the existing recommendations of 
iodine supplementation in Australia. The research found that a majority of Australian 
GPs questioned confirmed that they did not openly recommend iodine supplements 
to their patients (45). More recently an Australian-wide survey examined health 
professionals’ knowledge about iodine supplementation for pregnant and 
breastfeeding women, and results showed a clear lack of awareness of the appropriate 
dose and duration (46). Both Australian studies highlighted a need for iodine specific 
nutritional education initiatives being disclosed to all primary health care providers. 
Despite the current recommendation for taking iodine supplements during pregnancy 
and breastfeeding in New Zealand (14), the time at which supplement use should 
commence is currently under debate, To maintain adequate iodine status throughout 
pregnancy and lactation, adequate iodine stores in  the thyroid prior to conception 
are essential. The time required for iodine to be absorbed then incorporated into 
thyroid hormones may be several weeks. A recent study of women from Tasmania, 
Australia has reported a higher MUIC from women who were supplemented with 
iodine at 150 µg/day prior to conception than those who started supplementation 
during pregnancy (196 vs 140 µg/L, P = 0.032) (47). Starting iodine supplementation 
after a confirmed pregnancy could be too late for the iodine to have maximal effect 
(48). Thus, inadequate iodine stores prior to pregnancy may result in sub-optimal 
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iodine nutrition in mothers, their foetuses and infants, even if iodine supplementation 
commences after conception and continues throughout lactation. 
In the current study the iodine knowledge score was moderately correlated with the 
estimated iodine intake based on 4DDD. A previous study in the United Kingdom/and 
Ireland also had found a positive association between iodine knowledge and dietary 
iodine intake in women of childbearing age (20). However, in this study, iodine 
knowledge scores were not associated with maternal UIC, this aligns with a Norwegian 
lactating women’s study (21). The lack of association could be due to the variation in 
UIC due to hydration status (49). Further, a weak association was recorded with the 
maternal urinary iodine creatinine ratio (µg/g), which has been suggested to be a more 
reliable biomarker for iodine status (50). 
The current study was not able to compare iodine intake and status by ethnicity. The 
2014/2015 New Zealand Health Survey found both Maori and Asian women achieved 
the recommended MUIC cut-off of 100 µg/L for iodine adequacy (108 µg/L and 121 
µg/L, respectively), when compared to European women of 86 µg/L (51). A 
significantly higher BMIC was also reported in non-Caucasian South Australian 
mothers (n = 944), when compared to that of Caucasians, suggesting that different 
dietary behaviour or supplement use during lactation may contribute to these 
differences (40). 
6.5.3 Strengths and limitations 
The strength of this study was that it examined iodine intake and status in 
breastfeeding women coupled with knowledge and practice in New Zealand. It is the 
first study to report both breastfeeding women and their infants’ iodine status 
following the introduction of mandatory iodine fortification. Dietary intake was 
assessed using weighed 4DDD which is considered the gold standard of dietary 
assessment (52). To enable an overall understanding of iodine practice, iodine-
containing supplement use was assessed in three ways. Firstly, it was reported at the 
time of urine and breastmilk sample collection to allow accurate reflection on the 
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impacts of using supplements on biochemical measures. Secondly, women were also 
asked to include any dietary supplements consumed (including iodine-containing 
supplements) in their 4DDD to ensure correct reflection of their dietary iodine intake. 
Finally, retrospective data on their habitual use of iodine-containing supplements 
during this pregnancy and lactating period were collected to evaluate iodine practice 
among these breastfeeding women, as both pregnant and lactating period are critical 
in fetus and infant neurodevelopment. 
A limitation of this study is bias, women with pre-existing iodine knowledge may have 
been attracted to participate. Women in this study were better educated than the New 
Zealand population, typically, women who volunteer to participate in such studies are 
often more interested and motivated about health than the general population. 
However, if the iodine status of these women is inadequate, it is likely that women 
who are less well-educated and under-represented will have even poorer iodine status. 
Although this is a cohort study, dietary intakes and knowledge data were only assessed 
at three months postpartum, because this is a critical period of infant motor and 
neurodevelopment. A limitation of this study is its small sample size; therefore, the 
results need to be interpreted with caution. 
The use of a single spot urine samples can be affected by maternal hydration status; 
however, urinary creatinine values were determined to reduce the variation in 
maternal hydration. Due to the small sample of infant urine we were not able to 
measure creatinine in these samples, however there is less variation in infant 
hydration status. There is a high level of intra-individual variation in iodine intake 
research shows ten samples are required to determine habitual intake (53), thus using 
repeated measuring could have better predicted iodine status. (54). Iodised salt 
consumption was difficult to estimate accurately since the frequency and quantities 
recorded in the 4DDD can never be completely reliable. Therefore, 48 µg iodine per 
day was included for those women who self-reported regular usage of iodised salt at 
the table and/or in cooking (15) This method of estimation may still reflect a possible 
under or overestimate of iodine intake in this cohort. 
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6.6 Implications for research and practice 
Iodine deficiency of breastfeeding women after initiatives to improve iodine status is 
concerning, especially for those who do not use iodine-containing supplements. Only 
56% of participants were aware of the need for iodine supplements during lactation. 
There was also low awareness of the importance of iodine in health and good dietary 
sources of iodine. Further public health initiatives are important to ensure that both 
health professionals and women become aware of the need for iodine 
supplementation during lactation. It is essential that health professionals providing 
postnatal healthcare should promote iodine specific nutrition education to protect 
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Chapter 7 Iodine status of postpartum women and their infants 
aged 3, 6 and 12 months - Mother and Infant Nutrition 
Investigation (MINI) 
 
This chapter continues to report the research findings from the MINI study regarding 
iodine. One of the most important findings (noted in Chapter 6) was that breastfeeding 
women remain iodine deficient at three months postpartum, and only women who 
followed the recommendation of taking iodine-containing supplements achieved 
adequate status. This then led on to further investigation of iodine status in mothers 
and infants over the first postpartum year. This forthcoming publication centres on the 
research objective to examine iodine intake and status of postpartum women and their 
infants at three, six and twelve months postpartum. It describes the iodine status of 
mothers and their infants at all three time points by assessing urinary iodine 
concentrations; urinary iodine creatinine ratios; and breastmilk iodine concentrations. 
An increased expression of sodium iodide symporter in mammary glands increases 
iodine secretion in breastmilk (noted in Chapter 2). However, it is not clear how 
maternal iodine excretion is partitioned between urine and breastmilk during lactation. 
To address this research gap, this article will present the results from the analysis of 
data collected from exclusive breastfeeding mothers at three months postpartum. 
This article addresses hypothesis 3: Postpartum women and their infants will remain 
iodine deficient, despite two New Zealand government initiatives to improve iodine 
status. 
 
This chapter has been submitted for publication to the British Journal of 





Iodine is essential for adequately synthesising thyroid hormones. These hormones play 
a key role in the neurodevelopment of infants and children during the first three years 
of age. Few studies have investigated mother and infant iodine status during the first 
postpartum year. 
Objectives 
This study aims to describe iodine status of supplement users and non-users (for both 
mothers and infants) at three, six, twelve months postpartum (3MPP,6MPP,12MPP). 
Partitioning of iodine excretion, between urine and breastmilk, of exclusive 
breastfeeding women at 3MPP was determined. 
Methods 
Maternal spot urinary iodine concentration (UIC), breastmilk iodine concentration 
(BMIC) and infant UIC were determined. 
Results 
In total 87 mother-infant pairs were recruited at 3MPP, followed at 6MPP (n = 78) and 
12MPP (n = 71). Maternal median UIC (MUIC) (p25, p75) at 3MPP [82 (46, 157) µg/L], 
6MPP [85 (43, 134) µg/L] and 12MPP [95 (51, 169) µg/L] were < 100µg/L. The use of 
iodine-containing supplements increased MUIC only at 3MPP. Median BMIC (p25, p75) 
at three time points [69 (52, 119) µg/L], [59 (39, 108 µg/L], and [35 (26, 54) µg/L] were 
below 75 µg/L. Infant MUIC (p25, p75) at 3MPP [115 (69,182) µg/L] and 6MPP [120 (60, 
196) µg/L] were below 125 µg/L. Among exclusive breastfeeding women at 3MPP, an 
increased partitioning of BMIC (highest proportion 60%) was shown at lower iodine 
intakes, along with a reduced fractional iodine excretion in urine (lowest proportion 





In conclusion, this cohort of postpartum women was iodine deficient. Iodine status of 
their breastfed infants aged three and six months were suboptimal. Further research of 
the association between iodine status, infant thyroid function and neurodevelopment 




Iodine is an essential micronutrient for adequate production of thyroid hormones, 
including triiodothyronine (T3) and thyroxine (T4). Insufficient synthesis of thyroid 
hormones may impair the neurodevelopment of infants and children, particularly, in 
the first three years of life (1, 2). During lactation, maternal iodine requirement 
increases to allow the secretion of iodine into breastmilk and to maintain maternal 
thyroid hormone concentrations. Studies have suggested that during lactation 
mammary glands are able to concentrate 20-50 times more iodine than maternal 
blood due to the active sodium-iodide symporter (NIS) (3). The World Health 
Organization (WHO) recommends exclusive breastfeeding during the first six months 
of life, and to continue to breastfeed for up to two years and beyond (4). Exclusively 
breastfed infants rely fully on their mothers for an adequate iodine supply to 
synthesise sufficient thyroid hormones during the first six months, thereafter infants 
obtain additional iodine from appropriate complementary foods (5). 
The first postpartum year is important for women to re-adjust and meet their 
changing iodine requirements. Few studies have investigated iodine status at different 
time points from early lactation to the end of the first postpartum year (6, 7, 8, 9, 10). 
One small study of New Zealand women (n = 35) prior to government interventions 
reported median urinary iodine concentrations (MUIC) of 37 µg/L, 25 µg/L, and 47 
µg/L at three, six and twelve months postpartum, suggesting iodine deficiency (7). 
There continues to be a need for a more robust investigation into the iodine status of 
postpartum women and their infants. 
New Zealand soil typically provides low levels of available iodine, which results in low 
iodine concentrations in local food supply (11). Endemic goitre was prevalent in New 
Zealand in the early 20th Century, due to iodine deficiency. A voluntary salt iodisation 
programme was established in 1938 which dramatically reduced goitre rates by the 
1950s (12). However, public health messages have led to reduced salt consumption to 
prevent high blood pressure and reduce the risks of other chronic medical conditions. 
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The recent shifting from traditional home cooking with iodised salt to commercially 
prepared food with non-iodised salt has contributed to low use of iodised salt (13). 
Other possible reasons which may reduce population iodine intake include the 
cessation of using iodophors as cleaning agents in the New Zealand dairy industries 
which resulted in a drop of iodine content in milk (14), and the current dietary 
preferences of non-dairy milks made from soy, almond, rice and oat which contain 
low iodine < 0.02 mg/kg (15). Re-emerging iodine deficiency was reported in the 1990s 
for adults (16) and school children (12), also breastfed infants and toddlers (17). 
To combat iodine deficiency, mandatory fortification of bread with iodised salt (25-65 
mg iodine/kg salt) was introduced in New Zealand in September 2009, applicable to 
all commercial bread and bread products other than organic and unleavened (18). 
Recent studies in New Zealand have suggested that fortification has led to adequate 
intakes and status in the majority of school children (19, 20) and adults (21, 22). 
However, fortification was predicted to be inadequate for pregnant and breastfeeding 
women due to their increased requirements. Thus, in 2010, the use of government 
subsidised iodine-only supplements (150 µg/day) was recommended to all pregnant 
and breastfeeding women in New Zealand (23). A pilot study (n = 36) suggested 
breastfeeding women remain deficient (24), and reported mean breastmilk iodine 
concentrations (BMIC, 63 µg/L) (24) lower than suggested for adequacy (75 µg/L) (25); 
although iodine status of the breastfed infants was not investigated. 
The aim of this Mother and Infant Nutrition Investigation (MINI) was to describe 
iodine status of supplement users and non-users (for both mothers and infants) at 
three, six, twelve months postpartum. Further, it investigated partitioning of iodine 





7.3.1 Study population 
MINI was an observational longitudinal cohort study spanning the first postpartum 
year in Palmerston North, in the North Island of New Zealand. Breastfeeding women 
aged 16 years and older were recruited, who had given birth to a healthy term singleton 
three months prior. Women were excluded: 1) if they had pre-existing or developed 
complicated health problems, such as metabolic disorders and cancer; 2) if they had 
been diagnosed or treated at any time for hyperthyroidism or hypothyroidism. 
Recruitment spanned the 19-month period between June 2016 and December 2017. 
Posters to promote the study were placed at selected sites (General Practitioner 
surgeries, midwifery clinics, pharmacies, antenatal classes, ultrasound clinics, 
maternal wards in hospitals, local community playgroups, and early childhood 
centres, etc.). Local newspapers and social media sites were used to publicise the 
study. Local midwives, childbirth educators, and lactation consultants were asked to 
raise awareness of the MINI study to their clients. Potential participants responded by 
recording an expression of interest online or via telephone/email. Prospective 
participants were provided with a study information sheet. Interested participants 
then completed a screening questionnaire to ensure eligibility. Details of the study 
methods have been published previously (26). The first study visit for each mother-
infant pair was at approximately three months postpartum, and follow-up 
assessments took place at six months (2nd study visit) and 12 months (3rd study visit) 
postpartum. Written informed consent was obtained from all participants before their 
enrolments in the study. Mothers also gave the written consent to their infants’ 
participation in the study. 
7.3.2 Ethics approval 
All procedures performed in the MINI study involving human participants were in 
accordance with the ethical standards of the Health and Disability Ethics committee. 
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The MINI study was approved by the Health and Disability Ethics Committee 
(reference:15/NTA/172) in December 2015. 
7.3.3 Sample size 
The main outcome measure was urinary iodine concentration (UIC) and the sample 
size was calculated using G*Power 3.1 (Heinrich Heine University, Dusseldorf) (27) 
based on data [mean and standard deviation (SD)] from a preliminary study of 
breastfeeding women (24). The analysis utilised one–way ANOVA with two groups 
(95% power, alpha = 0.05, two tailed) and three repeat measures. Eighty participants 
were sought, using expected mean daily UIC of 140 and 100 µg/L for iodine supplement 
users and non-users, respectively, with a standard deviation of 60. 
7.3.4 Assessment of iodine status 
During each study visit, non-fasting spot urine samples were collected from each 
participating woman and her infant to assess iodine and creatinine excretion. A 
paediatric urine bag was placed inside the diaper and checked every 10 minutes during 
the study visit to collect infant urine samples. Women were asked to provide a 
breastmilk sample (approximately 30-50 mL) using an electric breast pump if needed. 
All samples were collected before 12 noon on the study visit day. Samples were stored 
without preservative at –20°C. Breastmilk samples were analysed for iodine 
concentration, allowing for estimations of daily excretion and infant iodine intake 
(28). Use of iodine-containing supplements was determined within 24 hours of the 
time of biological sample collections at each visit. 
Iodine concentrations of urine and breastmilk samples were determined by Hill 
Laboratories, Hamilton, New Zealand, using inductively coupled plasma mass 
spectrometry (29). Quality Control procedures included analysis of blanks, analytical 
repeats and spiked samples in order to ensure accuracy and precision. Calibration 
standards and checks were undertaken on every run with the limit of detection at 
0.002 mg/kg. Each batch (25 samples) of urinary samples was analysed together with 
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an external reference standard (Seronorm Trace Elements Urine, L-2, Norway) giving 
a mean ± SD iodine concentration of 286 ± 12 µg/L, with a coefficient of variance (CV) 
of 4.2% (n = 14). Creatinine was measured in maternal urine using the Jaffe Method 
Flexor (Randox Assayed Multisera levels 2&3) at Massey University Nutrition 
Laboratory in Palmerston North. Each batch of breastmilk samples was analysed 
together with an external reference standard (Skimmed milk powder, Elements in 
organic matrix, European) giving a mean ± SD iodine concentration of 1.603 ± 0.029 
mg/kg, with a coefficient of variance (CV) of 4.9% (n = 6). 
Iodine deficiency in a population is defined by a MUIC below 100 µg/L for lactating 
and non-lactating non-pregnant women, and children younger than two years (1). The 
WHO (2007) also recommends that for a population to be iodine sufficient no more 
than 20% should have a UIC less than 50 µg/L (1). There is no universal consensus on 
the optimal concentration for BMIC, however greater than 75 µg/L has been suggested 
to be sufficient for adequate infant iodine intake (25). 
7.3.5 Infant anthropometry 
At the initial visit, infant recumbent length was measured crown to heel using an 
infant length board and recorded to the nearest mm. Infant weight (without clothing 
and diapers) was measured, using a baby weighing scale (Nagata Scale Co Ltd) and 
recorded to the nearest 10 g. Infant’s weight-for-age Z-score (WAZ) and height-for-
age Z-score (HAZ) were calculated by entering the data into WHO-Anthro software 
(https://www.who.int/childgrowth/software/en/)(30). 
7.3.6 General demographic and health information 
At the initial visit, mode of infant feeding, maternal general health, and demographic 
information (including age, ethnicity, educational attainment, household size and 
income) were collected. Potential changeable information including mode of infant 
feeding and general health was also sought at the second and third visits.  Infants’ 
birth information including gestational age at birth, date of delivery, method of 
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delivery, birth weight, and gender was collected at the first visit, from the “Well Child 
Tamariki Ora” book (New Zealand child health record). Recorded date of delivery was 
used to calculate the age of infants on the day of study visit. 
7.3.7 Statistical analysis 
Data were analysed using IBM SPSS (Statistics Package for the Social Sciences, IBM, 
Armonk, NY, USA) version 20. Data were tested for normality using Shapiro-Wilk’s 
test. Non-parametric data were expressed as median with interquartile range (25th, 
75th percentile) and parametric data expressed as mean (± standard deviation; SD). 
Bivariate correlations were tested using the nonparametric Spearman’s rho correlation 
coefficient. Nonparametric data was natural log transformed for further analysis. A 
one-way mixed ANOVA with two groups was used to compare the mean differences 
between UIC of iodine-containing supplement users and non-users (based on iodine-
containing supplement use at three months postpartum) with a repeated measure at 
three, six and twelve months postpartum. Differences in iodine status for women who 
were breastfeeding at all three timepoints, determined by UIC, urinary iodine 
creatinine, and breastmilk iodine concentration (BMIC) between three measurement 
points were tested by one-way repeated measures ANOVA. 
For exclusive breastfeeding women (EBF), their daily maternal iodine excretion in 
urine was estimated based on 1.5 L of urine per day (31). Total estimated daily iodine 
excretion was the sum of urinary and breastmilk iodine excretions. The fractional 
excretions of iodine in urine and breastmilk were calculated as percentages of total 
daily iodine excretions (32). Assuming 92% of iodine consumed is excreted into urine 
and breastmilk together (31), total estimated maternal iodine intake was calculated. 
The estimated total daily iodine intake of their exclusively breastfed infants was 
calculated based on daily urine volume assumed at 0.5 L, with an assumption of 87% 
iodine consumed is excreted in infants’ urine (33). Independent t-test was used to 
compare natural log transformed maternal UIC, maternal urinary iodine creatinine 
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ratio, and BMIC between exclusive breastfeeding women who used iodine-containing 
supplements and non-users. 
7.4 Results 
7.4.1 Characteristics of mothers and their infants 
In total, 87 mother and infant pairs were recruited at three months postpartum 
(3MPP) and followed up at six months (n = 78, 6MPP) and twelve months (n = 71, 
12MPP).  A description of characteristics of breastfeeding women and infants at 
enrolment are shown in Table 7.1. All women were breastfeeding at 3MPP, and 96% of 
women continued to breastfeed their infants at 6MPP, but only 46% continued 
breastfeeding at 12MPP. 
Table 7.1 Description of breastfeeding participants and their infants at 3MPP 
Maternal characteristics at 3MPP Total  
 








(n = 52) 
Maternal age, years (Mean ± SD) 31.5 ± 4.2 32.3 ± 3.3 30.9 ± 4.6 
Tertiary Education (n, %) 67, 77 31, 89 37, 71 
Ethnicity – Maori (n, %) 9, 10 4, 11 5, 10 
Ethnicity – Caucasian (n, %) 66, 76 26, 74 40, 77 
Ethnicity – Asian (n, %) 9, 10 5, 14 4. 8 
Annual household income (> median, n, %)* 54, 62 23, 66 31, 60 
Primiparity (n, %) 38, 44 15, 43 23, 44 
Caesarean delivery (n, %) 19, 22 8, 23 11, 21 
Infant characteristics    
Gestational age at birth, weeks (Mean ± SD) 39.4 ± 1.5 39.3±1.7 39.4±1.46 
Age of infants, days (Mean ± SD)  88.5 ± 14.8 90.1 ± 15.6 87.4 ± 14.3 
Male (n, %) 52, 60 19, 54 33, 63 
Birth weight, kilograms (Mean ± SD) 3.6 ± 0.6 3.5 ± 0.5 3.7 ± 0.7 
Weight-for-age Z-score (Mean ± SD) -0.049 ± 1.050 -0.777 ± 0.989 -0.029 ± 1.098 
Height-for-age Z-score (Mean ± SD) 0.066 ± 1.386 0.025 ± 1.318 0.092 ± 1.442 
* Median annual household income based on Statistics New Zealand was 75,995 New Zealand dollars for the year ended June 2016(34). 
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7.4.2 Maternal iodine status at three, six and twelve months postpartum 
Maternal MUIC (25th, 75th percentile) at 3MPP [82 (46, 157) µg/L], 6MPP [85 (43, 134) 
µg/L], and 12MPP [95 (51, 169) µg/L] were < 100 µg/L, suggesting iodine deficiency. 
Further, greater than 20% of women had a UIC below 50 µg/L: 29% at 3MPP; 27% at 
6MPP; and 23% at 12MPP. Median (25th, 75th percentile) BMIC was below the 
suggested concentration at all three time points [69 (52, 119) µg/L], [59 (39, 108 µg/L], 
and [35 (26, 54) µg/L]. BMIC was moderately correlated with urinary iodine creatinine 
ratio at all three timepoints (r = 0.441, P < 0.001 at 3MPP; r = 0.552, P < 0.001 at 6MPP; 
r = 0.577, P = 0.001 at 12MPP; Appendix 17). No significant differences between 
maternal iodine status measures were found among exclusive breastfeeding (EBF), 
partial breastfeeding (PBF) or non-breastfeeding (NBF) women (Table 7.2). 
Table 7.2 Iodine status during the first postpartum year by mode of infant feeding 














































































3MPP: 3 months postpartum; 6MPP: 6 months postpartum; 12MPP: 12 months postpartum; BMIC: breastmilk iodine concentration; 
EBF: exclusive breastfeeding; PBF: partial breastfeeding; NBF: none-breastfeeding; UIC: urinary iodine concentration.  
 
Overall, among women who completed the study, 46% (33/71) took iodine-containing 
supplements at 3MPP, this reduced markedly to 11% (8/71) at 6MPP, and 6% (4/71) at 
12MPP. Defining women as supplement users or non-users at 3MPP, showed there was 
no significant main effect of time points on natural log UIC [F (2, 138) = 0.500, P = 
0.607, partial η2 = 0.007], with participants showing similar mean natural log UIC at 
3MPP (4.36), 6MPP (4.97), and 12MPP (4.49). However, there was significant 
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interaction between iodine supplement use and time points on the mean of natural 
log UIC [F (2,138) = 3.550, P = 0.031, partial η2 = 0.049] (Figure 7.1). At 3MPP, iodine-
containing supplement users showed a higher MUIC (111 µg/L) when compared to 
non-users (66 µg/L). The subgroup of women who were breastfeeding at the three 
timepoints showed a significant reduction in BMIC from 3MPP to 6MPP to 12MPP 
(Table 7.3).  However, there were no significant variations in UIC or maternal urinary 
iodine creatinine ratio over the three time points. 
 
Figure 7.1 UIC of women who completed the follow-ups at all three time points (n = 71). 





6MPP 12 MPP P-value* 
UIC µg/L 69 (46, 106) 80 (41, 133) 91 (58, 156) 
 
0.259 
Maternal urinary  
Iodine: creatinine ratio µg/g 132 (82, 243) 148 (98, 199) 127 (90, 173) 
 
0.420 
BMIC µg/L 71 (52, 102) 61 (36, 100) 35 (26, 54) 
 
0.001 
3MPP: 3 months postpartum; 6MPP: 6 months postpartum; 12MPP: 12 months postpartum; BMIC: breastmilk iodine concentration; 
UIC: urinary iodine concentration. 
* One-way ANOVA 
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7.4.3 Iodine status of infants aged three, six and twelve months 
In the current study, infant MUIC at the age of three, six and twelve months were all 
above 100 µg/L with fewer than 20% below 50 µg/L (Table 7.4), suggesting adequate 
iodine status. However, at six months, infants who were EBF had an MUIC (80 µg/L, 
n = 13) which was below the 100 µg/L cut-off  and significantly lower than infants who 
were mixed-fed with complementary food (147 µg/L, n = 29, P = 0.033). Exclusively 
breastfed infants at three months of age had a lower infant MUIC than those who were 
PBF, but this was not statistically significant (Table 7.4). Infant UIC was significantly, 
moderately correlated with BMIC at 3MPP, 6MPP and 12MPP (r = 0.598, P < 0.001; r = 
0.602, P < 0.001; r = 0.656, P = 0.011, respectively; Appendix 17). 

























UIC < 50 µg/L (n, %)  10, 15  5, 12  4, 12 








































EBF: exclusive breastfeeding; PBF: partial breastfeeding; NBF: none-breastfeeding; UIC: urinary iodine concentration.  
*Mann-Wihitney U test 
7.4.4 Iodine status of EBF women and their infants at 3MPP 
The MUIC for EBF women was 78 µg/L, below 100 µg/L, suggesting iodine deficiency 
(Table 7.2). Median BMIC was 68 µg/L also below the suggested 75 µg/L. Median 
estimated maternal iodine intake was 212 (138, 331) µg/day (Table 7.5), below the 
Recommended Dietary Intake (RDI) of 270 µg/day and 46% (33/72) had intakes below 
the Estimated Average Requirement (EAR) of 190 µg/day(35). Only 44% (32/72) of EBF 
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women took iodine-containing supplements (range 150-250 µg iodine/day). Women 
who used iodine-containing supplements showed significantly higher MUIC (105 vs 
66 µg/L, P = 0.027), urinary iodine creatinine ratio (173 vs 94 µg/L, P < 0.001) and BMIC 
(84 vs 61 µg/L, P < 0.001), when compared to those women who did not use iodine-
containing supplements. 
Table 7.5 Daily iodine excretions and intakes in mothers and their infants at 3MPP 
Median (p25, p75) Mothers (EBF)  
(n= 72) 
Infants (EBF)  
(n = 55) 
Estimated daily iodine excretion 
      Based on maternal UIC µg/d 116 (68, 225) - 
      Based on BMIC µg/d 53 (41, 84) - 
     Total µg/d 195 (127, 305) - 
     From urine %total 69 (53, 76) - 
     From breastmilk % total 31 (24, 47) - 
Estimated daily iodine intake Total µg/d 212 (138, 331)  
Estimated iodine intake, based on infant UIC µg/d  64 (35, 105) 
Estimated iodine intake, based on BMIC µg/d  53 (41, 84) 
BMIC: breastmilk iodine concentration. EBF: exclusive breastfeeding; UIC: urinary iodine concentration. 
Based upon a visual inspection of the scatter plot of the partitioning of maternal UIC 
and BMIC in total daily iodine excretion (Figure 7.2), it demonstrates when total daily 
iodine excretion below 300 µg, an increased partitioning of BMIC (the highest 
proportion of 60%) was observed, together with a reduced fractional iodine excretion 
in urine (the lowest proportion of 40%). When total daily iodine excretion was higher 





Figure 7.2 Fractional iodine excretion in urine and breastmilk in relation to total 
estimated daily iodine excretion (n=72, exclusive breastfeeding). 
7.5 Discussion 
7.5.1 Iodine sufficiency and deficiency during the first postpartum year 
The MINI study found women who used iodine-containing supplements at 3MPP had 
a significantly higher MUIC than non-users (111 vs 68 µg/L). A post-fortification study 
of Australian breastfeeding women (n = 60) at around three months after parturition 
showed a similar significant positive effect of taking iodine-containing supplements 
on maternal MUIC (206 vs 97 µg/L) (36). However, in the current study, there was no 
difference in MUIC at six and twelve months postpartum based on definition of 
supplement use at 3MPP. This is unexpected, although could be due to the low 
proportion of women using iodine-containing supplements in later lactation 11% 
(8/71) at 6MPP, and 6% (4/71) at 12 MPP. The low use is unsurprising and the lack of 
awareness of the need for iodine supplementation during lactation in this population 
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has been reported (37). The low use of iodine-containing supplements during later 
breastfeeding is especially concerning for women who do not consume iodine rich 
foods and those who become pregnant again. In Morocco, a randomised double-
blinded placebo-controlled trial (n = 241 mother-infant pairs) compared the 
effectiveness of using maternal supplementation, either with a single dose of 400 mg 
iodised oil or supplementing infants (aged ≤ 8 weeks) directly with a single dose of 150 
mg. This study found that maternal supplementation is more effective in ensuring 
adequate infant iodine status and maintaining BMIC levels until at least six months 
postpartum (38). Achieving adequate maternal iodine status throughout lactation, 
together during pre-conception or pregnant period is critical for infants’ growth (39) 
and contributes to optimal fetal neurodevelopment (40). 
Overall iodine deficiency was present in a group of women during the first postpartum 
year based on the WHO epidemiology criteria (1). Our results showed an 
improvement in maternal iodine status, when compared to the results reported in a 
pre-fortification study of postpartum women in the South Island of New Zealand in 
2001 (37 µg/L, 25 µg/L, 47 µg/L at three, six and twelve months postpartum) (7). This 
indicates that the government initiatives have improved iodine status of breastfeeding 
women but more needs to be implemented to strengthen these strategies.  
The trend for increase in MUIC across three time points in the MINI study was also 
found in a study of Sudanese breastfeeding women (n = 47) living in an area with 17.5% 
goitre rate, where MUIC increased from three (51 µg/L) to nine (63 µg/L) months 
postpartum (6). Similarly, a recent large Norwegian longitudinal study of postpartum 
women (n = 915) reported the lowest MUIC at six weeks postpartum (57 µg/L), which 
increased through six, twelve and eighteen months postpartum (70 µg/L, 79 µg/L, 87 
µg/L) (9). The Norwegian authors suggested the increase was possibly due to an 
assumed decrease of iodine excretion in breastmilk during the postpartum period. 
However, these studies on Norwegian and Sudanese women did not measure BMIC. 
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In the current study, among women who continued to breastfeed, iodine secreted into 
breastmilk significantly decreased from the highest concentration of 71 µg/L at three 
months, to 61 µg/L at six months, and with the lowest concentration of 35 µg/L at 12 
months postpartum. This pattern suggests reduced transport of iodine to breastmilk. 
Similar observations were made in a cohort of New Zealand iodine deficient lactating 
women without iodine supplementation during the first six months postpartum in 
2004-2005 decreasing from 43 µg/L in week one to 25 µg/L in week 24 (41). A reduction 
of BMIC from three months (60 µg/L) to nine months (26 µg/L) was also reported in 
Moroccan mothers who were supplemented with one oral dose (400 mg) of iodine 
after delivery (38). Research has reported a sharp decrease of iodine concentration 
from colostrum to mature milk, which could be due to the low volume of colostrum 
(42). The further reduction of BMIC from six to twelve months postpartum observed 
in the current study must be interpreted with caution due to the small number of 
samples at twelve months. However, for breastfed infants, breastmilk is still an 
important iodine source. Therefore, it is important for lactating women to achieve 
adequate iodine status. 
Adequate infant iodine status was observed at three time points of this current study, 
using the WHO epidemiological criteria (1). However, the calculated iodine intake 
from a UIC of 100 µg/L is 55 µg/day (based on approximately 0.5 L daily urine volume 
and 92% of dietary iodine excreted into urine) (33). This is much lower than the 
Institute of Medicine suggested adequate intake (AI) of 110 µg/day for infants up to 
age of six months (43). Infant MUIC between 180 and 225 µg/L (44) are necessary to 
achieve the WHO recommended iodine intake of 90 µg/day (1). Further, results from 
a recent dose-response crossover iodine balance study of euthyroid term Swiss infants 
with iodine sufficiency suggested 125 µg/L as a cut-off for infant MUIC (based on the 
estimated average requirement of 72 µg/day for infants aged two to five months)(33). 
Using this cut-off, the MUIC for infants aged three (115 µg/L) and six months (120 µg/L) 
in the current study would indicate iodine deficiency, which was consistent with the 
estimated suboptimal intake from BMIC. Further, infants aged six months who were 
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exclusively breastfed had an MUIC (80 µg/L) lower than 125 µg/L suggesting iodine 
insufficiency, which was significantly lower than those who were partially breastfed 
(147 µg/L). This shows the importance of adequate maternal iodine status for those 
infants who are exclusively breastfed at six months of age. 
In the present study, despite differing amounts of breastfeeding and ages of infants, 
BMIC was moderately correlated with infant UIC. This finding is supported by a 
systematic review of 14 eligible studies (42), which suggested BMIC was the primary 
indicator of iodine status in breastfed infant iodine status due to the positive 
association between BMIC and infant UIC. In the current study, median BMIC at three 
and six months postpartum (69 µg/L and 59 µg/L) suggested inadequate infant iodine 
intake. Further analysis from a South Australia post-fortification study in 2017 found 
that infants from mothers with lower BMIC (< 100µg/L) were less likely to achieve 
adequate iodine status (infant UIC > 100 µg/L), when compared to those with higher 
BMIC (≥ 100 µg/L) (45). The Australian authors suggest that achieving adequate iodine 
status for lactating women is essential to ensure sufficient iodine supply to their 
breastfed infants. 
7.5.2 Iodine status of exclusive breastfeeding women and their infants at 
three months postpartum 
This current MINI study found iodine deficiency was present in exclusive 
breastfeeding mothers at three months postpartum. The current MUIC remained 
similar to the value (74 µg/L in 2011) previously reported from the same region in New 
Zealand (24), although it showed a marked improvement from 34 µg/L in 2009 (prior 
to government interventions) (24). Women who reported consuming iodine-
containing supplements at 3MPP were more likely to achieve adequate iodine status 
when compared to those who did not use such supplements, this has been discussed 
in detail previously (37). Exclusively breastfed infants fully rely on maternal breastmilk 
intake for thyroid function. The MUIC of exclusively breastfed infants at three months 
of age was 111 µg/L, below the suggested cut-off of 125 µg/L (33) indicating iodine 
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deficiency. Lack of iodine intake may interrupt the motor and neurodevelopment of 
these infants at this crucial time (46). 
The present study suggests that among this cohort of exclusive breastfeeding women 
who were iodine deficient, increased partitioning of iodine secretion into breastmilk 
(the highest proportion of 60%) occurred when total daily iodine excretion was low 
(< 300 µg/day). This partitioning potentially provides a protective effect to ensure 
iodine supply to their breastfed infants. In comparison, a similar partitioning pattern 
(increased fraction of iodine into breastmilk but decreased iodine in urine when total 
daily iodine excretion < 300 µg/day) was observed from a large multi-centre study of 
lactating women (iodine sufficient based on median BMIC) in China (n = 386), 
Philippines (n = 371) and Croatia (n = 109) (32). This pattern may be due to an 
enhanced capacity of sodium-iodide symporter transportation by mammary glands 
during early lactation (47), which may ensure adequate iodine supply to exclusively 
breastfed newborn infants (32). However, in the MINI study, when total daily iodine 
excretion was higher than 300 µg, a constant partitioning of excretion was observed 
in urine (80%) and breastmilk (20%), which differed from the previous multi-centre 
study of EBF women from iodine deficient areas showing a continuous decreased 
excretion in breastmilk but a measurable increase in urine (32). This may be due to 
the smaller number of participants in the current study whose total iodine excretion 
was above 300 µg/day, thus the current results need to be interpreted with caution. 
7.5.3 Strengths and limitations 
This study is the first longitudinal cohort study in New Zealand to assess the iodine 
status simultaneously of both mothers and infants, subsequent to the introduction of 
mandatory fortification of bread with iodised salt (2009) and the provision of iodine-
containing supplements (150 µg/day) to breastfeeding mothers (2010). 
The study examined the iodine status of mother-infant pairs during the transitional 
period from exclusive, to partial, and in some cases, cessation of breastfeeding 
throughout the first postpartum year, which enhances the existing available 
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knowledge of iodine status throughout postpartum period. Maternal iodine status was 
measured in both urine and breastmilk to provide a thorough measure of each 
participant’s iodine status. The study also contributes to the limited knowledge on the 
fractional uptake of iodine from the mammary gland in response to variations in 
iodine intake while exclusive breastfeeding. Since the study sample size was small, the 
results need to be interpreted with caution. 
In order to determine iodine status throughout the postpartum period, participants 
were defined as iodine-containing supplement users or non-users at 3MPP, this could 
have diluted the effect, as many participants stopped using iodine supplements. Other 
limitations of this study also include that the self-selected participants were 
predominantly well-educated with a relatively high household income, thus the 
sample may not be representative of the overall New Zealand population. If these 
women were iodine deficient, iodine status of women who are less educated and of 
low income may be of even greater concern. In addition, a potentially high level of 
intra-individual variability in the iodine level of urine samples due to the variation in 
maternal hydration status and substantial variation in daily iodine intake, a single spot 
sample may not be indicative of usual iodine status. This may weaken or mask 
associations of interest. Urinary iodine creatinine ratios were used to reduce the 
variation due to maternal hydration. To determine habitual intake, using repeated 
measuring could have better predicted iodine status (48). Newborn TSH can be used 
as another indicator of young infants’ iodine status by following a standardized 
protocol (49). However, potential confounding factors including maternal iodine 
status, mode of delivery, sampling time, and maternal exposure to iodine-containing 
antiseptics may limit the use of newborn TSH measurement (49). 
7.6 Conclusions 
In conclusion, after two New Zealand government interventions in 2009 and 2010, this 
cohort of women throughout the first postpartum year was iodine deficient 
irrespective of the amount or duration of breastfeeding. Iodine status of their 
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breastfed infants aged three and six months may be inadequate. Achieving optimal 
maternal iodine status is essential in maintaining adequate iodine intake for 
breastfeed infants. Importantly, when exclusive breastfeeding mothers had a low 
iodine intake, an increased fractional iodine excretion into breastmilk was observed, 
this is possibly a protective mechanism for maintaining their breastfed infants’ iodine 
status over the mothers. Further studies to assess maternal and infants’ iodine status 
with their thyroid function, and infant neurodevelopment outcomes are needed, to 
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Chapter 8 Selenium intake and status of postpartum women and 
postnatal depression during the first year after childbirth in 
New Zealand – Mother and Infant Nutrition Investigation (MINI) 
Study 
 
Chapter 8, which focuses on selenium, is the last of four articles presenting research 
findings from the MINI study. A previous pilot study found suboptimal dietary selenium 
intake continued to be an issue for New Zealand breastfeeding women and their breastfed 
infants at three months postpartum (noted in Chapter 3). Although previous literature 
has suggested low dietary selenium intake is associated with negative mental health 
outcomes, there have been limited published studies which examine postpartum women’s 
selenium status in relation to the risk of postnatal depressive symptoms, particularly 
where continuous measurements were taken from birth to one year after (see Chapter 2). 
This article investigates the selenium intake and status of mothers and infants and aims 
to determine the relationship between maternal selenium status and the risk of postnatal 
depression during the 12 months postpartum. 
This article addresses hypothesis 4: Suboptimal selenium intake and status exist in New 
Zealand postpartum women; hypothesis 5: Selenium intakes of breastfed infants aged 
three and six months are suboptimal; and hypothesis 6: Low plasma selenium will 
increase the risk of postnatal depression at three, six and twelve months postpartum. 
 
This chapter has been published as: 
 Jin Y, Coad J, Pond R, Kim N, Brough L. Selenium intake and status of postpartum women 
and postnatal depression during the first year after childbirth in New Zealand – Mother 
and Infant Nutrition Investigation (MINI) Study. Journal of Trace Elements in Medicine 





Selenium (Se) plays an important role in selenoproteins as an antioxidant, and is 
involved in thyroid function, mental health and child development. Selenium is low in 
the local food supplies in New Zealand. Low selenium intake has been reported in 
women of childbearing age and postmenopausal women, however, there is little 
research relating to breastfeeding women and their infants. 
Objectives 
The study investigates maternal and infant selenium intake and status during the first 
year postpartum, and possible relationships to postnatal depression and anxiety. 
Methods 
The Mother and Infant Nutrition Investigation (MINI) study is an observational 
longitudinal cohort study. In total 87 breastfeeding mother-infant pairs were recruited 
and followed up at three, six and twelve months postpartum. Maternal selenium intake 
was estimated from a weighed four-day diet diary (4DDD). Selenium concentrations 
were measured in maternal spot urine, breastmilk and plasma, and infant spot urine 
samples. Postnatal depression was screened by the Edinburgh Postnatal Depression 
Scale (EPDS) questionnaire. 
Results 
Median maternal selenium intake was 62 (50,84) µg/day, with 56% below the Estimated 
Average Requirement (EAR) of 65 µg/day. At three, six, and twelve months postpartum, 
median (p25, p75) maternal urinary selenium creatinine ratios were 29.0 (22.4, 42.0), 
29.5 (23.1, 28.4), and 30.9 (24.3, 35.3) µg/g; median (p25, p75) infant urinary selenium 
concentrations (IUSC) were 8 (6,13), 11 (6, 15), and 24 (10, 40) µg/L; median (p25, p75) 
breastmilk selenium concentrations (BMSC) were 13 (11, 14), 11 (9, 11) and 12 (11, 13) µg/L; 
18%, 11% and 14% of women reported probable minor depression based on the EPDS 
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scores equal or above 10. Estimated median (p25, p75) infant selenium intake at three 
and six months were 9 (8,11) and 8 (7, 10) µg/day with 85% and 93% below the Adequate 
Intake of 12 µg/day. Median maternal plasma selenium was 105.8 µg/L at six months 
postpartum. Minor depression at three months postpartum was significantly different 
across tertiles of plasma selenium concentrations (P = 0.041), with the greatest at the 
medium tertile of 106 µg/L. 
Conclusions 
Suboptimal selenium intake was observed among breastfeeding mothers and their 
infants in the MINI study. Potentially, some women had insufficient selenium status. 
The relationship between selenium status and risk of postnatal depression and anxiety 
was inconclusive. Further research is required to explore effects on maternal thyroid 
function and infant neurodevelopment among women with inadequate selenium intake 




Selenium (Se) is essential in human health because selenoproteins play antioxidant and 
anti-inflammatory roles and contribute to optimal levels of thyroid hormones (1). 
Iodothyronine deiodinases are required for conversion of the inactive form of thyroid 
hormone (thyroxine, T4) to the active form (triiodothyronine, T3) (2). Selenium as a 
component of the selenocysteine-containing proteins, glutathione peroxidase (GPx), 
protects the thyroid from oxidative damage (3). Extremely low selenium intake has been 
associated with Keshan disease (4). Selenium is thought to play a key role in optimal 
brain functioning (5). Adequate dietary selenium intake has been found to improve 
mood among the general population, while low selenium intake is associated with low 
mood and an increased risk of de novo major depressive disorder in women (6, 7). This 
suggests that pregnant and postpartum women with low selenium intake may be more 
at risk of experiencing postnatal depression, which affects 13% of postpartum women 
globally (8). 
In New Zealand, low levels of selenium in the food supply, and low selenium intakes 
have been reported in women of childbearing age (9) and postmenopausal women (10). 
Low plasma selenium concentration among postpartum women and their infants 
residing in the South Island of New Zealand (1998-1999) suggested inadequate status 
(11). More recently, inadequate dietary selenium intake was reported in breastfeeding 
women three months after birth; however, selenium status from blood was not 
measured (12). There are no current data describing selenium status among 
breastfeeding women in New Zealand. Given changes in dietary habits, food product 
availability and agricultural practices, continual monitoring of both selenium intake 
and status in this vulnerable postpartum population is essential. This study aims to 
investigate maternal and infant selenium intake and status during the first year 
postpartum. Furthermore, the relationship between selenium status and postnatal 




8.3 Materials and Methods 
8.3.1 Study Population 
The Mother and Infant Nutrition Investigation (MINI) study is an observational 
longitudinal cohort study spanning the first year postpartum. Healthy breastfeeding 
women were recruited, in Palmerston North, New Zealand, from June 2016 to December 
2017. Women aged 16 years and older, who had given birth to a healthy term singleton 
infant aged less than three months were invited to join the study. Women were 
excluded: 1) if they developed significant health problems, such as metabolic disease or 
cancer; 2) if they had been diagnosed or treated at any time for thyroid disorders. 
The MINI study was approved by the Health and Disability Ethics Committee 
(15/NTA/172) in December 2015. The study was registered with the Australia and New 
Zealand Clinical Trials Registry (ACTRN12615001028594) in October 2015. Written 
consent was obtained from all participants. 
8.3.2 Questionnaires 
Sociodemographic information including age, ethnicity, educational attainment, 
household size and income was collected at the initial study visit. Potential changeable 
information including tobacco and alcohol use, breastfeeding patterns and general 
health was also sought at the second and third visits. 
The 10-item Edinburgh Postnatal Depression Scale (EPDS) was completed online by 
participating women at three, six and twelve months postpartum, to assess any 
symptoms of depression over the previous seven days. Questions of the EPDS include 
“Things have been getting on top of me,” “I feel so unhappy that I have had difficulty 
sleeping”, and “I have felt sad and miserable.” Women recorded severity of symptoms 
on a 4-point scale (13). A cut-off point of 10 or above was noted, which may indicate at 
least probable minor depression (14). A cut-off point of 13 or above was used to define 
high levels of depressive symptoms (13), which indicates probable major depression. 
Any woman whose EPDS score equalled 13 or above was advised to see her General 
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Practitioner (GP) for further evaluation and provided with an information sheet about 
postnatal depression services in New Zealand. Probable postnatal anxiety including 
generalised anxiety and panic disorder were evaluated by using EPDS-3A – a cluster of 
selected question items numbered 3, 4 and 5 from the original EPDS, as “I have been 
anxious or worried for no good reason”, “I have felt scared or panicky for no very good 
reason”, and “I have blamed myself unnecessarily when things went wrong”. A score of 
six or more on the EPDS-3A was used to indicate probable anxiety (15). The EPDS is a 
validated tool to screen for probable minor or major depression during the postpartum 
period (13), and the EPDS-3A cluster for probable anxiety (16). 
8.3.3 Dietary data collection 
Participants were asked to complete a weighed four-day diet diary (4DDD) within two 
weeks of the initial study visit. The four days were consecutive and included one 
weekend day. Each participant was requested to record food items, brands, amount 
consumed, and provide the nutritional information panel if possible. All food and 
beverage items consumed were weighed with an electronic kitchen scale (Digitech, 
QM-7288), or measured using household measurement cups and spoons, which were 
provided. All participants received both written and oral instructions as to how to 
complete the record, which included a written example for one day. Women were also 
asked to include any dietary supplements consumed. When eating or dining out, 
participants were asked to estimate the portion size of all food eaten. All dietary data 
were entered to Foodworks 9 Professional (Xyris software, Brisbane, Australia), 
analysed using data set from the New Zealand Foodfiles 2016 (17) to estimate nutrient 
intake. Dietary supplements used by participants were included in dietary data analysis. 
To ensure accuracy and completeness, a registered nutritionist (YJ) checked all dietary 
data and then transferred the data to IBM SPSS for statistical analysis. The estimated 
average requirement (EAR) cut-point method can be used to assess population nutrient 
intake providing nutrient requirements are normally distributed, such as selenium; the 
percentage below the EAR approximates the proportion that is at risk of dietary 
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inadequacy (18). Current intakes based on diet and urine data were compared to 
Australian and New Zealand recommendations; the EAR and Recommended Dietary 
Intake (RDI) for selenium for lactating women are 65 and 75 µg/day, respectively (19). 
8.3.4 Biological sample collection and analysis 
Spot urine samples from each woman and her infant were collected at each study visit, 
to assess selenium and creatinine excretion. Infants’ urine was collected using a 
paediatric urine bag (EMURIC, 100 mL), placed inside the diaper and checked every 10 
minutes. The collected urine was frozen and stored at -20°C for later analysis, without 
preservative. Women provided a breastmilk sample (approximately 30-50 mL) at each 
visit, using an electric Breast Pump (Unimom Allegro, Korea) if needed. All breastmilk 
samples were collected before 12 noon on the study day, and timing of breastmilk 
collection was not standardised, since no significant differences have been found in 
selenium concentrations between hind-milk and fore-milk (20). Samples were stored 
without preservative at – 20°C, prior to analysis. At the second study visit, non-fasting 
maternal venous blood samples (22 mL) were collected by a phlebotomist. Plasma 
samples were stored at -80°C for later analysis. 
Selenium concentrations of urine and breastmilk samples were determined by Hill 
Laboratories, Hamilton, New Zealand, using inductively coupled plasma mass 
spectrometry (ICP-MS) (21). Quality Control procedures included analysis of blanks, 
analytical repeats and spiked samples in order to ensure accuracy and precision. 
Calibration standards and checks were undertaken on every run with the limit of 
detection at 0.002 mg/kg.  Each batch (25 samples) of urine samples was analysed 
together with an external reference standard (Seronorm Trace Elements Urine, L-2, 
Norway) giving a mean ± SD selenium concentration of 75 (5) µg/L (published value 
and 95% confidence error: 71.7 ± 14.4 µg/L) with a coefficient of variance (CV) of 6.5% 
(n = 14). Each batch of breastmilk samples was analysed together with an external 
reference standard (Skimmed milk powder, Elements in organic matrix, European) 
giving a mean ± SD selenium concentration of 0.188 ± 0.009 mg/kg (published value 
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and 95% confidence error: 0.188 ± 0.014 mg/kg) with a coefficient of variance (CV) of 
4.9% (n = 6). Creatinine was measured using the Jaffe method Flexor E (Vital Scientific 
NV, 6956 AV Spankeren/Dieren, Rheden, Gelderland, The Netherlands) at Massey 
University Nutrition Laboratory. Plasma selenium was measured using ICP-MS at 
Canterbury Health Laboratories, New Zealand. 
8.3.5 Statistical analysis 
Data were analysed using IBM SPSS (Statistics Package for the Social Sciences, IBM, 
Armonk, NY, USA) version 20. Data were tested for normality using the Shapiro-Wilk’s 
test. Non-parametric data were expressed as median (25th, 75th percentile); and 
parametric data expressed as mean (± standard deviation; SD). Bivariate correlations 
were tested using the nonparametric Spearman’s rho correlation coefficient. Plasma 
selenium concentrations were categorised into tertiles, with one being the lowest and 
three being the highest. Independent sample Kruskal-Wallis tests were used to compare 
medians of EPDS and EPDS-3A scores across plasma selenium tertiles. Pearson chi-
square tests were used to compare prevalence of depression and anxiety across the 
tertiles of plasma selenium concentration. 
8.4 Results 
In total, 87 breastfeeding women were recruited at three months postpartum, and most 
were followed up at six months (n = 78) and twelve months (n = 71).  The mean age was 
32 years, and 83% were exclusively breastfeeding at three months after birth (Table 8.1). 
Most participants were Caucasian and had completed tertiary education. The majority 
had a vaginal delivery (78%) and for 44% this was their first child. Approximately a 
quarter (23/87) of the women reported being smokers, with all but one indicating they 





Table 8.1 Description of breastfeeding participants and their infants (n = 87). 
Maternal characteristics n % 
Maternal age, years (Mean ± SD) 31.5 ± 4.2  
Tertiary Education 67  77 
Ethnicity (Maori) 9  10 
Ethnicity (Caucasian) 66  76 
Ethnicity (Asian) 9  10 
Ethnicity (Other) 3  4 
Annual household income (above average household income) * 33  38 
Smokers 3 3 
Primiparity 38  44 
Caesarean delivery 19  22 
Gestational ages, weeks (mean ± SD) 39.4 ± 1.5  
Age of infants, days (mean ± SD)  86.5 ± 15.1  
Infants birth weight, kilograms (mean ± SD) 3.6 ± 0.6  
*Average annual household income based on Statistics New Zealand is 100,103 New Zealand dollars for the year ended June 2017 
 
Median maternal urinary selenium concentrations (MUSC) were 22, 22, and 26 µg/L at 
three, six, and twelve months postpartum, respectively (Table 8.2). Maternal urinary 
creatinine concentrations were used to correct spot urinary selenium concentrations 
expressed as µg/g. MUSCs were strongly correlated with urinary creatinine at three, six, 
and twelve months respectively (r = 0.868; r = 0.910; and r = 0.790, all Spearman’s P < 
0.001). Median infant urinary selenium concentration (IUSC) were 8, 11 and 24 µg/L at 
three, six and twelve months, respectively. IUSC at six months showed moderate 
correlations with the IUSC values measured at three months (r = 0.494, P = 0.003), and 
twelve months (r = 0.644, P = 0.002). 
Median maternal plasma selenium was 105.8 (95.6, 115.3) µg/L at six months; 23% (17/74) 
were below 95 µg/L which indicates saturation of GPx activity (22);  and 41% (30/74) of 
women met the criteria for maximum expression of selenoprotein P (> 110 µg/L), 
suggested by Hurst et al. (23). However, when compared to cut-offs suggested by 
Thomson (24), all the women in the current study showed adequate plasma selenium 
concentrations needed to achieve optimal activity of iodothyronine 5’ deiodinases (> 65 
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µg/L) and to maximize plasma GPx (> 80 µg/L). Supplement users had a significantly 
higher plasma selenium concentration (121.6 µg/L) than non-users (105.8 µg/L, P < 
0.001). Maternal plasma selenium was weakly but significantly correlated with 
breastmilk selenium concentrations (BMSC) at three months (r = 0.397, P < 0.001), and 
at six months (r = 0.373, P = 0.002), but not at twelve months (r = 0.112, P = 0.553); and 
with selenium: creatinine ratios at three months (r = 0.347, P = 0.004) and six months 
(r=0.452, P < 0.001), but not at twelve months (r = 0.110, P = 0.407). Assuming an intake 
of 750 mL breastmilk per day (25), median estimated infant intakes were 9 and 8 µg/day 
at three and six months. In total, 70% (49/72) would not have achieved an intake of 10 
µg/day based on the suggested adequate value extrapolated from adults (26) and 83% 
(60/72) did not achieve the Adequate Intake (AI) of 12 µg/day (27). BMSCs were 
associated with infant urinary selenium excretion at three and six months (r = 0.326, P 
= 0.007; r= 0.433, P = 0.005). 
Table 8.2 Selenium and creatinine in spot urine samples from women at 3, 6 and 12 
months after giving birth and urinary selenium from their infants. 
Median (p25, p75) 3 months 6 months 12 months 
Number of participants (n) 87 78 71 
Maternal Urinary Se concentration µg/L  22 (9, 34) 22 (8, 37) 26 (13,42) 
Maternal Urinary creatinine g/L  0.6 (0.3, 1.1) 0.8 (0.3, 1.2) 0.9 (0.4, 1.3) 
Maternal Urinary Se: Creatinine µg/g 29.0 (22.4, 42.0) 29.5 (23.1, 28.4) 30.9 (24.3, 35.3) 
Se in breastmilk µg/L 13 (11, 14) 11 (9, 11)a 12 (11, 13)b 
Infant Urinary Se concentration µg/L 8 (6, 13)c 11 (6, 15)d 24 (10, 40)e 
a
n = 72 and 
b
n = 33 for breastmilk samples 
c
n = 67 , 
d
n = 43 and 
e
n= 33 for infant urinary samples 
 
Only five out of 87 women were taking selenium-containing supplements ranging from 
25 to 65 µg/day. Median maternal selenium intake (including supplements) estimated 
from 4DDD was 62 (51, 85) µg/day, below the Recommended Dietary Intake (RDI) of 75 
µg/day and 56% had intakes below the EAR (Table 8.3). This suggests inadequate intake 
for over half of the population. Selenium intake was weakly but significantly correlated 
with urinary selenium: creatinine ratio (r = 0.324, P = 0.007). Using a proposed formula 
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to calculate selenium intake daily from blood plasma values (log Y = 1.623 log X +3.433; 
X = plasma Se, mg/L; Y = Se daily intake, µg/day) (28), estimated median selenium 
intake was 71 (60, 81) µg/day with 35% (26/74) below the EAR cut off. 
Table 8.3 Estimated maternal and infant selenium intakes 
Estimated Selenium Intake Median  











Mothers, w/o supplements, 
Based on 4 DDD 
(n = 77) 
58  
(50, 80) 
46 (60)   
Mothers, w/supplements, 
based on 4 DDD 
(n = 77) 
62  
(51, 85) 
43 (56) - - 
Mothers,  
based on plasma Se 
(n = 74) 
71  
(60, 81) 
26 (35) - - 
Infants, aged 3 months, 
based on breastmilk 
(n = 87) 
9  
(8, 11) 
- 59 (68) 58 (91) 
Infants, aged 6 months, 
Based on breastmilk 
(n = 72) 
8  
(7,10) 
- 55 (76) 65 (90) 
a
A daily intake of 10 µg of selenium is sufficient to meet nutritional requirement (25). 
b
The estimated daily selenium intake of infants up to six months old is 12 µg (26). 
 
Table 8.4 Maternal EPDS and EPDS-3A scores at 3, 6 and 12 months postpartum  
Postpartum EPDS score 
Median 
(p25, p75) 
EPDS-3A score  
Median 
(p25, p75) 
EPDS score  
equal to or 
above 10 
Probable minor 
depression a   
n (%) 
EPDS score  





EPDS-3A score  
equal to or 
above 6  
Probable 






















10 (14) 3 (4) 9 (13) 
a
 Suggested cut-off based on Matthey et al 2006 (14) and Leung et al 2013.(29). .  
b
 EPDS-3A – a cluster of selected question items numbered 3, 4 and 5 from the original EPDS, with a cut-off score six or more indicating 
probable anxiety (15). 
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At three months postpartum, 18% of women had an EPDS score equal to or greater than 
10, indicating probable minor depression (Table 8.4), and 9% had an equal or higher 
score than 13 suggesting probable major depression (14). At 12 MPP, of the 8 women 
with EPDS scores above 13 (i.e. with probable major depression) at 3MPP, 5 had 
withdrawn from the study and the remaining 3 continued to have scores above 13. EPDS 
scores at three months postpartum were moderately and significantly correlated to the 
EPDS scores at six months (r = 0.642, P < 0.001), and at twelve months (r = 0.392, P = 
0.001). Similarly, EPDS-3A scores at three months were significantly correlated to the 
EPDS-3A scores at six months (r = 0.558, P < 0.001), and at twelve months (r = 0.476, P 
< 0.001). 
Table 8.5 presents median EPDS scores at three, six and twelve months postpartum 
categorised by tertile of plasma selenium concentration. Only prevalence of major, 
minor depression and anxiety of women at three months postpartum is shown, owing 
to the small number of affected women at six and twelve months postpartum. The 
median of EPDS scores across three plasma groups were displayed, and no statistically 
significant differences were found using the Independent-Samples Kruskal-Wallis test. 
Prevalence of major depression and anxiety across plasma selenium tertiles was 
examined using Pearson Chi-Square test and no significant differences were found. 
However, minor depression at three months postpartum was significantly different 
across the tertiles of plasm selenium concentrations (P = 0.041). The highest prevalence 
of minor depression was observed among those women with mean plasma selenium at 




Table 8.5 Median EPDS scores at 3, 6 and 12 months postpartum and prevalence of 
depression and anxiety at 3 months postpartum categorised by plasma selenium tertiles. 
 Tertiles of plasma selenium concentration* 
 1 (n = 25) 2 (n = 24) 3 (n = 25)  
Selenium, µg/L, mean±SD 92.8±3.7 106±3.5 123.7±14.5  
Age, years 30.6±4.0 31.4±4.3 32.7±4.1  
    Kruskal-Wallis  
EPDS score at 3 months, median 4 5 4 0.437 
EPDS score at 6 months, median 3 7 4 0.247 
EPDS score at 12 months, median 3 5 4 0.374 
    Pearson Chi-Square 
Probable major depression 3 months 
(n= 5) 
2 2 1 0.795 
Probable minor depression 3 months 
(n =11) 
3 7 1 0.041* 
Probable anxiety 3 months (n=5) 2 3 0 0.209 
*1 is the lowest and 3 is the highest tertile. 
8.5 Discussion 
8.5.1 Sufficiency and deficiency 
Suboptimal levels of dietary selenium intake were observed in our study participants. 
Maternal estimated selenium intake from the 4DDD was higher than previously 
reported from breastfeeding women (51 µg/day) from Palmerston North in 2009 and 
2011 (12), and from Dunedin (South Island) between 2012 and 2013 (30). The increase 
could be due to different dietary methods used in these studies. Weighed food records 
are suggested to be the most precise dietary method in measuring usual nutrient intakes 
of individuals (31). A 4DDD used in the current study, does not rely on respondents’ 
memory; dietary information was recorded at the time of food preparation and 
consumption. However, 24-hour dietary recalls, used in the other studies, depend on 
subjects’ memories and are less reliable. Typically, lower selenium was reported in the 
South Island of New Zealand where bread is made from local wheat, compared to North 
Island where bread is manufactured from wheat imported from Australia which 
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contains higher levels of selenium (32). Further, an increase in selenium intake among 
females aged over 25 years from 2009 (56 µg/day) to 2016 (68 µg/day) was observed in 
the 2016 New Zealand Total Diet Survey compared to previous dietary surveys. This 
survey suggested that the increase in selenium intake was due to increased 
consumption of selenium rich food, such as chicken as there were no changes of 
selenium concentrations from key food contributors (33). 
Over 20% of current study participants potentially have selenium deficiency by not 
achieving the suggested 95 µg/L required to saturate GPx activity (21). Mean plasma 
selenium concentrations found in the current study results were much higher than 
those reported in postpartum women in South Island of New Zealand (72 µg/L), as 
locally grown wheat (low concentrations of selenium) was used in South Island women 
(11).  A recent Chinese study reported plasma selenium concentrations of women (42 
days after birth) who were living in selenium deficient (78 µg/L), sufficient (112 µg/L) 
and toxic (184 µg/L) areas (28). Results of our study of women 180 days after birth were 
similar to those found for women living in selenium sufficient areas, considering that 
the level of plasma selenium concentration was not affected by the stage of lactation 
(34). Based on the suggested plasma selenium cut-off value of Robinson et al. (22), 23% 
of women in the current study would have insufficient selenium status. It is understood 
that more selenium is required to saturate selenoprotein P than optimize GPx (35), 59% 
did not achieve the suggested plasma selenium concentration to fully express 
selenoprotein P (23), but all women achieved adequate functional selenium status for 
GPx activities and selenoproteins, in relation to Thomson’s suggested value. Overall, 
there remains no consensus on the established cut-off levels for plasma selenium at 
present, and therefore careful interpretation of such results is needed to assess the 
adequacy of selenium status. 
8.5.2 Relationship between dietary and plasma selenium 
In this MINI study, plasma selenium was not associated with dietary selenium intake. 
This finding is consistent with results from a study of Brazilian lactating women (36) 
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and a South Island New Zealand study (11), although in an earlier New Zealand study 
(37) significant correlations were found between dietary intakes and status in a mixed 
population group. Lack of an association between dietary and plasma selenium does 
not mean that dietary selenium is not the main factor determining selenium status. 
Rather, the result is likely to reflect reasonably rapid redistribution of recently absorbed 
selenium to various body tissues for which a range of biological half-lives exist (38). 
Another point to consider is that plasma selenium was more influenced by urinary 
excretion rather than dietary intake (39). During lactation, it has been suggested 3-6 
µg/day of absorbed dietary selenium is secreted into breastmilk, with the remainder 
contributing to maternal blood plasma concentrations and selenoproteins (40). The 
current study shows plasma selenium concentrations were associated with selenium 
concentrations in breastmilk. Coupled with the above finding this might suggest that 
plasma (and breastmilk) selenium may be more influenced by internal homoeostatic 
processes than by recent dietary intake. 
8.5.3 Selenium in breastmilk and urine 
In the present study, breastmilk selenium concentration was associated with maternal 
selenium intake and status. Selenium is generally found to be higher in colostrum (26 
µg/L), which then decreases to nadir levels in mature milk (1–3 months, 15 µg/L) (26). 
Median breastmilk selenium concentrations in the present study were similar to those 
reported in South Island of New Zealand in 1992 (13.4 µg/L) (41), and two recent North 
Island studies (11 and 14 µg/L, respectively) (12, 42). This indicates there was little change 
over the years, in contrast to the increase of dietary intake shown in the current study. 
Mean selenium in breastmilk from women at three months postpartum in the MINI 
study was 13 ± 2.8 µg/L, which was consistent with the values reported from Liangshan 
women in China, a traditionally selenium-deficient area (28). For exclusively breastfed 
infants, breastmilk is the only source of selenium; in the current study, estimated 
selenium intake of most infants did not achieve the suggested AI. This suggests that 
most infants in our study were at risk of selenium deficiency. 
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Urinary selenium excretion can be used as a proxy measure for selenium status, 
especially, after adjusting for creatinine (43). The urinary selenium: creatinine (µg/g) at 
three months postpartum was associated with dietary selenium intake, breastmilk, and 
plasma selenium concentrations. Using creatinine to adjust urinary selenium is a better 
indicator of status than urinary selenium excretion alone due to variations in hydration 
status. When compared to a previous study of breastfeeding women carried out in the 
same region (12), the current results were double on average (22 µg/L), which was also 
reflected in an increased dietary intake from this current study cohort. In the present 
study, infant urinary selenium concentrations demonstrated strong correlations with 
maternal breastmilk selenium concentrations at three and six months, when breastmilk 
is the major food source. In contrast, it was difficult to estimate dietary selenium intakes 
from their urinary excretion since there is no research on selenium concentrations in 
infant urine, although infant kidney glomerular filtration rates are reported to be low 
at birth but gradually reach the adult level at two years of age (44). 
8.5.4 Relationship to postnatal depression 
Results from the MINI study were not atypical, with 18% having probable minor 
depression at three months postpartum. An earlier study found 16% of Pacific women 
living in Auckland, New Zealand, had EPDS scores 13 or higher indicative of probable 
major depression (45). About 8% to 16% of new mothers in New Zealand are reported 
to suffer from postnatal depression, the most common and serious disorder for mothers 
in the first year after childbirth (46, 47). Approximately one quarter of affected women 
are still depressed when their infant reaches their first birthday. In addition, mothers 
are often reluctant to seek available help (48). Results from the MINI study showed that 
at twelve months postpartum, three of the seventy-one participants (4%) continued to 
be classified with probable major depression, and another five withdrew, possibly 
indicating that other social factors prevented them from continuing the study. Our 
results also showed a deceased prevalence of both major and minor depression at six 
months postpartum which remained similar at twelve months postpartum. However, 
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there was a similar prevalence of anxiety found at three and twelve months, with a 
decrease at six months postpartum. It has been evident that minor depressive 
symptoms during postpartum periods may increase the risk of recurrence of depression 
throughout the childbearing years (49). In addition to socioeconomic status (50) and 
dietary patterns (51), micronutrients, including selenium have been suggested to 
inversely affect mental health (6, 7, 52). 
In the MINI study, no significant association was observed between plasma selenium 
values and EPDS scores at three, six and twelve months postpartum. A possible reason 
may be that less than one third of participants showed low plasma selenium levels with 
the majority indicated to meet a saturation of GPx activity. A randomised clinical trial 
in Iran reported that a prenatal selenium supplementation at 100 µg daily may be 
effective in preventing early postnatal depression (eight weeks postpartum) (53). A 
previous study of young adults aged 17-25 years old found the lowest depressive 
symptoms prevalence occurred when serum selenium concentrations were between 82-
85 µg/L and if both below or above this value presented higher rates of depressive 
symptoms (based on the Centre for Epidemiological Studies-Depression Scale) (52). 
The U shape relationship indicted in the young adult study was not observed in the 
current study, which may be due to all plasma selenium being above 85 µg/L. We only 
found a significant higher prevalence of minor depression among women with medium 
levels of plasma selenium levels (106 µg/L). The possible effects of selenium on 
postpartum women’s mental health; and to a lesser degree, its mechanism, and possible 
effects on infant cognitive development, will necessitate further investigation. 
8.5.5 Strengths and limitations 
This study was an in-depth prospective study of selenium intake and status of women 
and their infants in the first year postpartum. The strength was to assess dietary intake, 
excretion and tissue selenium to provide an overall evaluation of selenium status in 
breastfeeding women and their infants. The chosen dietary method was the gold 
standard dietary assessment tool to examine selenium intake. A limitation was this 
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cohort consists of women who were mainly well educated and motivated in achieving 
optimum health, thus this study was not representative for New Zealand population. 
Further, the study did not measure functional selenium status, including serum or 
plasma selenoprotein P (23), plasma GPX3 and erythrocytes GPX1 (54), which are more 
reliable markers in identifying nutritional selenium deficiency and examining responses 
after supplementation trials (55, 56).  However, plasma selenium at tissue level and 
selenium excretion in urine can indicate the degree of insufficient intake (56). 
8.6 Conclusions 
In the present study selenium intake was suboptimal for some of the mothers and 
infants, despite some observed increases in intake in recent studies; and some women 
had potentially insufficient selenium status. Further research is required to investigate 
whether these suboptimal intakes negatively affect maternal thyroid function, the 
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Chapter 9 Discussion, Conclusions and Recommendations 
 
This chapter provides an overview of the major findings from both Study 1 – secondary 
data analysis of a previous Mother and Baby study, and Study 2 – Mother and Infant 
Nutrition Investigation (MINI). The overall aim of this PhD thesis and each research 
objective investigated in the two studies are considered closely, and summarised into 
five central aspects, including: 1) postpartum women’s thyroid function and its relation 
to iodine, selenium and iron; 2) maternal and infants’ iodine intake and status, and 
maternal use of iodine-containing supplements; 3) maternal and infants’ selenium 
intake and status, and postnatal depression; 4) iron status of postpartum women; 5) 
acknowledgement of the strengths and limitations of the studies. These results have 
contributed to current published literature, are likely to have implications for public 




9.1 Thyroid function, its relation to iodine, selenium, and iron  
Hypothesis 1: Suboptimal iodine, selenium or iron status will impede maternal thyroid 
function at six months postpartum. 
 
Abnormalities in thyroid function have been associated with anxiety, depression, 
cognitive deficit (1), and negative effects on reproductive health (2). Thyroid 
dysfunction during the first year after childbirth is defined as postpartum thyroiditis 
(PPT). The prevalence of PPT in a general population normally ranges from 1.1% to 
16.7% (3). Thyroid dysfunction is a significant health issue in New Zealand, with 
women suffering five times the prevalence of men (4, 5). However, few studies have 
investigated the prevalence of thyroid dysfunction in postpartum women in New 
Zealand. This has become of increased importance due to changes in dietary patterns, 
and the establishment of two government interventions to improve iodine status. 
In the MINI study, at six months after childbirth, 18% of women were experiencing 
thyroid dysfunction, including 3% with overt hypothyroidism and 15% with subclinical 
hyperthyroidism. The resulting overall prevalence was higher than that reported by a 
previous Australian study (n = 748) which identified 12% thyroid dysfunction among 
women at six months postpartum (6). This higher rate in our study could have 
occurred: 1) because women who participated had undiagnosed thyroid dysfunction 
during previous perinatal periods which may have increased their risk of thyroid 
dysfunction at this time; 2) because they could have a family history of thyroid 
dysfunction which may have encouraged their participation in this study; 3) because 
women who had autoimmune diseases that were previously unknown may have an 
increased risk of  developing PPT (3). Additionally, the risk of developing PPT may 
increase in women who presented positive thyroid peroxidase antibodies (TPOAb) 
during early pregnancy (7) or at childbirth (8). Our study also found positive TPOAb 
at six months postpartum was associated with abnormal TSH concentrations. After 
examining a cohort of Iranian women with subclinical and overt PPT, who were 
undergoing T4 therapy, Azizi reported that a trend of increasing numbers of women 
265 
 
with subclinical PPT developed permanent thyroid dysfunction than those with overt 
PPT, but such differences were not found to be statistically significant (9). However, 
Azizi suggested that identifying both subclinical and overt cases of PPT early can allow 
timely interventions. 
This MINI study has examined thyroid function in relation to iodine, selenium and 
iron status in postpartum women. The result has shown that selenium status 
measured as plasma selenium was the only significant predictor of the likelihood that 
women had abnormal thyroid stimulating hormone (TSH) concentrations. Women 
with a lower plasma selenium (< 95 µg/L) were more likely to experience thyroid 
dysfunction (41.2%), when compared to 10.5% of women with optimal plasma 
selenium to saturate glutathione peroxidases (GPx) activity. Numerous research 
studies have established the roles of selenium in thyroid function, including 
converting thyroxine (T4) to triiodothyronine (T3) via iodothyronine deiodinases; 
catalysing the reduction of hydrogen peroxide and protecting the thyroid gland from 
oxidative stress via GPx and selenoprotein P (10). Intervention studies have 
investigated selenium supplementation in the general population including pregnant 
women; selenium treatment may reduce TPOAb levels, improve thyroid echogenicity, 
and decrease the incidence of postpartum thyroid dysfunction, but researchers did 
not find significant effects of selenium on thyroid hormone synthesis (10, 11). However, 
this study finding raises questions as to who might benefit most from selenium 
supplementation, and what should be an effective dose and duration. 
In addition, iodine status determined by the urinary iodine concentration (UIC) and 
breastmilk iodine concentration (BMIC) did not predict thyroid dysfunction. One 
possible reason may be the high intra-individual variations in these measures, which 
predict status of populations rather than individuals. Alternative explanations may 
include that thyroid hormones remain in the normal range even in a mild-to-
moderate iodine deficient population (12). Further, the MINI study has found a high 
prevalence of subclinical hyperthyroidism (15%) in this cohort of iodine deficient 
postpartum women. This is consistent with the reports from Danish population 
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studies where the rate of hyperthyroidism was higher among those who were iodine 
deficient than those having adequate or excessive iodine intake (13, 14, 15). The MINI 
study found women using iodine-containing supplements (9/74) presented with 
normal TSH concentrations, while 20% (13/65) of women who did not use iodine-
containing supplements recorded abnormal TSH concentrations. This indicated a 
beneficial effect of iodine supplementation on optimal thyroid function in an iodine 
deficient population. However, the number of iodine-containing supplement users 
was too small to generate sufficient statistical power. 
Iron status in our study was not associated with thyroid hormone concentrations or 
thyroid volumes, which may be due to the predominantly adequate iron status of the 
women. However, a prospective study of iron deficient and anaemic (IDA) Turkish 
women of childbearing age (n = 66) found a significant reduction of thyroid volume 
after taking iron supplementation (16). This group of Turkish women were euthyroid 
and iodine deficient (MUIC, 83 µg/L). They were given equivalent to 100 mg elemental 
iron twice daily. Results showed that after a six-month treatment, their mean thyroid 
volume was significantly reduced from a baseline of 17 mL to 13 mL. Consequently, the 
authors suggested that iron status played a substantial role in the thyroid volume, 
possibly due to increased blood flow to thyroid gland, resulting in its subsequent 
enlargement occurring under iron deficiency anaemia (16). We may have found an 
association if more participants had ID or IDA.  
Data analysis from the MINI study confirms that hypothesis 1 was partly accepted, as 
selenium status assessed by plasma selenium was the only significant predictor of 
thyroid dysfunction among this cohort of women who were iodine deficient and who 
mostly achieved adequate iron status.  
9.2 Maternal and infants’ intake and status of iodine over the first 
postpartum year  
Hypothesis 2: Breastfeeding women who used iodine-containing supplements will 
achieve better iodine status for themselves and their breastfed infants. 
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Hypothesis 3: Postpartum women and their infants will remain iodine deficient, despite 
two New Zealand government initiatives to improve iodine status. 
 
To combat re-emerged iodine deficiency, mandatory fortification of bread (all 
commercial bread other than organic and unleavened) with iodised salt (25-65 mg 
iodine/kg salt) was implemented in New Zealand in 2009. Post-fortification studies 
showed an increase in the iodine status of adults [median UIC (MUIC) from 53 µg/L 
to 103 µg/L], and women of childbearing age (MUIC from 48 µg/L to 104 µg/L) (17), as 
well as children (MUIC from 68 µg/L to 113 µg/L), which is indicative of iodine 
adequacy (18). However, such fortification may not sufficiently meet the increased 
needs for pregnant and breastfeeding women (19). Thus, in 2010, using a 150 µg/day 
iodine supplement was recommended for all pregnant and breastfeeding women in 
New Zealand. Few studies in New Zealand have investigated the iodine status of 
pregnant and lactating women. 
The MINI study found iodine deficiency was present in the sample of New Zealand 
breastfeeding women at three months postpartum, despite the establishment of the 
two government initiatives. The maternal MUIC was 82 µg/L, which showed an 
improvement from 74 µg/L reported in a pilot study (n = 36) a year after the 
government initiatives (20). Furthermore, median BMIC was 69 µg/L in the MINI 
study, below the suggested index of 75 µg/L for adequacy (21). This remained similar 
to the mean BMIC of 63 µg/L reported in a New Zealand pilot study in 2011 (20). 
Both Denmark and Australia have implemented mandatory fortification of bread with 
iodised salt since 2000 (22) and 2009 (5), respectively. In addition, mandatory iodine 
fortification in household salt takes place in Denmark (23), however, in Australia and 
New Zealand, iodised fortification in household salt remains voluntary. Both Australia 
(24) and New Zealand (25) recommend iodine supplementation for all pregnant and 
breastfeeding women. In Denmark, currently, there remains no official 
recommendation of iodine supplementation for pregnant and lactating women. 
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A comparison study between pre- and post-fortification in Demark reported that 
breastfeeding women were still iodine deficient, following the establishment of 
mandatory iodised salt fortification, although an increment was observed from 50 
µg/L to 72 µg/L in MUIC (23). A small sample of pre- (n = 32) and post-fortification (n 
= 36) in New Zealand reported that iodine status of breastfeeding women was 
improved (34 to 74 µg/L), but still deficient (20). A recent cross-sectional study in 
South Australia compared the iodine status of breastfeeding women pre- and post- 
fortification, the results of which showed an increase in BMIC from 105 to 137 µg/L, 
confirming iodine adequacy (26). 
In the MINI study, women who took iodine-containing supplements achieved better 
iodine status than non-users. Women who used iodine-containing supplements 
obtained higher MUIC (111 vs 68 µg/L, P = 0.023) and median BMIC (84 vs 62 µg/L, P 
< 0.001) compared with non-users. This trend is consistent with a small sample post-
fortification study of 60 breastfeeding Australian women, recording a higher MUIC of 
206 µg/L in iodine supplement users than non-users (97 µg/L) (27). Similarly, another 
large sample post-fortification study of breastfeeding women in South Australia (n = 
653) reported a significantly higher BMIC of 195 µg/L in iodine supplement users 
compared to non-users (137 µg/L) (26). 
A post-fortification study of breastfeeding Danish women (n = 209) reported a higher 
median BMIC (112 vs 72 µg/L) and MUIC (83 vs 65 µg/L) of iodine supplement users 
than non-users (28). Despite no official recommendation of iodine supplementation 
in Demark, half of the postpartum women studied took supplements, and Danish 
researchers have suggested iodine supplementation for breastfeeding women in 
Denmark is essential (28). In the MINI study, despite of a government 
recommendation of using iodine supplementation during lactation, only 46% used 
iodine-containing supplements. This rate is lower than the rate (90%) reported in the 
South Australian post-fortification study (26), and slightly lower than the 50% 
reported in the Danish study. High rates of iodine-containing supplement use may 
have contributed to the achievement of adequate iodine status of breastfeeding 
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women and their infants in South Australia (29). Our findings together with other 
research showing  an improvement in iodine status of breastfeeding women who took 
iodine containing supplements supports the need for greater uptake of iodine 
supplements by breastfeeding women in New Zealand.  
In addition, infants of iodine-containing supplement users achieved a higher MUIC 
compared to those from non-users (150 vs 86 µg/L, P = 0.036). This result is 
comparable to the improved iodine status of Moroccan infants after their mothers 
were provided with a one-off supplementation of 400 mg iodine in early lactation (30). 
Therefore, urinary iodine results suggest that maternal iodine supplementation may 
benefit both breastfeeding mothers and infants. 
In the MINI study, supplementation advice from health professionals was 
communicated to pregnant women (86% used iodine-containing supplements), 
however, such practices reduced to 46% during lactation. A recent online survey of 
New Zealand women during their pregnancy phase (n = 442) and during the 0-6 
months postpartum period (n = 284) reported 95% and 63% (respectively) using 
iodine-containing supplements (31). These percentages are higher than was seen in 
our study, and higher than those reported previously (52% in 2017 for postpartum 
women) (32). However, the dosage, duration and frequency of iodine supplement use 
was not reported in the online survey, thus, it is difficult to know the adherence of 
iodine recommendations and whether iodine supplement use is sufficient (31). In the 
current study, the main predictor for using an iodine-containing supplement was 
iodine knowledge; however, 66% of women had nil or low iodine knowledge, 
including the importance of iodine in heath and good dietary sources of iodine; and 
79% and 54% were unaware of the 1st and 2nd government initiatives. One of the main 
reasons given by women for not using iodine supplements during this time was that 
very little advice concerning iodine supplementation during lactation was given by 
health professionals. A 2014 Australian study investigating antenatal care reported 
that a majority of Australian General Practitioners questioned did not openly 
recommend iodine supplement to their patients (33). Furthermore, a more recent 
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Australian nation-wide survey of health professionals (including general practitioners, 
obstetricians, gynaecologists, midwives, and dietitians, n = 396) reported a lack of 
awareness of the appropriate dose and duration of iodine supplementation that is 
recommended for pregnant and breastfeeding women (34). Although such data in 
New Zealand are at present unavailable, this Australian nation-wide survey 
highlighted a need for iodine specific nutritional education initiatives to be brought 
to the attention of all primary health care providers (34). 
To the best of our knowledge, only five studies have investigated iodine status at 
different time points from early lactation to the end of the first postpartum year, in 
Sudan (35), Switzerland (36), Norway (37), Sweden (38), and New Zealand (39) (Table 
9.1). The New Zealand study was carried out over twenty years ago with a small sample 
of 35 breastfeeding women, the MUIC (24 hours urine samples) recorded as 37, 25, and 
47 µg/L at three, six and twelve months postpartum, indicating iodine deficiency (39). 
In the MINI study, maternal MUIC of 82, 85, and 95 µg/L at three, six and twelve 
months postpartum, respectively were below the WHO cut-off of 100 µg/L, suggesting 
iodine deficiency. A trend for an increase in MUIC across three time points in the 
MINI study was also found in a study of Sudanese breastfeeding women (n = 47) living 
in an area with 17.5% goitre rate, where MUIC increased from three (51 µg/L) to nine 
(63 µg/L) months postpartum (35). Similarly, a recent Norwegian longitudinal study 
of postpartum women (n = 915) reported the lowest MUIC at six weeks postpartum 
(57 µg/L), which increased through six, twelve and eighteen months postpartum (70 
µg/L, 79 µg/L, 87 µg/L) (37). The Norwegian authors suggested the increase was 
possibly due to a decrease of iodine excretion in breastmilk during the postpartum 
period. Both decreased use of iodine-containing supplements and cessation of  
breastfeeding in the MINI study contributed to the increase of maternal UIC from 
3MPP to 12 MPP. However, these studies on Norwegian and Sudanese women did not 
examine the breastmilk iodine concentrations. 
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Table 9.1 Comparison of iodine status between four longitudinal studies and the MINI study. 
 
Country 
Iodine fortification at 






















Voluntary iodised salt 
(25-65 mg iodine/kg 
salt) 35 
3 months 37 




et al. 2001 
(39) 
6 months 25 
12 months 47 
Sudan 
Voluntary iodised salt 
(15 mg/kg), 14% 
household uses (40) 47 







et al. 2000  
(35) 
6 months 30 27 
9 months 63 24 
Switzerland 
Voluntary Iodised salt 
(20mg/kg), 90% 












et al. 2010 
(36) 12 months 42 103 
Norway 
Voluntary iodised salt 
(5 mg/kg) (42) 915 









et al. 2020 
(37) 
6 months 70 
12 months 79 
18 months 87 
Sweden 
Voluntary iodised salt 
(50µg/g salt) (43) 84 
0.5 month  
90 
19  11.8 (non 
EBF) vs 




et al. 2020 
(38) 
4 months 78 13 
12 months 107 11 
New Zealand 
Mandatory iodised 
salt in bread (25-65 
mg iodine/kg salt) and 
recommendation of 




82 69 40 n/a 115 
2017-
2018 
Jin et al. 
2020 
6 months 85 59 11 11.4 120 
12 months 95 35 6 n/a 118 
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In the MINI study, a continuous decrease of BMIC was detected as 69, 59, and 35 µg/L 
at three, six and twelve months postpartum. This pattern suggests reduced transport 
of iodine to breastmilk. A similar reduction was reported in the observational 
Switzerland study of women from six (51 µg/L) to twelve (42 µg/L) months postpartum 
(36). Past research reported a sharp decrease of iodine concentration from colostrum 
to mature milk, which could be due to the differences in volume levels (44). A further 
reduction was observed during the six to twelve months postpartum period in the 
MINI study, which was possibly due to infants starting complementary food, and 
therefore becoming less reliant on iodine supply in breastmilk. However, for infants 
(exclusively or partially breastfed), breastmilk remains an important source of iodine. 
A wide range of BMIC was observed in women in iodine-sufficient countries from 50 
µg/L in Finland to 270 µg/L in the United States, however, there was no consensus to 
adopt an adequate BMIC cut-off (45). In a systematic review published in 2009, Azizi 
reviewed BMIC from iodine-sufficient and -deficient countries and suggested a value 
above 75 µg/L as an index for adequate infant iodine intake (21). Based on the 
suggested average breastmilk consumption of 0.78 L (during the first six months of 
age) (45), estimated iodine intakes for infants aged three and six months in the MINI 
study was 54 and 46 µg/day, respectively. These are below the suggested Adequate 
Intake (90 µg/day) by the Australian New Zealand Nutrient Reference Value (46), 
thus, breastfed infants aged three and six months recorded insufficient iodine intake. 
In addition to indirectly estimating infant iodine intake from breastmilk, UIC in spot 
urine was used to evaluate infant’s iodine status in the MINI study. The WHO suggests 
a median  MUIC of at least 100 µg/L for population adequacy in infants (47), based on 
an estimated iodine intake is 55 µg/day (using approximately 0.5 L daily urine volume 
and 92% of dietary iodine excreted into urine) (48). This is much lower than the 
Institute of Medicine suggested adequate intake (AI) of 110 µg/day for infants up to 
age of six months (49). Furthermore, results from a 2016 dose-response crossover 
iodine balance study of euthyroid Swiss infants aged two to five months, suggested 125 
µg/L as a MUIC cut-off for population sufficiency (based on the estimated average 
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requirement of 72 µg/day for infants aged two to five months) (48). Using this cut-off, 
the MUIC for infants aged three (115µg/L) and six months (120µg/L) in the current 
study would suggest iodine deficiency, which was consistent with the estimated 
suboptimal intake from BMIC. Compared to adults, there is less variation in infant 
hydration status. Despite this, to assess individual status requires multiple samples 
and the number needed is similar for infants and adults (50, 51). Further investigation 
of health outcomes related to such measures may provide additional useful evidence 
to confirm an optimal cut-off for infant MUIC. Future studies need to explore the 
iodine status of young infants in relation to their neurodevelopment, as iodine 
deficiency is the most preventable cause for brain damage in early childhood (52, 53). 
Infant receiving complementary food  may be at an increased risk of iodine deficiency 
owing to their high requirement of iodine per body weight and the recommendation 
of not given infants neither iodised nor non-iodised salt up to one-year   (54). WHO 
recommends infants aged six months should receive complementary food in addition 
to breastmilk (55). In the present study, a significantly lower MUIC was found in 
infants aged six months who were exclusively breastfed, compared to infants who were 
mixed fed (80 vs 147 µg/L). Consumption of any complementary food or/and infant 
formula may contribute to such differences. Prior to the mandatory fortification of 
bread with iodised salt, the 2009 New Zealand Total Diet Survey (NZTDS) reported 
the mean iodine intake of infants aged 6-12 months was 66 µg/day which was mainly 
contributed by infant and follow on formula (56); after the fortification this was 
increased to 83 µg/day in the 2016 NZTDS , (57). This is possibly due to changes of 
iodine concentration in complementary foods. The 2016 NZTDS reported infants 
gained just under 70% of their iodine intake from infant formula and commercial 
infant foods, the balance was from other sources of dairy, grains, CEFM (chicken, eggs, 
fish, meat), and suggested that iodine intake of infants aged six to twelve months were 
less affected by the mandatory fortification of bread with iodine when compared to 
other populations, because infants have  less consumption of grain-based foods (57). 
In addition, the NZTDS only includes infants on formula and not those who are 
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breastfeeding, there is limited  data on iodine intake from complementary food 
sources in New Zealand. The current study results suggest the importance of iodine 
concentrations in breastmilk to enable adequate iodine intake for those who are not 
yet adding complementary foods. Recommended iodine supplementation of 150 µg/L 
for breastfeeding women in New Zealand may improve BMIC. 
Data analysis from the MINI study broadly accepts hypotheses 2. However, hypothesis 
3 is accepted in part since those women who used iodine-containing supplements and 
their breastfed infants both achieved adequate iodine status. 
9.3 Maternal intake and status of selenium, and postnatal depression 
Hypothesis 4: Suboptimal selenium intake and insufficient selenium status exist 
among New Zealand postpartum women. 
Hypothesis 5:  Selenium intakes of breastfed infants aged three and six months are 
suboptimal. 
Hypothesis 6: Lower plasma selenium will increase the risk of postnatal depression at 
three, six and twelve months postpartum. 
 
Numerous studies investigated selenium intake in New Zealand during the decade of 
1980-1990. However, a few studies have monitored selenium intake in recent years in 
children (58), women of childbearing age (59), and older adults (60, 61). Only two 
recent studies in 2004 (62) and 2012/2013 (63) from the South Island of New Zealand 
have explored the selenium intake and status of postpartum women and their infants. 
A secondary data analysis of the Mother and Baby study (2009/2011) found lactating 
women at three months postpartum had inadequate selenium intake [51 (36, 80) 
µg/day] when compared to the EAR (65 µg/day). In the 2017/2018 MINI study, a higher 
selenium intake of breastfeeding women was observed [62 (51, 85) µg/day], indicating 
a possible improvement in selenium intake in New Zealand women over time. The 
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2009/2011 dietary data were collected via repeated 24-hour dietary recalls, while data 
from the MINI study were collected from the weighed four-day diet diaries which are 
the gold standard method for estimating dietary intake. 
Using a weighed three-day diet diary, the 2016 study of postpartum women (n = 53) 
living in the South Island of New Zealand reported mean selenium intake was 47 
µg/day, which was much lower than that as reported in our studies (63). The 
differences may be due to the different methodologies. The importation of Australian 
wheat (containing ten times higher selenium content than New Zealand wheat) (64) 
has dramatically improved dietary selenium intake in the North Island of New 
Zealand, with less effect being observed in the South Island of New Zealand. From the 
results of the 2016 Total Diet Survey, bread from the North Island (0.1 mg selenium 
per kg bread) contains higher selenium than those from the South Island (< 0.005 mg 
selenium per kg bread) (57). Australian imported wheat is mainly used for making 
bread in the North Island, while locally produced wheat is mostly used for bread-
making in the South Island (57). The most recent New Zealand Total Diet Survey 
(2016) reported an increased selenium intake among females aged over 25 years from 
2009 (56 µg/day) to 2016 (68 µg/day) (57). This survey sampled 132 foods (the most 
consumed foods in New Zealand), and eight different samples of each food item were 
analysed. Food consumption data were based on 14 day simulated typical diets for 
different age-gender cohorts. This survey suggested increased consumption of 
selenium rich foods may contribute to the improvement of selenium intake since 
selenium concentrations of the key food contributors had remained unchanged (57). 
At three months postpartum, median urinary selenium concentration (MUSC) of 
lactating women in the MINI study [22 (9, 34) µg/L] was almost double from that 
recorded in the 2009/2011 Mother and Baby study [12 (8, 20) µg/L], and this may be 
due to an increased dietary selenium intake from 51 to  62 µg/day, and the sample size 
of the Mother and Baby study was much smaller. Further, in the MINI study, selenium 
concentrations were measured in spot urine samples, while 24-hour urine specimens 
had been used in the previous study conducted across 2009 and 2011. However, as 
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shown in Table 9.2, breastmilk selenium concentration (BMSC) in the MINI study [13 
(11, 14) µg/L] was slightly higher than 11 (10, 13) µg/L in the 2009/2011 study. It was also 
slightly higher than 11 µg/L in another 2012/2013 study conducted in the South Island 
of New Zealand (63). BMSC remained like those concentrations reported in the 1992 
study from the South Island of New Zealand (13 µg/L) (65), and a more recent study 
from the North Island of New Zealand (14 µg/L) (66). In contrast to the increase of 
dietary intake shown in the MINI study, these comparative results indicate little 
change of BMSC over the period stated above. It is arguable that, relatively constant 
selenium secretions in breastmilk (11 to 14 µg/L) could be due to adjustments in the 
supply of adequate selenium to breastfed infants. Thus, extra selenium from increased 
dietary intakes would be excreted into urine. BMSC are assumed to reflect maternal 
dietary intake, however whether mammary tissue sequesters selenium to provide for 
the infant is unclear, the lowest of 2.6 µg/L being recorded in an area of endemic 
Keshan disease in China (with 7.6 µg/L reported in New Zealand in 1983) increasing 
to the highest at 283 µg/L in an area of endemic human selenosis in China (67). The 
BMSC at three months postpartum in the MINI study was similar to the concentration 
from Liangshan women in China in 2016 (12 µg/L), living in a traditionally selenium-
deficient area (68). These BMSCs below the international reference range of 18.5 µg/L 
which provide adequate selenium intake for infants aged 0-6 months (13.9 µg/day) 
(69). To conclude, selenium intakes of breastfeeding women at three months 
postpartum were suboptimal in the 2009/2011 study and the 2017/2018 MINI study. 








Kendall (2015)  
(63) 
Dolmore et al 
(1992) (65) 













Data collection (year) 2009/2011 2017/2018 2012/2013 n/a n/a 
Participants (n) 68 87 53 70 78 
Timing (postpartum)  4 months 3 months 8 weeks up to 12 months 6-8 weeks 
MUSC, µg/L (median/mean) 12 22 n/a n/a n/a 




The MINI study explored both the MUSC and the BMSC of women at three, six and 
twelve months postpartum. Their maternal MUSC at three months postpartum (22 
µg/L) remained the same at six months postpartum but increased to 26 µg/L at 12 
months postpartum (P = 0.016). This significant increase could be due to less selenium 
being excreted in breastmilk to meet infants’ needs. Their BMSCs showed a slight 
variation from 13 µg/L at three months postpartum to 11 and 12 at six and twelve 
months postpartum, respectively. Reduction from three to six months postpartum 
was statistically significant (P = 0.003). Based on two review articles published in 1989 
and 2002 (67, 72), selenium is generally found to be higher in colostrum (26 ug/L), 
which then decreases to nadir levels in mature milk (1-3 months, 15 ug/L). Hence, this 
decrease of selenium concentrations may be both due to very low volume and high 
content of proteins in breastmilk during the early lactation period (72). 
In the MINI study, maternal selenium status was measured in blood plasma, the most 
common biomarker for selenium status in the published literature (73). It allows an 
ease of comparison of selenium status with other countries. In a systematic review of 
18 supplementation studies by Ashton et al. (2009) (73), plasma selenium significantly 
increased after selenium supplementation, suggesting it is useful in assessing 
selenium depletion. All women in the MINI study demonstrated adequate plasma 
selenium to achieve optimal activity of iodothyronine 5’ deiodinases (> 65 ug/L) (74), 
but 23% had  inadequate selenium status with plasma selenium below the 95 µg/L 
required for the saturation of GPx activity (75). Further, 59% of women did not achieve 
110 µg/L which is needed to achieve full expression of selenoprotein P (76). Median 
plasma selenium of lactating women in the MINI study (106 µg/L) was higher than 72 
µg/L reported by McLachlan et al. (2004) in the South Island of New Zealand (62), but 
remained lower than North American women at six months postpartum (138 µg/L) 
who lived in a selenium sufficient area (77). 
The current study is not able to evaluate the use of selenium supplementation due to 
the small number of women who took selenium-containing supplements (5/87). 
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Selenium supplementation studies are inconclusive as to the degree of health benefits. 
Also, supplementation requires caution because of the “U” shaped relationship 
between selenium status and health outcomes, for example, selenium deficiency may  
increase the risks of having thyroid autoimmune disease, viral infection, declined 
cognitive functions, and prostate cancer, while  excessive selenium may increase skin 
cancer, prostate cancer, and type 2 diabetes risks. (78, 79). Hence, further 
investigation is required to determine who will benefit  from selenium 
supplementations, to assess what a safe dose of supplementation might be (possible 
randomised placebo-controlled trials), and to identify what long-term effects may 
exist after the cessation of using supplements (longitudinal or retrospective studies). 
Hypothesis 5 states selenium intakes of breastfed infants aged three and six months 
are suboptimal. The current AI for infants aged 0-6 months (12 µg/day) was calculated 
from the average intake of 0.78 L breastmilk/day and BMIC of 15 µg/L [New Zealand 
study in 1992 (65) and Australian studies in 2000 (80)]. The estimated median infant 
selenium intake from the 2009/2011 cohort and the MINI study were identical at 9 
µg/day, which is below the recommended AI of 12 µg/day (AI) (46). The results also 
showed that 70% (45/64) in the 2009/2011 study and 70% (49/72) in the MINI study 
did not achieve an intake of 10 µg/day based on the suggested adequate value 
extrapolated from adults (67); thus, breastfed infants aged around three months were 
at risk of selenium deficiency. The estimated intake of infants aged six months in the 
MINI study was 8 (7, 10) µg/day, and 90% did not achieve AI, which suggests 
suboptimal selenium intake in this cohort. The current estimated selenium intake 
from breastmilk presents some difficulties due to the complexity of accurately 
measuring daily breastmilk consumption for infants. When infants start receiving 
complementary foods, it may become even more difficult to estimate their dietary 
intakes due to the variety of complementary foods and diverse of feeding practices. 
The MINI study has explored infant urinary selenium concentrations in spot urine 
samples. Infant MUSC was 8 (6, 13) µg/L at three months, 11 (6, 15) at six months, and 
24 (10, 40) at twelve months (P = 0.004). The significant increment from six to twelve 
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months may due to increased complementary food intake containing a more varied 
dietary selection of organic and inorganic selenium. Urinary selenium excretion 
directly reflects recent dietary intake, in adults, a 50-60% excretion rate is used to 
estimate selenium intake (81). There is limited research of young infants on their 
excretion rates of selenium in urine, therefore, it is difficult to estimate their selenium 
intake. Currently, there is no available cut-off for infant urinary selenium 
concentration to enable identification of selenium depletion in groups. It may be 
useful to investigate selenium excretion in urine from infants living in selenium-
sufficient countries to establish an optimal value for future research purposes. 
Infant selenium status can be measured using serum/plasma, or erythrocyte GPx 
activity in blood samples (80). However, it may be difficult to obtain parents’ consents 
to collect blood samples from their healthy infants. One of less invasive methods is to 
analyse selenium concentrations in the nail clippings of infants. Measuring selenium 
in nail clippings has been used in evaluating the relation to lung and prostate cancer 
in adults (81), and in assessing the preeclampsia risk for pregnant women (82). The 
main advantage of the method is to measure selenium intake over a long exposure 
time. This measurement may provide opportunity to explore selenium exposure in 
utero since nails grow at a slow rate and can be collected from participants over time. 
However, it is worth noting that one mm of nail samples can reflect approximately 
one-month accumulation of nutrient status (81), and there is also a need to 
acknowledge the varied nail growth rates which are affected by age, gender, metabolic 
rate, and health conditions. 
Prevalence of postnatal depression in the MINI study was typical, when compared to 
the results from a large longitudinal study - Growing Up in New Zealand - suggesting 
that 5% of women were experiencing depression symptoms at nine months 
postpartum (83). In the MINI study, the relation between selenium and postnatal 
depression was explored, but results remained inconclusive. No significant association 
was observed between plasma selenium and the Edinburgh Postnatal Depression 
Scale (EPDS) scores taken at three, six and twelve months postpartum. This may be 
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due to most women having plasma selenium higher than the 95 µg/L required for 
maximum GPx activity. In the event, our study found the highest prevalence of minor 
depression at three months postpartum and was only observed in women with a mean 
plasma selenium at 106 µg/L (the middle tertile), but not observed in other tertiles 
which may due to a small sample size. Another New Zealand study of young adults 
aged 17-25 years found a “U” relationship between serum selenium and the prevalence 
of depression, and the lowest depressive symptom prevalence occurred when serum 
selenium ranged between 82-85 µg/L (84). This phenomenon was not observed in the 
MINI study, since plasma selenium concentrations of all postpartum women were 
higher than 85 µg/L. The possible effects of suboptimal selenium on postpartum 
women’s mental health and its mechanism and possible effects on infant cognitive 
development, requires ongoing investigation. 
The data presented provides support for the hypotheses 4 and 5. Whether low plasma 
selenium increases the risk of postnatal depression (hypothesis 6), however, was 
inconclusive. 
9.4 Maternal iron status 
Hypothesis 7: High prevalence of iron deficiency and iron deficiency anaemia exist 
among women at six months postpartum. 
 
Hypothesis 7 was proposed in anticipation that most women would have inadequate 
iron status at six months postpartum. However, our findings showed that only 4% 
were iron deficient without anaemia (ID), and none were classified as iron deficiency 
anaemia (IDA). The low rate of ID in this current study cohort could be due to the 
protective benefits from six-month lactational amenorrhoea. The possible 
consumption of iron supplements during pregnancy (69% reported taking iron 
supplements although exact compliance was not measured) may also contribute to 
this low rate. Additionally, most women who experienced postpartum haemorrhage 
were immediately treated with iron or blood transfusion (62%), which may contribute 
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to low rates of ID, as severe blood loss is strongly related to an increased risk of 
postpartum ID and IDA (85).  In an iron status study of America women at six months 
postpartum, after controlling for confounding variables, the risk of ID in postpartum 
women, compared to non-pregnant women, was highest among those from low-
income groups (86). If our study had included a more representative sample in 
household income status than 62% of women reported acceptable household income 
above the median New Zealand household income, the prevalence of ID may have 
been higher. While the data collected does not provide support for the hypothesis 7, 
it does not exclude it. More work is needed to investigate the iron status of those in 
New Zealand who are less wealthy. 
9.5 Strengths and limitations 
To the best of our knowledge, the MINI study was the first study to examine iodine, 
selenium, and iron concurrently in relation to the thyroid function of postpartum 
women. It is one of a few studies to investigate the prevalence of thyroid dysfunction 
in a New Zealand postpartum cohort. This study examined the iodine status of 
mother-infant dyads during the transitional period from exclusive, to partial, and in 
some cases, cessation of breastfeeding at three time points after partition. Results 
from this current study add to the existing limited knowledge of iodine status 
throughout the postpartum period. A triangular method was used to assess iodine 
status, including UIC, BMIC and serum Tg. Furthermore, to evaluate selenium status 
in breastfeeding women, the excretion of selenium in urine and breastmilk (short-
term dietary selenium intake) and plasma selenium (the most common biomarker) 
were both assessed. Finally, both iron storage measuring SF and functional iron 
deficiency measuring serum sTfR which is less likely affected by inflammation status 
were assessed to provide a better understanding of iron status (87), and allow early 
detection of ID before the occurrence of IDA (88). Repeated measures on iodine and 
selenium concentrations in urine and breastmilk samples have rarely been carried out 
in other published literature. These measures applied in the MINI study provided a 
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continuous picture of iodine and selenium status in mothers and infants during their 
first postpartum year. 
A limitation of this study is selection bias, where women with pre-existing iodine 
knowledge may have been attracted to participate. Women in this study were affluent 
and highly educated, and, typically, women who volunteer to participate in such 
studies are often more interested and likely to be motivated about health than the 
general population (89). If the iodine and selenium status of these women were 
inadequate, it is likely that women in the community who are less well-educated and 
under-represented may present further reduced status.  
Since the study sample size was small, the results need to be interpreted with caution. 
However, the retention rates (90% and 82% at six and twelve months postpartum 
respectively) were sufficient to enable further analysis within follow-up visits. The 
MINI study did not measure functional selenium status, including serum or plasma 
selenoprotein P, plasma GPX3 and erythrocytes GPx1 in identifying selenium 
deficiency due to the cost and low stability. Biological samples cannot be measured 
immediately after sampling but need to be stored and measure in batches.  However, 
plasma selenium is the most used biomarker in other published research which 
allowed comparison. Few participants reported the use of dietary supplements 
containing selenium (1% -1/78) or iron (8% - 6/78) during postpartum, leading to this 
study having insufficient statistical power to examine the effects of such 
supplementation on thyroid function. 
9.6 Final Conclusions  
A high prevalence of thyroid dysfunction (assessed by serum TSH, fT4 and fT3) was 
observed in this cohort of women at six months postpartum, with 15% presenting with 
subclinical hyperthyroidism. Selenium status was the only significant predictor of 
thyroid dysfunction, while iodine status (measured by UIC and BMIC) and iron status 
(serum sTfR) were not implicated. Most postpartum women achieved adequate iron 
status with only 4% having ID. This cohort of women throughout the first year after 
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partition were iodine deficient irrespective of the amount or duration of 
breastfeeding, and despite two New Zealand government iodine interventions 
initiated in 2009 and 2010. The iodine status of their breastfed infants aged three and 
six months may be less than adequate. Women who used iodine-containing 
supplements were more likely to achieve adequate iodine status for themselves and 
their breastfed infants. Maternal selenium intake remained suboptimal, and some 
women may have insufficient selenium status. Most infants were at risk of selenium 
deficiency. Prevalence of postnatal depression was typical for women domiciled in 
New Zealand. Although minor depression at three months postpartum was 
significantly different across tertiles of plasma selenium concentrations, any close 
relationship between selenium status and risk of postnatal depression and anxiety was 
inconclusive. 
9.7 Implications for public health practice 
A high prevalence of thyroid dysfunction was found in this cohort of iodine-deficient 
postpartum women with suboptimal selenium intake. Literature has suggested that 
women with PPT might develop permanent hypothyroidism or experience PPT again 
after the subsequent pregnancies, and such risk increases if women had positive 
TPOAb during early pregnancy (3). However, screening for thyroid dysfunction is not 
routinely recommended for women who are either planning a pregnancy or become 
pregnant in New Zealand (90). Early screening of TPOAb may be useful in identifying 
women who are at a high risk of experiencing PPT, which can allow timely 
interventions. In addition, it would be useful for health professionals who care for 
postpartum women to offer a thyroid function check at six months postpartum, 
especially for women who had existing autoimmune diseases such as type 1 diabetes.  
This may help detect postpartum thyroid dysfunction and provide effective 
intervention to enhance future maternal reproductive health. However, a cost and 
benefit analysis is needed prior to implement this practice.  
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In the MINI study, low plasma selenium increased the risk of thyroid dysfunction of 
postpartum women. Literature has shown some positive effects of selenium 
supplementation for thyroid function, especially for patients with Graves 
ophthalmopathy (79). Although using selenium supplementation to treat thyroid 
dysfunction is presently inconclusive, it is worth considering the narrow window of 
optimal selenium intake and selenium status when managing maternal thyroid 
dysfunction. 
Despite recommendations made to date, the use of iodine-containing supplements 
was low in our lactating women. In the specific New Zealand context, mothers and 
their infants are cared for by midwives or obstetricians during the first six weeks after 
childbirth, then Plunket nurses, general practitioners (GPs), and lactation consultants 
all play an essential role in the postnatal care of mothers during the first postpartum 
year and beyond. Consequently, these health care workers are placed in an ideal 
position to provide timely advice to postpartum women. Here, we suggest promoting 
iodine specific nutrition education to all health professionals, especially midwives, 
obstetricians, Plunket nurses, and GPs. It is then recommended that these health 
professionals, as a trusted source of information, encourage the routine use of 
government subsidised iodine-only supplements during lactation. The MINI study 
found that using an iodine-containing supplement was strongly associated with 
maternal iodine knowledge. Such information should be considered for framing and 
targeting further educational interventions around iodine, as well as considering 
removing barriers for women to access these supplements. Providing practical advice, 
such as integrating iodine-related food sources in sample meal plans when developing 
nutrition specific educational resources, may be effective in improving maternal 
iodine status. 
The MINI study also found most women at six months postpartum achieved adequate 
iron status, with only 4% having ID and none classified as IDA.  However, as discussed 
earlier, the women in this study cohort were typically affluent and highly educated. 
As such, iron status of women in New Zealand who have low socioeconomic 
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backgrounds and are less well-educated may be of greater concern, since they may not 
be able to afford iron rich foods, such as meat. Also, postpartum haemorrhage is one 
of the significant risk factors in developing postpartum iron deficiency. In our study, 
most women who experienced haemorrhage at childbirth were treated with either 
iron or blood transfusion, however, their iron status was not followed up. The 2016 
WHO guideline recommends oral iron supplementation may be provided to women 
at six to twelve weeks postpartum where a prevalence of gestational anaemia is higher 
than 20% (91).  It is important to note that iron deficiency negatively impacts on 
maternal physical and mental health and assessing iron status in the early lactating 
period is pivotal. Overall, early detection of any stages of iron deficiency is important 
to ensure women have adequate iron status, especially before conceiving again. We 
recommend maternal iron status checks take place routinely at the six weeks 
postpartum medical check-up, as it is an opportune time when mothers and infants 
are individually assessed for their postnatal health by GPs. In practice, a full blood test 
examining both haemoglobin and serum ferritin is recommended. Alternatively, point 
of care equipment such as the HemoCue Hb 201+ system could be used to identify 
women at risk in the first instance, before referring them for a full blood test to further 
examine their iron status if necessary. However, women who have low iron stores 
without being anaemic may fail to benefit from this alternative approach. 
9.8 Research Recommendations 
1. Further investigation should be undertaken to examine the effects of iodine 
and/or selenium supplementation on maternal and infant thyroid function; for 
example, a randomised controlled trial with lactating women by dispensing 
only iodine or a combined iodine-selenium supplementation. 
2. To achieve optimal iodine status is crucial during the first two years in 
supporting optimal neurodevelopment. Thus, further research should focus on 
investigating maternal postpartum iodine status in relation to infants’ 
neurodevelopment for those early years after childbirth. 
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3. The current study confirmed that women who used iodine-containing 
supplements achieved adequate iodine status for themselves and their infants. 
Future cohort studies with iodine-depleted populations are indicated to 
confirm if iodine supplementation during conception and pregnancy can 
enhance future beneficial health outcomes for both mothers and their infants. 
4. Future quality evidence from health research is needed to further clarify the 
optimal cut-off of MUIC to ensure iodine adequacy during infancy. For 
example, a large cohort study might investigate infant MUIC in iodine 
sufficient populations and use neonatal heel blood TSH to measure infant 
thyroid function as an indicator of optimal iodine status. 
5. Future research studies should confirm how much iodine intake is contributed 
by infant formula or complementary foods in New Zealand; such results could 
help provide useful guidelines for improving infant iodine intake and status, 
particularly for infants having complementary feedings. 
6. Research is required to better clarify the association between maternal 
selenium status and the development of postnatal depression and anxiety; for 
example, a case control study to examine selenium status (by measuring serum 
or plasma selenoprotein P, plasma GPX3 and erythrocytes GPx1) in women who 
have been confirmed with PND, conjunctively with women without PND. 
7. Nail clippings have been used to determine selenium concentrations in large 
cohorts or epidemiological studies. Measuring selenium in nail clippings would 
be a useful biomarker representing long-term selenium exposure, from three 
to twelve months. Notably, in the MINI study, nail clippings have been 
collected, and further analysis presents a future opportunity to measure in 
utero selenium exposure for both mothers and their infants. 
8. Larger cohort studies are required to provide a greater understanding of the 
role of selenium status, when combined with other micronutrients, needed for 
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Appendix 5 – MINI Study Health Screening Questionnaire 
 
Date of visit: _____ Day_____ Month_____ Year   
 
 
Thank you volunteering to take part in this study. I would like to ask you a few 
questions to check that you are a suitable subject and provide you with an opportunity 
to ask any questions that you may have about the study.    
What is your age?   
Are you currently breastfeeding?   
When was your baby born?   
Do you have any contagious blood borne disease, eg. Hepatitis A or HIV?   
Do you currently have any medical conditions?   
Have you ever been diagnosed with thyroid disease such as thyroid enlargement or goiter/ 
hyperthyroidism/ hypothyroidism?   
If yes, are you currently receiving any treatment or consuming medication containing iodine? Or, 
are you now fully recovered?   
Are you taking iodine contain supplements due to other reasons rather than 
pregnancy or lactation?   
Are you taking any other medication? If yes, can you please indicate the type or name of the 
medication(s) that you are taking?   
Does your baby have any health complications, eg. Preterm?  
 




Appendix 6 – MINI Study Participant Information Sheet 
 
Study title: [MINI - Mother and Infant Nutrition Investigation] 
Locality: Palmerston North Ethics committee ref: 15/NTA/172 
Lead 
investigator: 
Ying Jin Contact email: mini@massey.ac.nz 
Register your interest – 
www.massey.ac.nz/ministudy 
Phone: +64 (06) 9517556 
               027 399 4138 
 
Would you like to help us? 
We invite you to take part in a research study: Mother and Infant Nutrition Investigation 
(MINI). This sheet gives detailed information about the study. Please read it carefully before 
deciding whether you wish to join our study. 
We need mothers and their infants to take part. It is important that you understand why 
we are doing this research, and what it may involve for you. Please take time to read the 
sheet carefully. Feel free to discuss it with other people, such as your family, whānau, 
friends, or your health care providers. Please ask us questions if anything seems unclear, or 
if you wish to know more details. 
Introducing the researchers 
This research is led by PhD scholar Ms Ying Jin. Ying’s supervisors are Dr Louise Brough and 
Professor Jane Coad. They are human nutritionists in the School of Food and Nutrition, 
Massey University, Palmerston North. Anne Broomfield, research officer, will also assist in 
the study.  
What is the purpose of this study? 
After the birth of their baby, most women continue to see their health care professionals. 
However, the focus is often on the infant’s health. Only limited attention is given to the 
mother’s mental health. This study will monitor the mothers’ health by assessing her 
nutrient status, thyroid function and mental health. The thyroid is a small butterfly-shaped 
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gland at the base of the neck which produces hormones. How a mother’s health status 
might affect her baby’s development during early life is important. The three nutrients we 
are studying are iodine, selenium, and iron. Understanding these nutrients will help to 
provide better health care to future mothers. This leads to greater knowledge about the 
health and wellbeing of both the mothers and their infants.  
 
Do I have to take part? 
No. It is entirely up to you to decide whether you wish to take part. If you do agree, you will 
be asked to sign a Consent Form.  You will be given a copy of both the Participant 
Information Sheet and the Consent Form to keep.  
Should you change your mind about being in the study, you are free to withdraw from the 
study at any time without giving any reason. 
What would your participation involve? 
If you are interested in taking part in the study, please phone or email us. You can also enter 
your details on this study’s “Express of Interest” webpage. We will reply immediately and 
arrange a brief telephone conversation. We will ask you some questions to ensure that you 
are eligible. You must feel totally comfortable about taking part in the study.  
Soon after, we shall make an appointment for you and your baby to come into the Human 
Nutrition Research Unit at Massey University. If this is not possible, we may visit you either 
at home, at a local community Centre, or at a health professionals’ clinic. 
During the first visit, we shall 
ask you some questions about your nutrient supplement use, and your nutrition 
knowledge. We will also ask you about your health, diet and some personal information;  
• measure your weight, height, and body composition; 
• ask you to provide small samples of urine and breastmilk which we will use to 
assess your nutrient status; 
• measure your baby’s weight, length, and head circumference.  
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• collect a small urine sample from your baby to assess his/her nutrient status. 
• Your first visit should take no more than two hours.  
After the first visit, you will be given 
• two small paper bags for you to collect nail clippings from yourself and from your 
baby to assess selenium status.  
• a 4-day food record diary to measure your nutrient intake.  
Within a month after your first visit, at a convenient time, we will collect the samples and 
food diary from you at home.  
The 2nd visit will be when your baby is 6 months old. The 3rd visit will be when your baby is 
12 months old. We will ask you to complete questionnaires to assess your child’s 
development at 4, 8 and 12 months. A Flow Chart is included in this Information Sheet.  
How would the required samples be collected? 
A clear detailed instruction of how to collect infant or adult nail clippings would be given at 
the first visit. Infant urine samples will be collected by placing a pad inside the nappy, 
checking every 10 minutes until wet, and then urine aspirated (extracted) with a syringe. 
Blood samples will be drawn by experienced phlebotomist. The collected biological samples 
will be frozen, labelled with a unique code (no personal information will be displayed on the 
samples), and then stored for 10 years to allow a number of analyses to take place. After 10 
years, the samples will be properly disposed in biohazard bags to be incinerated (burned) 
by a professional company who specialise in destroying biological samples. We 
acknowledge that the use and storage of tissue is a cultural concern for some Māori people. 
We are unable to return body fluids such as blood, urine and breastmilk due to safety 
(microbiological) issues. However, if you wish, the nail clippings, after analysis, will be 
returned to you if you request this in advance.  
What are the possible risks to you? 
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There are small risks when taking blood samples such as discomfort, bruising, infection, or 
fainting. To minimise any risk, your blood will only be taken by experienced and fully trained 
research staff. 
Any risks involved in this study are very minor. All the checks are routinely made. If you have 
any concerns during the study, you may discuss these with any of the study team. 
Any complaints you may make will be fully investigated. If you have any concerns about any 
aspect of this study, you should speak immediately to a member of the study team. They 
will do their best to answer all your questions fully.  
What are the advantages of taking part in the study? 
Your thyroid gland size, thyroid function and iron status will be monitored during the study. 
These are not normally covered by primary health care services; 
Repeated monitoring of your wellbeing during the first year after delivering a baby;  
Based on your food diary, you will receive feedback on your intake of nutrients within a 
month after we receive the dietary diary. This will be compared to New Zealand standard 
dietary guidelines.  
You will also receive information about your child’s development assessments at 4, 8 and 
12 months.  
Will my participation in the study be kept confidential? 
Yes. All information collected about you and your baby during the study will be kept strictly 
confidential. Each mother will be given a unique code which will be used on all data 
collected. No identifying details will be recorded on the interview sheets or other records. 
When the study results are presented, you will not be named or recognised from any of the 
information given. All information will be entered into a protected database at Massey 
University. Information collected about you and your baby will be kept strictly confidential 
and secure in a locked filing cabinet. All electronic files on computers will have passwords 
and restricted access. Only the named members of research team will have access to 
detailed personal information.  
Massey University maintains a central record of all research projects undertaken. This does 
not include personal information about those who take part. The data (without containing 
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personal information) will be held for 10 years after the youngest person in the study has 
reached the age of consent or 16 years old.  
What will happen to the results? 
Should you wish, you will receive all the results about you and your baby. Should your 
results be, in any way, unusual, you will be encouraged to contact your general practitioner 
and seek appropriate medical advice. Once the whole study has ended, we can send you a 
summary of the study results, should you wish to have it. The results will also be presented 
at scientific meetings or published in peer reviewed journals. This ensures that a wider 
community, including health professionals, can know and read about the findings. You and 
your baby will not be identified by any of these publications or presentations.  
What would happen if you were injured in the study?  
If you were injured in this study, which is unlikely, you would be eligible for compensation 
from ACC. This would be the same as if you were injured in an accident at work or at home.   
If you have private health or life insurance, you may wish to check with your insurer that 
taking part in this study will not in any way affect your cover. 
Who has reviewed the study? 
This project has been reviewed and approved by the Northern A Health and Disability Ethics 
Committee through the full review pathway. 
Contact for further information:  
If you have any further questions or if you have any concerns whilst taking part in the 
study then please contact: 
Ms Ying Jin, Lead Investigator/PhD Scholar 
Email:  mini@massey.ac.nz, or go to www.massey.ac.nz/ministudy 
  Cell phone: 027 399 4138 
Telephone: +64 (06) 9517556 
 
Dr. Louise Brough, Principle Supervisor/Senior Lecturer 




Where can you go for more information about the study, or to raise concerns or 
complaints? 
If you have any questions, concerns or complaints about the study at any stage, you can 
contact:  
 Ms Anne Broomfield, Research Technical Officer 
Human Nutrition Research Unit 
 Massey Institute of Food Science and Technology  
Telephone: +64 (06) 356 9099 ext. 84566  
  Email:  A.M.Broomfield@massey.ac.nz  
 
If you want to talk to someone who is not involved with the study, you can contact an 
independent health and disability advocate on: 
Phone:  0800 555 050 
Fax:   0800 2 SUPPORT (0800 2787 7678) 
Email:   advocacy@hdc.org.nz 
 
If you feel you would like to talk to a Māori health support person, please contact: 
Dr Maureen Holdaway 
Associate Director, Research Centre for Maori Health & Development 
Telephone: +64 (06) 356 9099 ext. 85092 
Email:  M.A.Holdaway@massey.ac.nz 
 
You can also contact the health and disability ethics committee (HDEC) that approval this 
study on: 
 Phone:  0800 4 ETHICS 








Appendix 8 - MINI Study Consent Form 
 
Please tick to indicate you consent to the following 
I have been given sufficient time to consider whether or not to 
participate in this study. 
  
I have had the opportunity to use a legal representative, whanau/ 
family support or a friend to help me ask questions and understand 
the study. 
  
I am satisfied with the answers I have been given regarding the 
study and I have a copy of this consent form and information sheet. 
  
I understand that taking part in this study is voluntary (my choice) 
and that I may withdraw from the study at any time without this 
affecting my medical care. 
  
I consent to the research staff collecting and processing my 
information, including information about my health. 
  
If I decide to withdraw from the study, I agree that the information 
collected about me up to the point when I withdraw may continue 
to be processed. 
Yes  No  
I consent to my GP or current provider being informed about my 
participation in the study and of any significant abnormal results 
obtained during the study. 
Yes  No  
I understand that my participation in this study is confidential and 
that no material, which could identify me personally, will be used in 
any reports on this study. 
  
I know who to contact if I have any questions about the study in 
general. 
  
I wish the nail clippings to be returned to me after analysis Yes  No  
I wish to receive a summary of the results from the study. Yes  No  






Declaration by a member of the research team: 
 
I have given a verbal explanation of the research project to the participant and have 
answered fully any of the participant’s questions concerning this study.   
 
I believe that the participant fully understands the details of this study and has given 









Appendix 9 - MINI Study General Questionnaire - when your child is 
born 




I would like to ask you about what you usually eat and your meal preparation.   
1. Do you add any SALT to your food (either AT THE TABLE or in COOKING)?
  No (go to Q 4) 
   Yes 
 
2.  Do you add SALT to your food AT THE TABLE?   
 No (go to Q3)   
 Yes   
2a. If yes, what type of SALT do you mainly use (more than 60%)?   
 Plain table salt   
 Iodised salt (go to Q2b.)   
 Other mineral salt (rock, sea salt)   
 Others______________________   
2b. Considering only IODISED SALT added AT THE TABLE, please indicate the average 
amount of your individual portion used DAILY. 
 Less than 1/4 teaspoon   
1/4 teaspoon   
 1/2 teaspoon   
 1 teaspoon   
 More than 1 teaspoon   
 
3.  Do you add SALT to your food in COOKING?   
 No (go to Q4)   
 Yes   
 
 




3a. If yes, what type of SALT do you mainly use (more than 60%)?   
 Plain table salt   
 Iodised salt (go to Q3b.)   
 Other mineral salt (rock, sea salt)   
 Others_________________________   
 
3b. Considering only IODISED SALT added in COOKING please indicate the average amount 
of your individual portion used DAILY.   
 Less than 1/4 teaspoon   
1/4 teaspoon   
 1/2 teaspoon   
 1 teaspoon   
 More than 1 teaspoon   
4. Which of the following foods do you EXCLUDE from your usual diet? (Tick all that 
apply)   
 Eggs   
 Dairy   
 Fish   
 Seafood   
 Chicken   
 Beef   
 Lamb   
 Pork   
 Other meat or animal products   
 
I would like to ask you what you know about nutrition.   
5.  Which part of the body needs IODINE to produce hormones?   
 Brain   
 Heart   
 Bone   
 Thyroid gland 
 Do not know   
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6. What health issues are associated with inadequate intake of IODINE? (tick all that apply)   
 Neural Tube Defects   
 Goiter   
 Birth defects   
 Weak bone and teeth   
 Mental retardation   
 Impaired physical development during childhood   
 Blindness   
 Do not know   
7.  Do you think there is currently a problem with IODINE deficiency in New Zealand? 
  No 
 Yes 
 Do not know 
8.  From your knowledge, which of the following describes the current fortification in the   
manufacture of bread in New Zealand? (Tick all that apply)   
 Producers must add iodised salt (mandatory fortification)   
 Producers must add folic acid (mandatory fortification)   
 Producers may add or may not add iodised salt (voluntary fortification)   
 Producers may add or may not add folic acid (voluntary fortification)   
 Do not know   
9.  Since 2010, which target population groups routinely are recommended to take an IODINE   
supplement? (Tick all that apply)   
 Pregnant women    
 Breastfeeding women    
 All women of childbearing age   
 All babies   




10. From your knowledge, which of the following foods contribute good sources of IODINE?   
 
   I would like to ask about your supplement usage DURING REGNANCY.   
11. Did you take any supplements?   
 Yes (go to Q13)   
 No    
11a. If no, which if the following statements are the reasons for not taking any supplements?  
(Tick all that apply)   
 I was not advised to take them by doctor/nurse practitioner/mid-wife   
 I could not tolerate them because of nausea (or any other side effects)   
 I could not afford to purchase them   
 I did not feel the need to as my health is good   
 I believed that I could obtain adequate nutrients from my diet   
 Others ________________________   
 
 
 Good source Poor source Do not know 
Milk    
Potatoes    
Fish    
Carrots    
Bread (excluding organic)    
Organic bread    
Beef    
Seaweed    
Lettuce    
Eggs    
Sea salt    
Rock salt    
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12. Please complete the following table with details of any supplements you took.   
 
I would like to ask about your CURRENT supplement usage SINCE THE BABY WAS BORN 
13. Are you taking any supplements?   
 Yes (go to Q 14)   
 No    
13a. If no, which if the following statements are the reasons for not taking any supplements? 
(Tick all that apply)   
 I was not advised to take them by my doctor/nurse practitioner/mid-wife   
 I could not tolerate them because of nausea (or any other side effects)   
 I could not afford to purchase them   
 I did not feel the need to as my health is good   
 I believed that I could obtain adequate nutrients from my overall diet   








Brand name  
(manufacture)   
GPs or   
Midwife’s   
prescription   
Start  
date   
Stop  
date   
Frequency   
Times per week   Dosage each   
time   
7   6   5   4   3   2   1   
Eg.Blackmores  
Pregnancy and  
breastfeeding   
gold capsule   
Yes   12/04/2015   12/08/2015               √   
  
2 tablets   
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14. Please complete the following table with details of any supplements you are taking now.   
Note to the interviewer: If the participant is not able to remember details please ask 
them to send us an email later with details. (Email requested  Email received )   
I will now ask you some questions about your smoking habits SINCE YOUR BABY WAS BORN.     
15. Have you ever smoked a total of more than 100 cigarettes in your entire life?   
 No (go to Q18)   
 Yes   
16. Did you smoke regularly during THIS pregnancy?    
 No (go to Q17)   
 Yes   
16a. If yes, on average, how many cigarettes did you smoke each day?   
 Less than 1 per day   
 1-5 per day   
 6-10 per day   
 11-15 per day   
 16-20 per day   
 21-25 per day   
 26-30 per day   
 31 or more a day      
17. Now, after the delivery of your baby, do you continue to smoke?   
 No (go to Q18)   
 Yes   
Brand name  
(manufacture)   
GPs or   
Midwife’s   
prescription   
Start  
date   
Stop  
date   
Frequency   
Times per week   Dosage each   
time   
7   6   5   4   3   2   1   
Eg.   
Blackmores   
Pregnancy   
and   
breastfeeding  
gold capsule   
Yes   12/04/2015   12/08/2015               √   
  
2 tablets   
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17a.If yes, on average, how many cigarettes do you now smoke each day?   
 Less than 1 per day   
 1-5 per day   
 6-10 per day   
 11-15 per day   
 16-20 per day   
 21-25 per day   
 26-30 per day   
 31 or more a day   
18. Are you regularly exposed to secondhand smoke; for example, does someone smoke around   
you, or in your house or a house you visit often?                   
 No   
 Yes   
18a. If yes, how many hours per day are you exposed to the smoking of others?   
________________Hours   
I will now ask you some questions about your use of alcoholic drinks SINCE YOUR BABY 
WAS BORN.     
19. Have you had a drink containing alcohol?    
  No (go to Q 20)   
  Yes   
    19a. If yes, how often have you had a drink containing alcohol?    
  Monthly or less   
  Up to 4 times a month   
  Up to 3 times a week   















About your child   
20. What did you give your child to drink routinely during the FIRST WEEK of life? 
(Tick all that apply)   
 Breastmilk   
 Water   
 Sugar water   
 Infant formula/milk formula   
 Pasteurized/bottled cow’s milk   
 Soy formula   
 Hypoallergenic formula   
 Fruit juices/water down juice/cordial   
 Herbal drinks   
 Tea/coffee   
 Fizzy drinks   
 Other, specify: _________________   
 
21. Do you add sugar to your child’s drink?   
 No   
 Yes   
 
 
Beer, cider and RTDs   Wine   Spirits   
    
   330ml glass   100ml glass   30 ml short   
How many             
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22. Since the baby was born, have you been breastfeeding your baby, including feeding   
expressed milk?   
 No (go to Q 26)   
 Yes   
22a. If yes, which of the choices below most describes your breastfeeding pattern?   
 Exclusive (100%) breastfeeding   
 Medium (50-80%) breastfeeding   
 Partial (less than 50%) breastfeeding   
 Artificial (less than 10%) breastfeeding   
23. On average, how many times a day (during the 24hour period) do you currently breastfeed 
our baby?   
______ Times   
24. On average, how long does it take for each breastfeed?   
______ minutes ______ hours   
25. How old was your baby when you stopped 
breastfeeding?   
 ______months______ weeks_______ days   
 I continue to breastfeed (go to Q 27)   
26. Tick the reason (s) you chose not to breastfeed, or to stop breastfeeding your baby: 
(Tick all that apply)   
 Have breastfed long enough   
 Baby had trouble latching on   
 Did not have enough milk   
 Breastmilk alone did not seem to satisfy my baby   
 Painful breast   
 Baby not gaining enough weight   
 Baby lost interest/self-weaned   
 I wanted/needed someone else to feed the baby   
 Went back to work and expressing breastmilk was not convenient/possible   
 New pregnancy   
 Baby was old enough that the difference between breastmilk and formula was minimal   




27.  How often do you give your child the following to drink at the moment?   
 
Now I am going to ask a few questions about you and your current living situation. The 
answers to these questions help us to check that we have selected a representative 
sample of New Zealanders to participate in this survey.   
28.  Which country were you born in?   
 New Zealand   
 Australia   
 England   
 Scotland   
 China (People's Republic of China)   
 India   
 South Africa   
 Samoa   
 Cook Islands   
 Other (specify) ___________________   
29. What is your first language?  _____________.   
 
Type of drinks   Never   
 
(seldom) 
1-3 times/   
week 
4-6 times/   
week 
More than  
once a day 
Breastmilk   
    
Pasteurized/bottled cow’s milk   
    
Regular Infant formula/milk formula   
    
Hypoallergenic formula   
    
Soy formula   
    
Water    
    
Gripe water   
    
Sugar water   
    
Fruit juices/water down juice/cordial   
    
Herbal drinks   
    
Tea/coffee   
    
Other   




30. Which ethnic group or groups do you identify with? (tick all that apply)   
 NZ European    
 Maori    
 Samoan    
 Cook Island Maori    
 Tongan   
 Niuean    
 Chinese   
 Indian    
 Other (specify) ____________   
 
31. If from overseas, in what year did you arrive to live in New Zealand? _________Year    
32. What is your date of birth?    
 _____ Year _____ Month (range Jan-Dec) _____ Day (range 1-31)   
 
33. How old are you?   
 <20    
 20-24    
 25-29    
 30-34    
 35-39    
 40-45    
 >45   
 
34. What is your highest completed qualification?    
 School   
 Trade Certificate   
 Diploma/Bachelor/Tertiary education   
 Postgraduate qualification   






35. Who do you live with? (Tick all that apply)   
 Husband/partner    
 Other Children (not including new baby)    
 My siblings   
 My parents    
 Parents in laws   
 Other relatives   
 On my own (with my baby)   
 Others, specify ________________   
36. What is the total income of your household from all sources, before tax or any other   
deductions, in the last 12 months?    
 Loss   
 Zero income   
 $1 – $5,000   
 $5,001 – $10,000   
 $10,001 – $15,000   
 $15,001 – $20,000   
 $20,001 – $25,000   
 $25,001 – $30,000   
 $30,001 – $35,000   
 $35,001 – $40,000   
 $40,001 – $50,000   
 $50,001 – $60,000   
 $60,001 – $70,000   
 $70,001 – $100,000   
 $100,001 – $150,000   
 $150,001 or more   
 




Appendix 10 – MINI Study General Questionnaire – when your child is 
around 6 months old 
Date of visit: _______ Day_______ Month_________ Year 
1.  Which of the following foods do you EXCLUDE from your usual diet? (Tick all that apply)   
 Eggs   
 Dairy   
 Fish   
 Seafood   
 Chicken   
 Beef   
 Lamb   
 Pork   
 Other meat or animal products   
2.  How often do you eat red meat?   
 Never    
 Less than once a week   
 1-2 times per week   
 3-4 times per week   
 5-6 times per week   
 7+ times per day   
3.  How often do you use a cast-iron fry pan, wok or pot when preparing your meals?   
 Never or less than once a month   
 1-3 times per month   
 Once a week   
 2-3 times per week   
 4-6 times per week   
 Once a day   
 2-3 times per day   
 4+ times per day   
 




4.  Some foods and drinks have iron added to them (eg. Some breakfast cereals) when you are   
choosing foods and drinks, how often do you choose the product with added iron instead of 
the product without?   
 Whenever I can   
 Usually   
 Sometimes   
 Never   
 I do not know    
 I do not consider whether the product has iron added   
5.  On average, how many slices of bread/toast or bread rolls do you eat per day?   
 None, I do not eat bread or toast   
 Less than one per day   
 1-2 per day   
 3-4 per day   
 5-6 per day   




6. Have you had any of the following symptoms since the baby was born?  If you know symptoms 
are due to allergy and not infection, do not check.  Please check the correct answer: 
(Carr Infection Symptom Checklist)   
0 = No symptoms    1 = Mild symptoms    2 = Moderate symptoms              
3 = Strong symptoms      4 = Severe symptoms        
 
   0   1   2   3   4   
Cold sores                     
Canker sores                  
Nasal stuffiness                       
Sore throat                        
Sinus drainage                        
Sinus pain/pressure                        
Swollen glands                        
Diarrhea                  
Abdominal cramps                        
Burning on urination                        
Dark, smelly urine                        
Earache                  
Hoarseness                  
Styes                        
Runny nose                        
Skin infections                        
Acne                  
Red eyes                        
Vaginal itching                        
Vaginal yeast infection                        
Vaginal herpes                        
Fever                  
Fingernail infection                        
Wheezing                  
Cough                  
Shingles                      
Generalized flu-like                        
Breast infection                        
Episiotomy infection                        
Dental abscess                     
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7.  Apart from when you were in hospital immediately after having your baby, have you 













8. Overall, how would you describe your physical health at the moment?   
 Excellent   
 Very good   
 Good   
 Fair   
 Poor   
9.  Do you take or have taken cod liver oil, vitamins or other dietary supplements since 
the previous questionnaire?   
 No   
 Yes   
9a. If yes, which product, when did you take it and how often (one line for each product)   
   Never   Rarely   Occasionally   Often   
Extreme tiredness/exhaustion               
More frequent coughs/colds/minor illness than 
usual   
            
Severe headache or migraines               
Lower back pain               
Upper back pain               
Painful perineum               
Pain from caesarean section wound               
constipation               
hemorrhoids               
Breast problems               





10. How often are you physically active at present?   
 
 
11. Have you ever suffered from low iron stores, iron deficiency or iron deficiency anemia?   
 No   
 Yes   
 
Brand name  
(manufacture)   
GPs or   
Midwife’s   
prescription   
Start  
date   
Stop  
date   
Frequency   
Times per week   Dosage each   
time   
7   6   5   4   3   2   1   
Eg. Blackmores  
Pregnancy and  
breastfeeding   
gold capsule   
Yes   12/04/2015   12/08/2015               √   
  
2 tablets   
            
 Never  1-3 times a 
month 
   
walking                  
brisk walking                  
running/jogging/orienteering                  
cycling                  
training studio/weight training                  
special gymnastics/aerobics for women                  
aerobics/gymnastics/dancing without   
running and jumping   
     
aerobics/gymnastics/dancing with 
running and jumping   
     
dancing (swing, rock, folk)                  
skiing                  
ball sport                  
swimming                  
riding                  
other                  
Once a   
week   
Twice a   
week   
Three times or   





you ever been treated for iron deficiency or iron deficiency anemia?   
 
  
1 3 .  Have you had a severe blood loss during delivering your baby?   
 No   
 Yes   
 
14. Do you have or have you had any medical condition which has resulted in blood loss?   
If yes, please describe it and give approximate date________________________________   
15. Have you had a blood donation during the last 6 months?   
 No   
 Yes   
15a. If yes, how many times did you donate your blood? _____________.   
16. Have you had a blood transfusion during the last 12 months?   
 No   
 Yes   
16a. If yes, do you know why you received the blood transfusion _________________   
17. Have you noticed any form of blood loss during the last 6 months?   
 Not at all   
 Yes, in stools   
 Yes, in urine   
 Yes, when brushing my teeth   
 Yes, from a wound   
18. Are you pregnant at the moment?   
 No   
 Yes   
18a. If yes, how many weeks have you been pregnant? ____________.   
19. Has your period started again?   
 No   
 Yes   
Diagnosis date   Diagnosed by   Any further details   
         
Type of treatment   Duration   Any further details   
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19a.If yes, please give an approximate date _____________.   
About your child    
20. How old was your baby when you stopped breastfeeding?   
 ______months______ weeks_______ days   
 I continue to breastfeed (go to Q 22)   
21. Tick the reason (s) you chose not to breastfeed or stop breastfeeding your baby (Tick all that   
apply)   
 Have breastfed long enough   
 Baby had trouble latching on   
 Did not have enough milk   
 Breastmilk alone did not seem to satisfy my baby   
 Painful breast   
 Baby not gaining enough weight   
 Baby lost interest/self-weaned   
 I wanted/needed someone else to feed the baby   
 Went back to work and expressing breastmilk was not convenient/possible   
 New pregnancy   
 Baby was old enough that the difference between breastmilk and formula was minimal   
 Others ________________________________   
22. Including times of weaning, what is the total time your baby was breastfed?    
 Weeks   
 Months   
 Less than one week   
23. At what age was your baby first given infant formula regularly? 
_____Weeks ______ Months   
24. At what age was your baby first given solid food regularly? 




25. How often do you give your child the following to drink at the moment? 
 
26. Do you give your child cod liver oil, vitamins, iron or any other dietary supplements?   
 No   
 Yes   
26a. if yes, specify  
Name of product How many 
teaspoons/time 
How often  How old was your child at first time 
consumption (months) 
    




   Never   
/seldom   
  At least   
once a day   
Breastmilk               
Pasteurised Cow’s milk               
Pasteurised Goat’s milk               
Evaporated milk               
Organic milk products (milk, yoghurt)               
Standard infant formula/formula milk               
Standard formula milk with Omega-3               
Hypoallergenic formula               
Water               
Gripe water               
Sugar water               
Cold flavored milk drinks               
Fizzy (carbonated) drinks               
Squash, artificially sweetened               
Baby cordial, artificially sweetened               
Fruit juice               
Herbal drinks               
Tea/Coffee               
Others _________________               
1-3   
times/week   
4-6   
times/week   
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27. Has your child had the following health problems? 
 





Did you visit a 
doctor/clinic 
Has your child 
been admitted to 
hospital for this 
Common cold  Yes   No   Yes   No  Yes   No 
Throat infection  Yes   No   Yes   No  Yes   No 
Ear infection  Yes   No   Yes   No  Yes   No 
Bronchitis 
pneumonia 
 Yes   No   Yes   No  Yes   No 
Diarrhea  Yes   No   Yes   No  Yes   No 
wheezing  Yes   No   Yes   No  Yes   No 
vomiting  Yes   No   Yes   No  Yes   No 
High temperature  Yes   No   Yes   No  Yes   No 
Urinary tract 
infection 
 Yes   No   Yes   No  Yes   No 
Colic  Yes   No   Yes   No  Yes   No 
Nappy rash  Yes   No   Yes   No  Yes   No 
An accident  Yes   No   Yes   No  Yes   No 
 
28. How would you describe the health of your baby now: 
 Very healthy 
 Healthy, but a few minor problems 
 Sometimes quite ill 
 Almost always unwell 
29. Since your last visit, have you changed your smoking habits? 
 No 
 Yes, specify _____________________________________. 
30. Since your last visit, have you changed your drinking habits? 
 No 
 Yes, specify _____________________________________. 
 





Appendix 11 – MINI Study General Questionnaire – when your child is 
around 12 months old 
Date of visit: _______ Day_______ Month_________ Year 
 
I would like to ask you about what you usually eat and your meal preparation. 
1. Do you add any SALT to your food (either AT THE TABLE or in COOKING)?  
  No (go to Q 4) 
  Yes 
2. Do you add SALT to your food AT THE TABLE? 
 No (go to Q3) 
 Yes 
2a. If yes, what type of SALT do you mainly use (more than 60%)? 
 Plain table salt 
 Iodised salt (go to Q2b.) 
 Other mineral salt (rock, sea salt) 
 Others______________________ 
2b. Considering only IODISED SALT added AT THE TABLE, please indicates the average 
amount of your individual portion used DAILY. 
 Less than 1/4 teaspoon 
1/4 teaspoon 
 1/2 teaspoon 
 1 teaspoon 
 More than 1 teaspoon 
3. Do you add SALT to your food in COOKING? 
 No (go to Q4) 
 Yes 
3a. If yes, what type of SALT do you mainly use (more than 60%)? 
 Plain table salt 
 Iodised salt (go to Q3b.) 
 Other mineral salt (rock, sea salt) 
 Others_________________________ 
Questionnaire – when your child is around 12 months old 
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3b. Considering only IODISED SALT added in COOKING please indicate the average amount 
of your individual portion used DAILY. 
 Less than 1/4 teaspoon 
1/4 teaspoon 
 1/2 teaspoon 
 1 teaspoon 
 More than 1 teaspoon 









 Other meat or animal products 
















Times per week 
Dosage each 
time 





Yes 12/04/2015 12/08/2015     √ 
  
2 tablets 
            




6. Have you had any of the following symptoms since the baby was born? If you know symptoms are 
due to allergy and not infection, do not check. Please check the correct answer:       
0 = No symptoms    1 = Mild symptoms    2 = Moderate symptoms            
3 = Strong symptoms      4 = Severe symptoms       
 
 0 1 2 3 4 
Cold sores         
Canker sores      
Nasal stuffiness           
Sore throat            
Sinus drainage            
Sinus pain/pressure            
Swollen glands            
Diarrhea      
Abdominal cramps            
Burning on urination            
Dark, smelly urine            
Earache      
Hoarseness      
Styes            
Runny nose            
Skin infections            
Acne      
Red eyes            
Vaginal itching            
Vaginal yeast infection            
Vaginal herpes            
Fever      
Fingernail infection            
Wheezing      
Cough      
Shingles          
Generalized flu-like            
Breast infection            
Episiotomy infection            
Dental abscess         
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7. How often are you physically active at present? 
 






3 times or 
more/week 
Walking      
Brisk walking      
Running/jogging/orienteering      
cycling      
Training studio/weight training      
Special gymnastics/aerobics for women      
Aerobics/gymnastics/dancing without 
running and jumping 
     
Aerobics/gymnastics/dancing with 
running and jumping 
     
Dancing (swing, rock, folk)      
Skiing      
Ball sport      
Swimming      
Riding      
Other      
 
8. Overall, how would you describe your physical health at the moment? 
 Excellent 
 Very good 
 Good 
 Fair 
 Poor, specify _______________________ 
 
About your child  
 
9. How old was your baby when you stopped breastfeeding? 
 ______months______ weeks_______ days 
 I continue to breastfeed (go to Q 11) 
 
10. Tick the reason (s) you chose not to breastfeed or stop breastfeeding your baby (Tick all that apply) 
 Have breastfed long enough 
 Baby had trouble latching on 
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 Did not have enough milk 
 Breastmilk alone did not seem to satisfy my baby 
 Painful breast 
 Baby not gaining enough weight 
 Baby lost interest/self-weaned 
 I wanted/needed someone else to feed the baby 
 Went back to work and expressing breastmilk was not convenient/possible 
 New pregnancy 
 Baby was old enough that the difference between breastmilk and formula was minimal 
 Others ________________________________ 
 
11. At what age was your baby first given infant formula regularly? 
_____Weeks ______ Months 
 
12. At what age was your baby first given solid food regularly?  
_______ Weeks _______ Months  
 
13. Do you give your child cod liver oil, vitamins, iron or any other dietary supplements since 
your last visit? 
 No 
 Yes, specify  
 
Name of product How much each 
time 
How often  How old was your child at first time 
consumption (months) 
    
    














once a day 
Breastmilk     
Pasteurised Cow’s milk     
Pasteurised Goat’s milk     
Evaporated milk     
Organic milk products (milk, yoghurt)     
Standard infant formula/formula 
milk 
    
Standard formula milk with Omega-3     
Hypoallergenic formula     
Water     
Gripe water     
Sugar water     
Cold flavored milk drinks     
Fizzy (carbonated) drinks     
Squash, artificially sweetened     
Baby cordial, artificially sweetened     
Fruit juice     
Herbal drinks     
Tea/Coffee     





15. Has your child had the following health problems since your last visit? 
 




Did you visit a 
doctor/clinic 
Has your child 
been admitted to 
hospital for this 
Common cold 
 





 Yes   No   Yes   No  Yes   No 
Other type of 
throat infection 
       
Ear infection  Yes   No   Yes   No  Yes   No 
Pseudcroup        
Bronchitis 
pneumonia 
 Yes   No   Yes   No  Yes   No 
Gastric 
flu/Diarrhea 
 Yes   No   Yes   No  Yes   No 
Urinary tract 
infection 
       
Wheezing/ 
whistling in the 
chest 
 Yes   No   Yes   No  Yes   No 
Vomiting  Yes   No   Yes   No  Yes   No 
High 
temperature 
 Yes   No   Yes   No  Yes   No 
Urinary tract 
infection 
 Yes   No   Yes   No  Yes   No 
Colic  Yes   No   Yes   No  Yes   No 
Nappy rash  Yes   No   Yes   No  Yes   No 
An accident  Yes   No   Yes   No  Yes   No 
 
16. How would you describe the health of your baby now: 
 Very healthy 
 Healthy, but a few minor problems 
 Sometimes quite ill 




17. Are there any changes in your living situation since your last time completing the 
questionnaire? 
 No 
 Yes, please specify___________________________ 
18. Since your last visit, have you changed your smoking habits? 
 No 
 Yes, specify _____________________________________. 
19. Since your last visit, have you changed your drinking habits? 
 No 
 Yes, specify _____________________________________. 
 
 




Appendix 12 - MINI Study Maternal Health Questionnaire –  
Edinburgh Postnatal Depression Scale 
 




As you have recently had a baby, we would like to know how you are feeling. Please check the 
answer that comes closest to how you have felt IN THE PAST 7 DAYS, not just how you feel today. 
 
Before you start, I will show you an example question that has already been completed. 
 
I have felt happy: 
 Yes, all the time 
⊠ Yes, most of the time  
 No, not very often 
 No, not at all 
 
This would mean: “I have felt happy most of the time” during the past 7 days. Please complete the 
other questions in the same way. 
 
In the past 7 days: 
 
1. I have been able to laugh and see the funny side of things 
 As much as I always could 
 Not quite so much now 
 Definitely not so much now 
 Not at all 
2. I have looked forward with enjoyment to things 
 As much as I ever did 
 Rather less than I used to  
 Definitely less than I used to  
 Hardly at all 
3. I have blamed myself unnecessarily when things went wrong 
 Yes, most of the time 
 Yes, some of the time 
 Not very often 
 No, never 
Maternal Health Questionnaire  
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4. I have been anxious or worried for no good reason 
 No, not at all 
 Hardly ever 
 Yes, sometimes 
 Yes, very often 
5. I have felt scared or panicky for no very good reason 
 Yes, quite a lot 
 Yes, sometimes 
 No, not much 
 No, not at all 
6. Things have been getting on top of me 
 Yes, most of the time I have not been able to cope at all 
 Yes, sometimes I have not been coping as well as usual 
 No, most of the time I have coped quite well 
 No, I have been coping as well as ever 
7. I have been so unhappy that I have had difficulty sleeping 
 Yes, most of the time 
 Yes, sometimes 
 Not very often 
 No, not at all 
8. I have felt sad or miserable 
 Yes, most of the time 
 Yes, quite often 
 Not very often 
 No, not at all 
9. I have been so unhappy that I have been crying 
 Yes, most of the time 
 Yes, quite often 
 Only occasionally 
 No, never 
10. The thought of harming myself has occurred to me 
 Yes, quite often 
 Sometimes 
 Hardly ever 
 Never  
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Appendix 13 - MINI Study Maternal and Infant data collection sheets 
 




Age:  Weeks after giving birth: 
 
Prior to Pregnancy: Estimated usual body weight ____________ kg 
Pregnancy: Blood hemoglobin  _____________  
Any complications:   
Maternal delivery Information 
Date of delivery: ______ Day _______ Month 
Time of delivery: ________________________ 
Method of delivery:  ________________________ 
Usage of iodine containing sanitizer: ________________________ 
Any severe blood loss ________________________ 
Pain relief used ________________________ 
Baby’s summary 
Gestation: ______________ weeks 
Gender:  ______________ 
Apgar score at 1 minute ______________ 
Apgar score at 5 minutes ______________ 
Birth weight: ______________ kg Head circumference: _____________ cm 
Body length:______________ cm  
Guthrie test :  __________________(positive or negative) 
Maternal Data  
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Have you given birth to any other children?      
   
 Yes = 1/ No = 0 
 




Method of feeding  
(probe duration of bf) 
     
     
     
 
 
Anthropometric measurement - Visit One 
 
Body weight _______________kg 
_______________ kg 
_______________ kg 
Average ___________ kg 
Body height _______________ cm 
_______________ cm 
_______________ cm 
Average ___________ cm 
BMI __________________  
BIA results  
  




Anthropometric measurement - Visit Two 
 
 
Body weight _______________ kg 
_______________ kg 
_______________ kg 
Average ___________ kg 
Body height _______________ cm 
_______________ cm 
_______________ cm 
Average ___________ cm 
BMI __________________  
BIA results  
BodPod Results  
  
 
Anthropometric measurement - Visit Three 
 
Body weight _______________ kg 
_______________ kg 
_______________ kg 
Average ___________ kg 
Body height _______________ cm 
_______________ cm 
_______________ cm 
Average ___________ cm 
BMI __________________  
BIA results  





Infant Anthropometric measurement – Visit One 
 
Body weight:                    _____________ kg  
                                            _____________ kg 
                                             _____________ kg                                        Average ___________ kg 
Body length:                       _____________ cm 
                                              _____________ cm 
                                             ______________ cm                                    Average ___________ cm 
Head circumference:         _____________ cm 
_____________ cm 




Infant Anthropometric measurement – Visit Two 
 
Body weight:                       _____________ kg  
                                               _____________ kg 
                                               _____________ kg                                        Average ___________ kg 
Body length:                           ____________ cm 
                                                 _____________ cm 
                                                 _____________ cm                                    Average ___________ cm 
Head circumference:         ______________ cm 
  ______________ cm 
  ______________ cm                                    Average ___________ cm 
  
Infant Data  
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Infant Anthropometric measurement – Visit Three 
Body weight:                  _____________ kg  
                                         _____________ kg 
                                         _____________ kg                                        Average ___________ kg 
Body length:                    ____________ cm 
                                          _____________ cm 
                                          _____________ cm                                    Average ___________ cm 
Head circumference:         _____________cm 
 _____________cm 
 _____________cm                                    Average ___________ cm 
 
First week 
Body weight: _____________ kg 
2-4 weeks 
Body weight: ____________ kg Head circumference: _________________cm 
4-6 weeks 
Body weight: _____________ kg Head circumference__________ cm 
Body length: _____________ cm 
8-10 weeks 
Body weight: _____________ kg Head circumference__________ cm 
Body length: _____________ cm 
3-4 months 
Body weight: _____________ kg Development 
5-7 months 
Body weight: _____________ kg Development 
9-12 months 
Body weight: _____________ kg Body length: _____________ cm 
Development 
(Notes taken from the Well Child Book)  
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Appendix 14 - MINI Study Maternal Thyroid Gland Measurement sheet 
 





Width: _____________  
AP Diameter: _____________ 
Length: _____________ 




Width: _____________  
AP Diameter: _____________ 
Length: _____________ 
Tvol (R): _____________ 
 
 
Calculation of Thyroid Volume 
 




Isthmus:     _________________ 
 
Note: Tvol Lobe = Width x AP Diameter x Length x 0.479 
  
 




Appendix 15 – MINI Study - 4-Day Dietary Diary (Maternal) 
 





PLEASE READ THROUGH THESE PAGES BEFORE STARTING YOUR DIARY 
 
We would like you to record in this diary everything you eat and drink over 4 DAYS, including food consumed at home and outside the 
home. It is very important that you continue to eat and drink what you normally eat and drink during the period of recording. Please 
describe all the food you eat in as much detail as possible. Be as specific as you can.  
When to fill in the diary 
Please record the food you eat as you go, do not list from memory at the end of the day. Use written notes on a notepad if you 
forget to take your diary with you. Each diary day covers a 24-hour period, so please include any food or drinks that you may have 
had through the night. Remember to include foods and drinks between meals (snacks) including water. 
Home-made dishes 
Please record the name of the recipe, ingredients with amounts (including water and other fluids) for the whole recipe, the number 




Take-away and eating out 
Please record as much detail about the amount and ingredients as you can, eg. Vegetable curry containing chickpeas, eggplant, onion 
and tomato.  
Brand name 
Please note the brand name (if known). Most packed foods will list a brand name, e.g. Bird’s eye, Hovis, or Supermarket own brands 
Portion Size 
Examples for how to describe the quantity or portion size you had of a particular food or drink are shown on pages 17-21 of this diary. 
 
For foods, quantity can be described using: 
o household measures, e.g. two thick slices of bread, 4 tablespoons (tbsp) of peas.  
o weights from labels, e.g. 500g steak, 420g tin of baked beans, 125g pot of yoghurt 
o number of items, e.g. 4 fish fingers, 2 pieces of chicken nuggets,  
For drinks, quantity can be described using (see page 21 for a real size glass): 
o the size of glass, cup or the volume (e.g. 300ml). 
o volumes from labels (e.g. 330ml can of fizzy drink). 
We would like to know the amount that was actually eaten which means taking any leftovers into account. You can do this in two 
ways: 
• Record what was served and make notes of what was not eaten e.g. 3 tbsp of peas, 1 tbsp not eaten: 1 large sausage roll, ½ 
not eaten 
• Only record the amount actually eaten e.g. 2 tbsps of peas, ½ a large sausage roll  
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At the end of each recording day, you will be prompted to tell us  
 
Was it a typical day? 
After each day of recording you will be prompted to tell us whether this was a typical day or whether there were any reasons why 
you ate or drank more or less than usual. 
Did you take any supplements?  
At the end of each recording day there is a section for providing information about any supplements you took. Brand name, full name 
of supplement, strength and the amount taken should be recorded. 
 





Thank you for your time- we really appreciate it! 
  










DAY 1  Date: __________Day ____________Month________Year 
Time Where Food/drink description & preparation Brand name Portion size or quantity eaten 
6am to 9am 
6.30am Kitchen Filter coffee, decaffeinated 
Milk (fresh, blue top) 
Sugar white 
 










1 level teaspoon 
 
1 slice 
1 heaped teaspoon 
9am to 12noon 










Time Where Food/drink description & preparation Brand name Portion size or quantity eaten 
12noon to 2pm 
12.30am Work 
tearoom 
Ham salad sandwich from home: 
Bread wholemeal thick sliced 
Margarine light 
Smoked ham thin sliced 
Lettuce, iceberg 













4 thin slices 













Time Where Food/drink description & preparation Brand name Portion size or quantity eaten 
5pm to 8pm 






Bolognese sauce (see recipe) 
Courgettes 
















10pm to 6am 





Please record the details of any recipes or (if not already described) ingredients of made up dishes or take-away dishes. 
Write in recipes or ingredients of made-up dishes or take-away dishes 
Name of Dish: Bolognese sauce Serves: 4  
Ingredients Amount Ingredients Amount 
Low fat beef mince 500g   
garlic 3 cloves   
Brown onion 100g    
Sweet red pepper (capsicum) 50g   
Watties chopped tomatoes 400g   
Tesco tomato puree 1 tablespoon   
Pams canola oil 2 tablespoons   
Greggs mixed herbs 2 tablespoons   
Pams Worcester sauce 1 teaspoon   
Brief description of cooking method: 






Use the pictures to help you indicate the size of the portion you have eaten. 
Write on the food record the picture number and size A, B or C nearest to your own helping. 
 
Remember that the pictures are much smaller than life size. 
The actual size of the dinner plate is 10 inches (25cm), the side plate, 7 inches (18cm), 
and the bowl, 6.3 inches (16cm). 
 
The tables on pages 16-21 also give examples of foods that you might eat and how much 
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Life Size Glass 








DAY 1  Date: __________Day ____________Month________Year 
Time Where Food/drink description & preparation Brand name Portion size or quantity eaten 
6am to 9am 
     
 
 9am to 12noon 
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Time Where Food/drink description & preparation Brand name Portion size or quantity eaten 
12noon to 2pm 
     
2pm to 5pm 
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Time Where Food/drink description & preparation Brand name Portion size or quantity eaten 
5pm to 8pm 
     
8pm to 10pm 
     
10pm to 6am 
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1. Was the amount of food that you had today about what you usually have, less than usual, or more than usual? 
 Yes, usual 






2. Was the amount you had to drink today, including water, tea, coffee and soft drinks (and alcohol), about what you usually 
have, less than usual, or more than usual? 
 Yes, usual 








3. Did you finish all the food and drink that you recorded in the diary today? 
 Yes    No 
Please tell us why you had less than usual Please tell us why you had more than usual 
Please tell us why you had less than usual Please tell us why you had more than usual 
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If no, please go back to the diary and make a note of any leftovers 
 
4. Did you take any vitamins, minerals, or other food supplements today? 
 Yes    No 
 
If yes, please describe the supplements you took below 
 
Brand Name (in full) including strength Number of pills, capsules, teaspoons 
Example 
Thomson’s 
Calcium (1000mg) with vitamin D 1 tablet 
   
   
   
   
 
  




Please record the details of any recipes or (if not already described) ingredients of made up dishes or take-away dishes 
Write in recipes or ingredients of made-up dishes or take-away dishes 
Name of Dish: Serves:  
Ingredients Amount Ingredients Amount 
    
    
    
    
    
    
    
    
    
Brief description of cooking method: 
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Write in recipes or ingredients of made-up dishes or take-away dishes 
Name of Dish: Serves:  
Ingredients Amount Ingredients Amount 
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Appendix 16.1 – Selenium in 24-hour urine samples in breastfeeding women using Spearman’s rho 
 























Urine Selenium µg/L 
r -0.631        
p .000        
Urine Selenium µg/day 
r  0.642       
p ns .000       
Urine Creatinine g/L 
r -0.871 0.657       
p .000 .000 ns      
Urine Creatinine g/day 
r         
p ns ns ns ns     
Selenium Creatinine ratio µg/g 
r  0.580 0.879      
p ns .000 .000 ns ns    
Milk Selenium µg/day 
r   0.269   0.280   
p ns ns .000 ns ns .025 ns  
Dietary Selenium µg/day 
r    -0.357     
p ns ns ns .003 ns ns ns  
Total Energy Intake 
r .247       .405 
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Appendix 16.2 - Selenium in 24-hour urine samples in pregnant women using Spearman’s rho 




















Selenium intake  
(dietary data) 
μg/day 
Urine Selenium µg/L 
r -0.719       
p .000       
Estimated Selenium intake 
(urine) 
µg/day 
r  0.485      
p ns .000     
 
Urine Creatinine g/L 
r -0.863 0.760      
p .000 .000 ns     
Urine Creatinine g/day 
r   0.380 0.259    
p ns ns .003 0.047    
Selenium Creatinine ratio 
µg/g 
r  0.466 0.804     
p ns .000 .000 ns ns   
Estimated Selenium intake  
(dietary data) 
µg/day 
r   .230     
p ns ns .079 (ns) ns ns ns 
 
Total Energy intake kJ 
r       0.263 
p ns ns ns ns ns ns 0.044 
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Correlation Coefficient .275** .441** .563** .125 .279* -.101 .007 .110 
Sig. (2-tailed) .010 .000 .000 .277 .016 .576 .952 .393 




Correlation Coefficient  .276* .075 .225* -.051 -.043 .171 -.197 
Sig. (2-tailed)  .014 .533 .048 .664 .813 .155 .125 
N  79 72 78 74 33 71 62 
Urinary 
I:Cr_V1_ugg 
Correlation Coefficient   .168 .005 .454** -.039 -.047 -.050 
Sig. (2-tailed)   .182 .968 .000 .835 .713 .708 
N   65 70 67 31 65 58 
BMIC_V2 
_ug/L 
Correlation Coefficient    .253* .552** .015 .062 .156 
Sig. (2-tailed)    .032 .000 .936 .621 .246 




Correlation Coefficient     .185 .068 .381** .045 
Sig. (2-tailed)     .115 .706 .001 .728 
N     74 33 71 62 
Urinary I:Cr 
_V2_ugg 
Correlation Coefficient      -.074 .077 .193 
Sig. (2-tailed)      .692 .537 .146 
N      31 67 58 
BMIC_V3 
_ug/L 
Correlation Coefficient       .301 .577** 
Sig. (2-tailed)       .089 .001 




Correlation Coefficient        .340** 
Sig. (2-tailed)        .007 
N        62 
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Appendix 18 – Statement of Contribution Doctorate with 
Publications/Manuscripts 
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